IL323619A - Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof - Google Patents
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereofInfo
- Publication number
- IL323619A IL323619A IL323619A IL32361925A IL323619A IL 323619 A IL323619 A IL 323619A IL 323619 A IL323619 A IL 323619A IL 32361925 A IL32361925 A IL 32361925A IL 323619 A IL323619 A IL 323619A
- Authority
- IL
- Israel
- Prior art keywords
- saccharide
- serotype
- glycoconjugate
- another embodiment
- acetyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Description
1 Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof Field of the Invention The present invention relates to the field of immunogenic compositions and vaccines, their 5manufacture, and the use of such compositions in medicine.More particularly, it relates to isolated Streptococcus pneumoniae serotype 38saccharides, glycoconjugates thereof, methods for making Streptococcus pneumoniae serotypeglycoconjugates and immunogenic composition comprising a Streptococcus pneumoniaeserotype 38 glycoconjugate. 10The invention also relates to analytical methods to analyze isolated S. pneumoniaeserotype 38 polysaccharide, reduced serotype 38 polysaccharide or Streptococcus pneumoniaeserotype 38 glycoconjugates.The Streptococcus pneumoniae serotype 38 saccharide and glycoconjugates of theinvention can be used as a vaccine. 15 Background of the Invention The approach to increasing immunogenicity of poorly immunogenic molecules byconjugating these molecules to "carrier" molecules has been utilized successfully for decades(see, e.g., Goebel et al. (1939) J. Exp. Med. 69: 53). For example, many immunogenic 20compositions have been described in which purified capsular polymers have been conjugated tocarrier proteins to create more effective immunogenic compositions by exploiting this "carriereffect." Schneerson et al. (1984) Infect. Immun. 45: 582-591). Conjugation has also been shownto bypass the poor antibody response usually observed in infants when immunized with a freepolysaccharide (Anderson et al. (1985) J. Pediatr. 107: 346; Insel et al. (1986) J. Exp. Med. 158: 25294).Conjugates have been successfully generated using various cross-linking or couplingreagents, such as homobifunctional, heterobifunctional, or zero-length crosslinkers. Manymethods are currently available for coupling immunogenic molecules, such as saccharides,proteins, and peptides, to peptide or protein carriers. Most methods create amine, amide, 30urethane, isothiourea, or disulfide bonds, or in some cases thioethers. A disadvantage to the useof cross-linking or coupling reagents which introduce reactive sites into the side chains of reactiveamino acid molecules on carrier and/or immunogenic molecules is that the reactive sites, if notneutralized, are free to react with any unwanted molecule either in vitro (thus potentially adverselyaffecting the functionality or stability of the conjugates) or in vivo (thus posing a potential risk of 35adverse events in persons or animals immunized with the preparations). Such excess reactivesites can be reacted or "capped", so as to inactivate these sites, utilizing various known chemicalreactions, but these reactions may be otherwise disruptive to the functionality of the conjugates. 2Thus, there remains a need for new glycoconjugates appropriately capped and methodsto prepare said conjugates, such that the functionality is preserved, and the conjugate retains theability to elicit the desired immune response.Pneumococcal polysaccharides, in particular capsular polysaccharides, are importantimmunogens found on the surface of the bacteria. This has led to them being an important 5component in the design of pneumococcal vaccines. They have proved useful in eliciting immuneresponses especially when linked to carrier proteins.Thus, there is a need for antigens which are able to generate a robust immune responseto Streptococcus pneumoniae serotype 38.The present invention provides in particular Streptococcus pneumoniae serotype 38 10glycoconjugates.
Summary of the Invention To meet these and other needs, the present invention relates an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: 15 where n represents the number of repeating units, wherein Y represents either a Serine or a 20Glycine residue and wherein all the repeating units comprise the same Y residue.
In an aspect the present invention pertains to an isolated S. pneumoniae serotype 38saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O- 30acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 0% to about 100% of therepeating units. In an embodiment said O-acetyl group is present in about 50% to about 100% ofthe repeating units. Preferably, said O-acetyl group is present in about 80% to about 100% of therepeating units. Even more preferably, said O-acetyl group is present in about 90% to about 100%of the repeating units. 35 In certain embodiments, the isolated S. pneumoniae serotype 38 saccharide of theinvention has between 10 and 5,000 repeating units. [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 3In an aspect, the invention provides a glycoconjugate consisting of a saccharide having theabove disclosed repeating unit conjugated to a carrier protein.
The invention further provides Streptococcus pneumoniae serotype 38 glycoconjugates nbearing reduced α-D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (α-D-Sug) residues.
In an aspect the invention relates to mode of preparation of such conjugates. 5In an embodiment the invention relates to an immunogenic composition comprising a S.pneumoniae serotype 38 saccharide of the invention and/or a Streptococcus pneumoniaeserotype 38 glycoconjugate of the invention.The invention further pertains to analytical methods of S. pneumoniae serotype 38saccharides and conjugates. 10 Detailed description of the drawings Figures 1A and 1B. Schematic of pneumococcal polysaccharide serotype 38 repeat unitorganization, including the most common form (serine form) (A) and the secondary form (glycineform) (B). 15 Figure 2. The structure of Streptococcus pneumoniae serotype 38-serine form equilibratingbetween the hydrate and keto state. The two states are shown by black circle. Figure 3. Expanded anomeric and methyl region 1DH spectra of O-acetylated (bottom panel)and de-O-acetylated (top panel) serotype 38 polysaccharides (serine form). The anomeric andthe methyl signals are annotated for both spectra. Shaded box denotes the resonances observed 20due to the O-acetylation of β-D-Galf residue and are absent in the de-O-acetylated serotype 38polysaccharide. Figure 4. Expanded carbonyl, anomeric and methyl region 1DC spectra of O-acetylated(bottom panel) and de-O-acetylated (top panel) serotype 38 polysaccharides (serine form).Panels A to D shows the expanded regions of keto, carbonyl, anomeric and methyl resonances, 25respectively. Shaded box denotes the resonances observed due to the O-acetylation of β-D-Galpresidue and are absent in the de-O-acetylated serotype 38 polysaccharide. Figure 5. 1DH spectrum of reduced serotype 38 polysaccharides. (Inset shows the expandedanomeric region). The anomeric and the methyl signals are annotated. Figure 6. Schematic of serotype 38 repeat unit (serine form) before and after reduction with 30NaBH 4. Reduction forms FucpNAc and QuipNAc sugar. Figure 7. Pn38 specific opsonophagocytic geomean titers (OPA GMT) of sera from micevaccinated with serotype 38 polysaccharide conjugated to either CRM 197 or SCP using eitherRAC/Aqueous, RAC/DMSO or Click conjugation. Figure 8. Pn38 specific opsonophagocytic geomean titers (OPA GMT) of sera from mice 35vaccinated with serotype 38 polysaccharideconjugated to either CRM 197 or SCP using eitherRAC/Aqueous or Click conjugation. 4 Detailed description of the Invention The present invention is based, in part, on the identification of novel pneumococcalpolysaccharide structure(s) by using NMR spectroscopy. It is believed that the structure providedherein is the first identification or the first correct identification of S. pneumoniae serotype 38.The produced (and purified) polysaccharide was used to generate polysaccharide-protein 5conjugate (glycoconjugates). S. pneumoniae serotype 38 has a unique polysaccharide structure,which results in unique consideration when designing conjugate production process. The S.pneumoniae serotype 38 glycoconjugates of the invention also have a unique structure anddesign. 1. Isolated Streptococcus pneumoniae serotype 38 saccharide of the invention As used herein, the term "isolated" in connection with a saccharide refers to isolation ofS. pneumoniae serotype specific capsular polysaccharide from purified polysaccharide usingpurification techniques known in the art, including the use of centrifugation, depth filtration,precipitation, ultrafiltration, treatment with activate carbon, diafiltration and/or column 15chromatography. Generally, an isolated polysaccharide refers to partial removal of proteins,nucleic acids and non-specific endogenous polysaccharide (C-polysaccharide). The isolatedpolysaccharide contains less than 10%, 8%, 6%, 4%, or 2% protein impurities and/or nucleicacids. The isolated polysaccharide contains less than 20% of C-polysaccharide with respect totype specific polysaccharides. 20The term "saccharide" throughout this specification may indicate polysaccharide oroligosaccharide and includes both. In preferred embodiments, the saccharide is a polysaccharide,in particular a S. pneumoniae serotype 38 capsular polysaccharide.The term "serotype 38 saccharide", "serotype 38 capsular saccharide", "S. pneumoniaeserotype 38 saccharide" throughout this specification refers to S. pneumoniae serotype 38 25capsular saccharide and may be used interchangeably herein.The structure of S. pneumoniae serotype 38 capsular polysaccharide is disclosed for the firsttime and is shown in Figure 1A and 1B. The inventors found that the serotype 38 polysaccharideis a penta-saccharide: α-D-glucosamine (A), α-D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose( α-D-Sug) (B), O-acetylated β-D-galactose (C), α-D-galactose (D), and β-D-galactofuranose (E). 30Residue C (O-acetylated β-D-galactose) is further linked at the 6 position to serine or glycineamino acid, thus representing the serotype 38 serine and glycine forms of polysaccharide.The inventors have found that certain strains of S. pneumoniae serotype 38 produce a capsularpolysaccharide which has a serine amino acid linked to Galp4OAc sugar (Figure 1A) whereasother strains make polysaccharide where glycine is attached to Galp4OAc sugar (Figure 1B). 35After characterizing several strains of serotype 38, the serine form has been shown to be themore abundant form. 5Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue and wherein all the repeating units comprise the same Y residue.Therefore, in one embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: 10 where n represents the number of repeating units. 15 In another embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: where n represents the number of repeating units.
As shown at figure 1A and 1B, β-D-Galp4OAc,6Ser(or Gly) (residue C) of serotype 38 25polysaccharide is O-acetylated at carbon 4 position. O-acetylation level may vary from one strainto another. Furthermore, native S. pneumoniae serotype 38 saccharide can be deacetylated, forexample by treatment with a base (alkaline pH). As shown in the example section, native serotypepolysaccharide can be completely deacetylated after incubating with 0.25N NH4OH at roomtemperature for 24 hours. 30Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 38 saccharide with the following repeating unit: [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 6where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 0% to about 100% of therepeating units. In an embodiment said O-acetyl group is present in about 50% to about 100% ofthe repeating units. Preferably, said O-acetyl group is present in about 80% to about 100% of the 5repeating units. Even more preferably, said O-acetyl group is present in about 90% to about 100%of the repeating units.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O- 15acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 100% of the repeating units.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 95% of the repeating units. 25Accordingly, in one embodiment, the present invention provides an isolated S.pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Ser is present in about 0% to about 100% of the repeating units. In anembodiment said O-acetyl group is present in about 50% to about 100% of the repeating units.Preferably, said O-acetyl group is present in about 80% to about 100% of the repeating units. 35Even more preferably, said O-acetyl group is present in about 90% to about 100% of the repeatingunits. [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 7In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Ser is present in about 100% of the repeating units.In one particular embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: 10 where n represents the number of repeating units and wherein the O-acetyl group at position 4 of 15β-D-Galp4OAc,6Ser is present in about 95% of the repeating units.In another embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Gly is present in about 0% to about 100% of the repeating units. In anembodiment said O-acetyl group is present in about 50% to about 100% of the repeating units. 25Preferably, said O-acetyl group is present in about 80% to about 100% of the repeating units.Even more preferably, said O-acetyl group is present in about 90% to about 100% of the repeatingunits.In another embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: 30 where n represents the number of repeating units and wherein the O-acetyl group at position 4 of 35β-D-Galp4OAc,6Gly is present in about 100% of the repeating units. [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 8In a particular embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Gly is present in 95% of the repeating units.In an embodiment, the S. pneumoniae serotype 38 saccharide of the invention does notbear an O-acetyl group at carbon 4 position of the β-D-Galp4OAc,6Ser(or Gly) residue. Therefore, 10in one embodiment, the present invention provides an isolated S. pneumoniae serotype 38saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serineor a Glycine residue and wherein all the repeating units comprise the same Y residue.In one embodiment, the present invention provides an isolated S. pneumoniae serotypesaccharide with the following repeating unit: 20 where n represents the number of repeating units. 25In another embodiment, the present invention provides an isolated S. pneumoniaeserotype 38 saccharide with the following repeating unit: where n represents the number of repeating units.
As mentioned above, the β-D-Galp4OAc,6Ser(or Gly) residues (residue C) of serotype 38saccharide maybe O-acetylated at carbon 4 position. O-acetylation level may not be 100% in thesaccharide and when the structure of a saccharide is provided with a repeating unit represented 35with an O-acetyl group at this position, it should not be understood that such a saccharide alwaysbears an O-acetyl group at every position 4 of β-D-Galp4OAc,6Ser (or Gly) residue of the [→ 3)-β-D-Galp,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp,6 (Y) -(1→3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 9saccharide. Rather, this indicates that a majority of these residues are O-acetylated, preferably,said O-acetyl group is present in about 80% to about 100% of the repeating units. Even morepreferably, said O-acetyl group is present in about 90% to about 100% of the repeating units.In certain embodiments, the isolated S. pneumoniae serotype 38 saccharide of theinvention has between 10 and 5,000 repeating units. In certain aspects, the isolated saccharide 5has between 50 and 4,500 repeating units. In certain aspects, the isolated saccharide hasbetween 100 and 4,500 repeating units. In certain aspects, the isolated saccharide has between150 and 2,000 repeating units.Isolated capsular saccharides from S. pneumoniae serotype 38 can be prepared bystandard techniques known to those of ordinary skill in the art. Typically capsular polysaccharides 10are produced by growing a S. pneumoniae serotype 38 strain in a medium (e.g., in a soy-basedmedium), the polysaccharides are then prepared from the bacteria culture. Serotype 38Streptococcus pneumoniae strains may be obtained from established culture collections (such asfor example the Streptococcal Reference Laboratory (Centers for Disease Control andPrevention, Atlanta, GA)) or clinical specimens. 15The population of the organism (S. pneumoniae serotype 38) is often scaled up from aseed vial to seed bottles and passaged through one or more seed fermentors of increasingvolume until production scale fermentation volumes are reached. At the end of the growth cyclethe cells are lysed and the lysate broth is then harvested for downstream (purification) processing(see for example WO 2006/110381 and WO 2008/118752, U.S. Patent App. Pub. Nos. 202006/0228380, 2006/0228381, 2008/0102498 and US2008/0286838). The polysaccharides aretypically purified through centrifugation, precipitation, ultra-filtration, and/or columnchromatography (see for example WO 2006/110352, WO 2008/118752 and WO2020/170190).The isolated polysaccharide can be characterized by different parameters including, forexample the weight average molecular weight (Mw). The molecular weight of the polysaccharide 25can be measured by Size Exclusion Chromatography (SEC) combined with Multiangle Laser LightScattering detector (MALLS).In an embodiment, the isolated S. pneumoniae serotype 38 saccharide of the inventionhas a weight average molecular weight between 5 kDa and 5000 kDa. In an embodiment, theisolated S. pneumoniae serotype 38 saccharide has a weight average molecular weight between 30kDa and 2000 kDa.In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharide has a weightaverage molecular weight between 50 kDa and 5000 kDa. In an embodiment, the isolated S.pneumoniae serotype 38 polysaccharide has a weight average molecular weight between 50 kDaand 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharide has a 35weight average molecular weight between 50 kDa and 1000 kDa.In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharide has a weightaverage molecular weight between 100 kDa and 5000 kDa. In an embodiment, the isolated S. 10pneumoniae serotype 38 polysaccharide has a weight average molecular weight between 100kDa and 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharidehas a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment, theisolated S. pneumoniae serotype 38 polysaccharide has a weight average molecular weightbetween 100 kDa and 500 kDa. 5In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharide has a weightaverage molecular weight between 300 kDa and 5000 kDa. In an embodiment, the isolated S.pneumoniae serotype 38 polysaccharide has a weight average molecular weight between 300kDa and 2000 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharidehas a weight average molecular weight between 300 kDa and 1000 kDa. 10In an embodiment, the isolated S. pneumoniae serotype 38 polysaccharide has a weightaverage molecular weight between 500 kDa and 3000 kDa. In an embodiment, the isolatedpolysaccharide has a weight average molecular weight between 500 kDa and 2000 kDa. In anembodiment, the isolated polysaccharide has a weight average molecular weight between 500kDa and 1000 kDa. 15Preferably, in order to generate glycoconjugates with advantageous filterabilitycharacteristics, immunogenicity and/or yields, sizing of the saccharide to a target molecularweight range is performed prior to the conjugation to a carrier protein.Advantageously, the size of the purified capsular S. pneumoniae serotype 38 saccharideis reduced while preserving critical features of the structure of the polysaccharide. Mechanical or 20chemical sizing maybe employed.In an embodiment, the size of the purified S. pneumoniae serotype 38 capsular saccharideis reduced by chemical hydrolysis. Chemical hydrolysis maybe conducted using a mild acid (e.g.,acetic acid, formic acid, propanoic acid). In an embodiment, chemical hydrolysis is conductedusing formic acid. In an embodiment, chemical hydrolysis is conducted using propanoic acid. In 25a preferred embodiment, chemical hydrolysis is conducted using acetic acid. Chemical hydrolysismay also be conducted using a diluted strong acid (such as diluted hydrochloric acid, dilutedsulfuric acid, diluted phosphoric acid, diluted nitric acid or diluted perchloric acid). In anembodiment, chemical hydrolysis is conducted using diluted hydrochloric acid. In an embodiment,chemical hydrolysis is conducted using diluted sulfuric acid. In an embodiment, chemical 30hydrolysis is conducted using diluted phosphoric acid. In an embodiment, chemical hydrolysis isconducted using diluted nitric acid. In an embodiment, chemical hydrolysis is conducted usingdiluted perchloric acid.The size of the purified S. pneumoniae serotype 38 capsular saccharide can also bereduced by mechanical homogenization. In an embodiment, the size of the purified capsular 35saccharide is reduced by high pressure homogenization. High pressure homogenization achieveshigh shear rates by pumping the process stream through a flow path with sufficiently small 11dimensions. The shear rate is increased by using a larger applied homogenization pressure, andexposure time can be increased by recirculating the feed stream through the homogenizer.The high-pressure homogenization process can be appropriate for reducing the size ofthe purified capsular saccharide while preserving the structural features of the saccharide.In a preferred embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide 5is sized to a weight average molecular weight between 10 kDa and 1000 kDa. In an embodiment,the isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weight averagemolecular weight between 50 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniaeserotype 38 capsular saccharide is sized to a weight average molecular weight between 50 kDaand 400 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide is 10sized to a weight average molecular weight between 50 kDa and 250 kDa.In a preferred embodiment, the isolated S. pneumoniae serotype 38 capsular saccharideis sized to a weight average molecular weight between 100 kDa and 1000 kDa. In an embodiment,the isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weight averagemolecular weight between 100 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniae 15serotype 38 capsular saccharide is sized to a weight average molecular weight between 100 kDaand 400 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide issized to a weight average molecular weight between 100 kDa and 250 kDa.In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide is sizedto a weight average molecular weight between 250 kDa and 1000 kDa. In an embodiment, the 20isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weight average molecularweight between 250 kDa and 500 kDa. In an embodiment, the isolated S. pneumoniae serotypecapsular saccharide is sized to a weight average molecular weight between 250 kDa and 400kDa. In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide is sized toa weight average molecular weight between 200 kDa and 800 kDa. 25In a preferred embodiment, the isolated S. pneumoniae serotype 38 capsular saccharideis sized to a weight average molecular weight between 150 kDa and 300 kDa.In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide capsularsaccharide is sized to a weight average molecular weight of about 250 kDa. In an embodiment,the isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weight average 30molecular weight of about 300 kDa. In an embodiment, the isolated S. pneumoniae serotype 38capsular saccharide is sized to a weight average molecular weight of about 350 kDa. In anembodiment, the isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weightaverage molecular weight of about 400 kDa. In an embodiment, the isolated S. pneumoniaeserotype 38 capsular saccharide is sized to a weight average molecular weight of about 450 kDa. 35In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharide is sized to aweight average molecular weight of about 500 kDa. In an embodiment, the isolated S.pneumoniae serotype 38 capsular saccharide is sized to a weight average molecular weight of 12about 550 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 capsular saccharideis sized to a weight average molecular weight of about 600 kDa. In an embodiment, the isolatedS. pneumoniae serotype 38 capsular saccharide is sized to a weight average molecular weightof about 700 kDa. In an embodiment, the isolated S. pneumoniae serotype 38 capsularsaccharide is sized to a weight average molecular weight of about 800 kDa. In an embodiment, 5the isolated S. pneumoniae serotype 38 capsular saccharide is sized to a weight averagemolecular weight of about 900 kDa. In an embodiment, the isolated S. pneumoniae serotype 38capsular saccharide is sized to a weight average molecular weight of about 1000 kDa.In an embodiment, the isolated capsular saccharide is not sized.The isolated capsular saccharide described above may be activated (e.g., chemically 10activated) to make them capable of reacting and then incorporated into glycoconjugates, asfurther described herein. 2. Streptococcus pneumoniae serotype 38 glycoconjugates of the invention For the purpose of the invention the term ‘glycoconjugate' indicates a capsular saccharideconjugated to a carrier protein via covalent or non-covalent bonds. In an embodiment, the 15capsular saccharide is conjugated to a carrier protein via non-covalent bonds (such as therhizavidin/biotin system, see e.g. WO2012155007, WO2020056202). Preferably, the capsularsaccharide is conjugated via covalent bonds. In one embodiment the capsular saccharide isconjugated directly to a carrier protein. In a second embodiment the capsular saccharide isconjugated to a carrier protein through a spacer/linker. 20 The present invention provides glycoconjugates in which saccharides as provided for aboveare conjugated to a carrier protein. Therefore, in an embodiment, the invention provides aglycoconjugate comprising a saccharide having the above disclosed repeating unit conjugated toa carrier protein.
In an embodiment, the invention provides a glycoconjugate consisting of a saccharide having 25the above disclosed repeating unit conjugated to a carrier protein. 2.1 Attributes of the Streptococcus pneumoniae serotype 38 glycoconjugates of the inventionThe isolated polysaccharide described above may be activated (e.g., chemically activated) tomake them capable of reacting (e.g. with a linker or directly with the carrier protein) and thenincorporated into glycoconjugates, as further described herein. 30Before activation, the size of the isolated polysaccharide can be reduced while preservingcritical features of the structure of the polysaccharide. Mechanical or chemical sizing maybeemployed. In an embodiment, the size of the isolated polysaccharide is reduced by chemicalhydrolysis. The size of the isolated polysaccharide can also be reduced by mechanicalhomogenization. In an embodiment, the size of the isolated polysaccharide is reduced by high 35pressure homogenization. High pressure homogenization achieves high shear rates by pumpingthe process stream through a flow path with sufficiently small dimensions. The shear rate is 13increased by using a larger applied homogenization pressure, and exposure time can beincreased by recirculating the feed stream through the homogenizer.The weight average molecular weight (Mw) of the saccharide before conjugation refers to theMw before the activation of the saccharide (i.e. after an eventual sizing step but before reactingthe saccharide with an activating agent). In the context of the present invention the Mw of the 5saccharide is not substantially modified by the activation step and the Mw of the saccharideincorporated in the conjugate is similar to the Mw of the saccharide as measured before activation.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 50 kDa and 1,000 kDa. 10In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 polysaccharide wherein the weight average molecular weight (Mw) of saidpolysaccharide before conjugation is between 100 kDa and 600 kDa.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 polysaccharide wherein the weight average molecular weight (Mw) of said 15polysaccharide before conjugation is between 100 kDa and 400 kDa.In a preferred embodiment, the serotype 38 glycoconjugate of the present inventioncomprises a serotype 38 polysaccharide wherein the weight average molecular weight (Mw) ofsaid polysaccharide before conjugation is between 150 kDa and 300 kDa.In some embodiments, the serotype 38 glycoconjugate of the invention has a weight average 20molecular weight (Mw) of between 250 kDa and 20,000 kDa.In other embodiments, the serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 15,000 kDa.In other embodiments, the serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 500 kDa and 10,000 kDa. 25In still other embodiments, the serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 750 kDa and 7,500 kDa.In other embodiments, the serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 5,000 kDaIn preferred embodiments, the serotype 38 glycoconjugate has a weight average molecular 30weight (Mw) of between 1,000 kDa and 10,000 kDa.Another way to characterize the serotype 38 glycoconjugates of the invention is by thenumber of lysine residues in the carrier protein (e.g., CRM 197, SCP, DT or TT) that becomeconjugated to the saccharide which can be characterized as a range of conjugated lysines(degree of conjugation). The evidence for lysine modification of the carrier protein, due to covalent 35linkages to the polysaccharides, can be obtained by amino acid analysis using routine methodsknown to those of skill in the art. Conjugation results in a reduction in the number of lysine residuesrecovered compared to the carrier protein starting material used to generate the conjugate 14materials. In a preferred embodiment, the degree of conjugation of the serotype 38glycoconjugate of the invention is between 2 and 15. In an embodiment, the degree of conjugationof the serotype 38 glycoconjugate of the invention is between 2 and 10. In an embodiment, thedegree of conjugation of the serotype 38 glycoconjugate of the invention is between 3 and 5. Inan embodiment, the degree of conjugation of the serotype 38 glycoconjugate of the invention is 5between 2 and 6. In a preferred embodiment, the degree of conjugation of the serotype 38glycoconjugate of the invention is between 4 and 10.The serotype 38 glycoconjugates of the invention may also be characterized by the ratio(weight/weight) of saccharide to carrier protein. In some embodiments, the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. In other 10embodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 2.0. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.5. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.8 and 1.2. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.5 and 1.0. In otherembodiments, the saccharide to carrier protein ratio (w/w) is between 1.0 and 1.5. In other 15embodiments, the saccharide to carrier protein ratio (w/w) is between 1.0 and 2.0. In furtherembodiments, the saccharide to carrier protein ratio (w/w) is between 0.8 and 1.2. In furtherembodiments, the ratio of serotype 38 saccharide to carrier protein in the conjugate is between0.7 and 1.1. In preferred embodiments, the ratio of serotype 38 saccharide to carrier protein inthe conjugate is between 0.5 and 1.5. In some such embodiments, the carrier protein is CRM 197. 20In some preferred embodiments, the carrier protein is SCP.The serotype 38 glycoconjugates and immunogenic compositions of the invention maycontain free saccharide that is not conjugated to the carrier protein but is nevertheless present inthe glycoconjugate composition. The free saccharide may be noncovalently associated with (i.e.,noncovalently bound to, adsorbed to, or entrapped in or with) the glycoconjugate. In a preferred 25embodiment, the serotype 38 glycoconjugate comprises less than about 50% of free serotype 38saccharide compared to the total amount of serotype 38 saccharide. In a preferred embodiment,the serotype 38 glycoconjugate comprises less than about 25% of free serotype 38 saccharidecompared to the total amount of serotype 38 saccharide. In an even preferred embodiment, theserotype 38 glycoconjugate comprises less than about 20% of free serotype 38 saccharide 30compared to the total amount of serotype 38 saccharide. In a yet preferred embodiment, theserotype 38 glycoconjugate comprises less than about 15% of free serotype 38 saccharidecompared to the total amount of serotype 38 saccharide.The serotype 38 glycoconjugates may also be characterized by their molecular size distribution(Kd). Size exclusion chromatography media (CL-4B) can be used to determine the relative 35molecular size distribution of the conjugate. Size Exclusion Chromatography (SEC) is used ingravity fed columns to profile the molecular size distribution of conjugates. Large moleculesexcluded from the pores in the media elute more quickly than small molecules. Fraction collectors 15are used to collect the column eluate. The fractions are tested colorimetrically by saccharideassay. For the determination of Kd, columns are calibrated to establish the fraction at whichmolecules are fully excluded (V0), (Kd=0), and the fraction representing the maximum retention(Vi), (Kd=1). The fraction at which a specified sample attribute is reached (Ve), is related to Kd bythe expression, Kd = (Ve - V0)/ (Vi - V0). 5In a preferred embodiment, at least 30% of the serotype 38 glycoconjugate has a Kd below orequal to 0.3 in a CL-4B column. In a preferred embodiment, at least 40% of the glycoconjugatehas a Kd below or equal to 0.3 in a CL-4B column. In a preferred embodiment, at least 60% of theserotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. In a preferredembodiment, between 50% and 80% of the serotype 38 glycoconjugate has a Kd below or equal 10to 0.3 in a CL-4B column. In a preferred embodiment, between 65% and 80% of the serotype 38glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 2.2 Streptococcus pneumoniae serotype 38 glycoconjugates of the invention bearingreduced α-D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (α-D-Sug) residues 15 The process to prepare the serotype 38 glycoconjugate of the invention may comprise theuse of reducing agent. In particular, unreacted aldehyde groups following oxidation (in particularwhen reductive amination is used, see below) may be capped using a suitable capping agent(reducing agent). In one embodiment this capping agent is sodium borohydride (NaBH4). 20As shown at Example 4, the α-D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug)residue is sensitive to reduction using NaBH4. Treatment of serotype 38 polysaccharide withNaBH 4 specifically reduces the position 4 of the D-Sug residue from a ketone/hydrate to analcohol and transform the D-Sug to a mixture of D-FucNAc and D-QuiNAc, characterized byposition 4 hydroxyl at axial and equatorial orientations, respectively as illustrated in Figure 6. 25In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 70 N-acetyl-D-fucosamine(D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 68 N-acetyl-D-fucosamine (D- 30FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 35capsular saccharide comprising between about 1 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 16In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 50 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 40 N-acetyl-D-fucosamine (D- 5FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 30 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 10capsular saccharide comprising between about 1 to about 20 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 10 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 1 to about 5 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 70 N-acetyl-D- 20fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 25capsular saccharide comprising between about 10 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 50 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 40 N-acetyl-D-fucosamine (D- 35FucNAc) residues in every 100 saccharide repeat units of the saccharide. 17In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 30 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 20 N-acetyl-D-fucosamine (D- 5FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 10capsular saccharide comprising between about 20 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 50 N-acetyl-D-fucosamine (D- 20FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 40 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 25capsular saccharide comprising between about 20 to about 30 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 40 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 40 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 40 to about 65 N-acetyl-D-fucosamine (D- 35FucNAc) residues in every 100 saccharide repeat units of the saccharide. 18In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 40 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 40 to about 50 N-acetyl-D-fucosamine (D- 5FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 50 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 10capsular saccharide comprising between about 50 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 50 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 50 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 60 to about 70 N-acetyl-D- 20fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 60 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 25capsular saccharide comprising between about 60 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 70 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 68 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 65 N-acetyl-D-fucosamine (D-FucNAc) 35residues in every 100 saccharide repeat units of the saccharide. 19In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 60 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 50 N-acetyl-D-fucosamine (D-FucNAc) 5residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 40 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 10serotype 38 capsular saccharide comprising about 30 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 20 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 10 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 5 N-acetyl-D-fucosamine (D-FucNAc) 20residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 1 N-acetyl-D-fucosamine (D-FucNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 25serotype 38 capsular saccharide comprising between about 0.5 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 25 N-acetyl-D-quinovosamine (D- 35QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 20In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 20 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 15 N-acetyl-D-quinovosamine (D- 5QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 10 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 10capsular saccharide comprising between about 0.5 to about 5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 0.5 to about 2.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 15 In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 20capsular saccharide comprising between about 5 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 25In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 5 to about 25 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 5 to about 20 N-acetyl-D-quinovosamine (D- 30QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 5 to about 15 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 35capsular saccharide comprising between about 5 to about 10 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 21In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 32 N-acetyl-D-quinovosamine (D- 5QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 10capsular saccharide comprising between about 10 to about 25 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 20 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 10 to about 15 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 35 N-acetyl-D- 20quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 25capsular saccharide comprising between about 20 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 20 to about 25 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 25 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 25 to about 32 N-acetyl-D-quinovosamine (D- 35QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 22In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 25 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 30 to about 35 N-acetyl-D- 5quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising between about 30 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 10serotype 38 capsular saccharide comprising about 35 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 32 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 30 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 25 N-acetyl-D-quinovosamine (D-QuiNAc) 20residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 20 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 25serotype 38 capsular saccharide comprising about 15 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 10 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 5 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 2.5 N-acetyl-D-quinovosamine (D-QuiNAc) 35residues in every 100 saccharide repeat units of the saccharide. 23In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 0.5 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 70 N-acetyl-D-fucosamine 5(D-FucNAc) residues and between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 68 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) 10residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 65 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 32.5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 15In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 60 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 20serotype 38 capsular saccharide comprising between about 1 to about 50 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 25 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 40 N-acetyl-D-fucosamine 25(D-FucNAc) residues and between about 0.5 to about 20 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 30 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 15 N-acetyl-D-quinovosamine (D-QuiNAc) 30residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 20 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 10 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 35In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 10 N-acetyl-D-fucosamine 24(D-FucNAc) residues and between about 0.5 to about 5 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 5 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 2.5 N-acetyl-D-quinovosamine (D-QuiNAc) 5residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 1 to about 2 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 0.5 to about 1 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 10In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 70 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 15serotype 38 capsular saccharide comprising between about 5 to about 68 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 65 N-acetyl-D-fucosamine 20(D-FucNAc) residues and between about 2.5 to about 32.5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 60 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) 25residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 50 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 25 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 40 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 20 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 35serotype 38 capsular saccharide comprising between about 5 to about 30 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 15 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide. 25In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 5 to about 20 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 10 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 5serotype 38 capsular saccharide comprising between about 5 to about 10 N-acetyl-D-fucosamine(D-FucNAc) residues and between about 2.5 to about 5 N-acetyl-D-quinovosamine (D-QuiNAc)residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 70 N-acetyl-D- 10fucosamine (D-FucNAc) residues and between about 5 to about 35 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 5 to about 32 N-acetyl-D-quinovosamine 15(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 5 to about 32.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 20In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 5 to about 30 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 25serotype 38 capsular saccharide comprising between about 10 to about 50 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 5 to about 25 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 40 N-acetyl-D- 30fucosamine (D-FucNAc) residues and between about 5 to about 20 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 30 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 5 to about 15 N-acetyl-D-quinovosamine 35(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 10 to about 20 N-acetyl-D- 26fucosamine (D-FucNAc) residues and between about 5 to about 10 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 35 N-acetyl-D-quinovosamine 5(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 32 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 10In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 32.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 15serotype 38 capsular saccharide comprising between about 20 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 30 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 50 N-acetyl-D- 20fucosamine (D-FucNAc) residues and between about 10 to about 25 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 40 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 20 N-acetyl-D-quinovosamine 25(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 20 to about 30 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 10 to about 15 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 30 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 15 to about 35 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 35serotype 38 capsular saccharide comprising between about 30 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 15 to about 32 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 27In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 30 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 15 to about 32.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 5serotype 38 capsular saccharide comprising between about 30 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 15 to about 30 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 30 to about 50 N-acetyl-D- 10fucosamine (D-FucNAc) residues and between about 15 to about 25 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 30 to about 40 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 15 to about 20 N-acetyl-D-quinovosamine 15(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 40 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 20 to about 35 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 20In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 40 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 20 to about 32 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 25serotype 38 capsular saccharide comprising between about 40 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 20 to about 32.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 40 to about 60 N-acetyl-D- 30fucosamine (D-FucNAc) residues and between about 20 to about 30 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 40 to about 50 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 20 to about 25 N-acetyl-D-quinovosamine 35(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 50 to about 70 N-acetyl-D- 28fucosamine (D-FucNAc) residues and between about 25 to about 35 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 50 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 25 to about 32 N-acetyl-D-quinovosamine 5(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 50 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 25 to about 32.5 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 10In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 50 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 25 to about 30 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 15serotype 38 capsular saccharide comprising between about 60 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 30 to about 35 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 60 to about 68 N-acetyl-D- 20fucosamine (D-FucNAc) residues and between about 30 to about 32 N-acetyl-D-quinovosamine(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising between about 60 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues and between about 30 to about 32.5 N-acetyl-D-quinovosamine 25(D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 1 N-acetyl-D-fucosamine (D-FucNAc) residueand about 0.5 N-acetyl-D-quinovosamine (D-QuiNAc) residue in every 100 saccharide repeatunits of the saccharide. 30In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 2 N-acetyl-D-fucosamine (D-FucNAc)residues and about 1 N-acetyl-D-quinovosamine (D-QuiNAc) residue in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 35serotype 38 capsular saccharide comprising about 5 N-acetyl-D-fucosamine (D-FucNAc)residues and about 2.5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide. 29In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 10 N-acetyl-D-fucosamine (D-FucNAc)residues and about 5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 5serotype 38 capsular saccharide comprising about 20 N-acetyl-D-fucosamine (D-FucNAc)residues and about 10 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 30 N-acetyl-D-fucosamine (D-FucNAc) 10residues and about 15 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 40 N-acetyl-D-fucosamine (D-FucNAc)residues and about 20 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide 15repeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 50 N-acetyl-D-fucosamine (D-FucNAc)residues and about 25 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide. 20In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 60 N-acetyl-D-fucosamine (D-FucNAc)residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a 25serotype 38 capsular saccharide comprising about 68 N-acetyl-D-fucosamine (D-FucNAc)residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising about 70 N-acetyl-D-fucosamine (D-FucNAc) 30residues and about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising N-acetyl-D-fucosamine (D-FucNAc) residues and N-acetyl-D-quinovosamine (D-QuiNAc) residues where preferably the number of D-FucNAc 35residues is about the double of the number of D-QuiNAc residues.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide comprising N-acetyl-D-fucosamine (D-FucNAc) residues and N- 30acetyl-D-quinovosamine (D-QuiNAc) residues where preferably the number of D-FucNAcresidues is about the double of the number of D-QuiNAc residues.In any of the above embodiments, the remaining sugar residues at the same position inthe repeat unit may be D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug). Therefore, in anembodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 38 5capsular saccharide comprising N-acetyl-D-fucosamine (D-FucNAc), N-acetyl-D-quinovosamine(D-QuiNAc) and D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide comprising at the same position of the repeat unit either a N-acetyl-D-fucosamine (D-FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2- 10acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. In an embodiment, the number of D-FucNAc residues is about the double of the number of D-QuiNAc residues.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue wherein all the repeating units comprise the same Y residue and where X 20represents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine(D-QuiNAc) residue. In an embodiment, said serotype 38 capsular saccharide comprises aboutN-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. In an embodiment, saidserotype 38 capsular saccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) 25residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide.In an embodiment, essentially all the D-Sug residues have been reduced. Therefore, inan embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotypecapsular saccharide with the following repeating unit: 30 where n represents the number of repeating units, wherein Y represents either a Serine or a 35Glycine residue wherein all the repeating units comprise the same Y residue and where Xrepresents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine(D-QuiNAc) residue. In an embodiment, said serotype 38 capsular saccharide comprises about [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf 31N-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. In an embodiment, saidserotype 38 capsular saccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc)residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 sacchariderepeat units of the saccharide. 5In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 capsular saccharide with the following repeating unit: where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. In an embodiment, said serotype 38capsular saccharide comprises between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc) 15residues, between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues andbetween about 0 to about 98.5 D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residuesin every 100 saccharide repeat units of the saccharide.In an embodiment, essentially all the D-Sug residues have been reduced. Therefore, inan embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 20capsular saccharide with the following repeating unit: 25where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine (D-QuiNAc) residue. In anembodiment, said serotype 38 capsular saccharide comprises about 70 N-acetyl-D-fucosamine(D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. In an embodiment, said serotype 38 capsular 30saccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide.
In an embodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 35capsular saccharide with the following repeating unit: [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. In an embodiment, said serotype 38capsular saccharide comprises between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc)residues, between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues and 10between about 0 to about 98.5 D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residuesin every 100 saccharide repeat units of the saccharide.In an embodiment, essentially all the D-Sug residues have been reduced. Therefore, inan embodiment, essentially all the D-Sug residues have been reduced. Therefore, in anembodiment, the serotype 38 glycoconjugate of the present invention comprises a serotype 38 15capsular saccharide with the following repeating unit: where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine (D-QuiNAc) residue. In anembodiment, said serotype 38 capsular saccharide comprises about 70 N-acetyl-D-fucosamine(D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. In an embodiment, said serotype 38 capsular 25saccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 2.3 Mode of preparation of the Streptococcus pneumoniae serotype 38 glycoconjugates 30of the inventionThe serotype 38 glycoconjugate of the present invention can be prepared by any couplingtechnique known to those of ordinary skill in the art.In an embodiment, the serotype 38 saccharide is coupled to the carrier protein via non-covalent bonds (see e.g. WO2012155007, WO2020056202). 35In an embodiment, the serotype 38 saccharide is conjugated via covalent bonds. In oneembodiment the capsular saccharide is conjugated directly to a carrier protein. In a secondembodiment the capsular saccharide is conjugated to a carrier protein through a spacer/linker. [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑ [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf β-D- Galf 33ln an embodiment, the serotype 38 glycoconjugate of the present invention is conjugatedto the carrier protein via a linker, for instance a bifunctional linker. The linker is optionallyheterobifunctional or homobifunctional, having for example a reactive amino group and a reactivecarboxylic acid group, two reactive amino groups or two reactive carboxylic acid groups. Thelinker has for example between 4 and 20, 4 and 12, 5 and 10 carbon atoms. 5A possible linker is adipic acid dihydrazide (ADH). Other linkers include B-propionamido(WO 00/10599), nitrophenyl-ethylamine (Gever et al (1979) Med. Microbiol. lmmunol. 165; 171-288), haloalkyl halides (US4057685), glycosidic linkages (US4673574, US4808700), hexanediamine and 6-aminocaproic acid (US4459286).ln an embodiment, the serotype 38 glycoconjugate of the present invention is conjugated 10directly to the carrier protein (without a linker).ln general the following types of chemical groups on a protein carrier can be used forcoupling / conjugation:1) Amino group (for instance via lysine). ln one embodiment this group is linked to carboxyl groupson saccharides directly or to a carboxyl group on a linker with carbodiimide chemistry e.g. with 15EDAC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide). ln another embodiment this group islinked to hydroxyl groups activated with CDAP or CNBr on saccharides directly or to such groupson a linker; to saccharides or linkers having an aldehyde group; to saccharides or linkers havinga succinimide ester group.2) Carboxyl (for instance via aspartic acid or glutamic acid). ln one embodiment this group is 20linked to amino groups on saccharides directly or to an amino group on a linker with carbodiimidechemistry e.g. with EDAC.3) Sulphydryl (for instance via cysteine). ln one embodiment this group is linked to a bromo orchloro acetylated saccharide or linker with maleimide chemistry. ln one embodiment this group isactivated/modified with bis diazobenzidine. 254) Hydroxyl group (for instance via tyrosine). ln one embodiment this group is activated/modifiedwith bis diazobenzidine.5) lmidazolyl group (for instance via histidine). ln one embodiment this group is activated/modifiedwith bis diazobenzidine.6) Guanidyl group (for instance via arginine). 307) lndolyl group (for instance via tryptophan).On the serotype 38 saccharide, in general the following groups can be used for a coupling:OH, COOH or NH2. Aldehyde groups can be generated after different treatments known in theart such as: periodate, acid hydrolysis, hydrogen peroxide, etc.ln an embodiment, the serotype 38 glycoconjugate of the present invention is prepared 35using CDAP chemistry. In said embodiment, the serotype 38 saccharide is activated with 1-cyano-4-dimethylamino pyridinium tetrafluoroborate (CDAP) to form a cyanate ester. The activatedsaccharide can then be coupled directly or via a spacer (linker) group to an amino group on the 34carrier protein. For example, the spacer could be cystamine or cysteamine to give a thiolatedpolysaccharide which can be coupled to the carrier via a thioether linkage obtained after reactionwith a maleimide-activated carrier protein (for example using N-[ γ-maleimidobutyrloxy]succinimide ester (GMBS)) or a haloacetylated carrier protein (for exampleusing iodoacetimide, N-succinimidyl bromoacetate (SBA; SIB), N-succinimidyl(4- 5iodoacetyl)aminobenzoate (SlAB), sulfosuccinimidyl(4-iodoacetyl)aminobenzoate (sulfo-SIAB),N-succinimidyl iodoacetate (SIA), or succinimidyl 3-[bromoacetamido]proprionate (SBAP)).In a preferred embodiment, the cyanate ester of the activated saccharide is coupled with hexanediamine or adipic acid dihydrazide (ADH) and the amino-derivatised saccharide is conjugated tothe carrier protein using carbodiimide (e.g., EDAC or EDC) chemistry via a carboxyl group on the 10protein carrier. Such conjugates are described for example in WO 93/15760, WO 95/08348 andWO 96/129094.ln an embodiment, the serotype 38 glycoconjugate of the present invention is preparedusing carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S--NHS, EDC, TSTU. Many are described in International Patent Application 15Publication No. WO 98/42721. Conjugation may involve a carbonyl linker which may be formedby reaction of a free hydroxyl group of the saccharide with CDI (see Bethell et al. (1979) 1. Biol.Chern. 254:2572-2574; Hearn et al. (1981) J. Chromatogr. 218:509-518) followed by reaction witha protein to form a carbamate linkage. This may involve reduction of the anomeric terminus to aprimary hydroxyl group, optional protection/deprotection of the primary hydroxyl group, reaction 20of the primary hydroxyl group with CDI to form a CDI carbamate intermediate and coupling theCDI carbamate intermediate with an amino group on a protein.
Direct reductive aminationIn an embodiment, the serotype 38 glycoconjugate of the present invention is prepared by 25direct reductive amination (see e.g. US 4365170, US 4673574, WO2006/110381,WO2008/079653, WO2008/143709, WO2008/079732, WO2011/110531, WO2012/119972,WO2015110941, WO2015110940, WO2018/144439, WO2018/156491).According to the present invention, reductive amination involves two steps, (1) oxidation(activation) of the serotype 38 purified saccharide, (2) reduction of the activated saccharide and 30the carrier protein (e.g., CRM 197, TT or SCP) to form a glycoconjugate.As mentioned above, before oxidation, sizing of the serotype 38 saccharide to a target molecularweight (MW) range can be performed. Therefore, in an embodiment, the isolated polysaccharideis sized before oxidation.In an embodiment, the serotype 38 saccharide of the invention is conjugated to a carrier 35protein by a process comprising the step of:(a) reacting said serotype 38 saccharide with an oxidizing agent;(b) compounding the activated saccharide of step (a) with a carrier protein; and (c) reacting the compounded activated saccharide and carrier protein with a reducing agent toform a glycoconjugate.
In an embodiment, the serotype 38 saccharide of the invention is conjugated to a carrierprotein by a process comprising the step of: 5(a) reacting said serotype 38 saccharide with an oxidizing agent;(a’) quenching the oxidation reaction by addition of a quenching agent;(b) compounding the activated saccharide of step (a’) with a carrier protein; and(c) reacting the compounded activated saccharide and carrier protein with a reducing agent toform a glycoconjugate. 10Following the oxidation step (a) the saccharide is said to be activated and is referred to as"activated saccharide".In an embodiment, the oxidizing agent is any oxidizing agent which oxidizes a terminalhydroxyl group to an aldehyde. In an embodiment, the oxidizing agent is periodate. For thepurpose of the present invention, the term "periodate" includes both periodate and periodic acid; 15the term also includes both metaperiodate (IO4-) and orthoperiodate (IO65-) and the various saltsof periodate (e.g., sodium periodate and potassium periodate).In an embodiment, the oxidizing agent is periodate in the presence of bivalent cations (seeWO2008/143709).In an embodiment, the oxidizing agent is periodic acid. In an embodiment, the oxidizing 20agent is periodic acid in the presence of bivalent cations. In an embodiment, the oxidizing agentis periodic acid in the presence of Mg2+. In an embodiment, the oxidizing agent is periodic acid inthe presence of Ca2+. In an embodiment, the oxidizing agent is orthoperiodate.In a preferred embodiment, the oxidizing agent is sodium periodate. In an embodiment,the periodate used for the oxidation is metaperiodate. In an embodiment the periodate used for 25the oxidation is sodium metaperiodate.When a polysaccharide reacts with periodate, periodate oxidises vicinal hydroxyl groups to formcarbonyl or aldehyde groups and causes cleavage of a C-C bond. For this reason, the term"reacting a polysaccharide with periodate" includes oxidation of vicinal hydroxyl groups byperiodate. 30In one embodiment step a) comprises reacting the polysaccharide with 0.01-2 molarequivalents of periodate. In one embodiment step a) comprises reacting the polysaccharide with0.1-1.0 molar equivalents of periodate. In one embodiment step a) comprises reacting thepolysaccharide with 0.1-0.5 molar equivalents of periodate.In an embodiment, the oxidizing agent is a mixture of a stable nitroxyl radical compound 35with an oxidant (see WO2014097099).In an aspect, said stable nitroxyl radical compound is a molecule bearing a TEMPO or aPROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the ability 36to selectively oxidize primary alcohol in the presence of an oxidant, to generate aldehyde groups,without affecting secondary hydroxyl groups. More preferably said molecule has the ability toselectively oxidize primary alcohol in the presence of an oxidant, to generate aldehyde groups,without over oxidation to carboxyl groups. In an aspect, said stable nitroxyl radical compound isTEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 54-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPOfree radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO or 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably saidstable nitroxyl radical compound is TEMPO. In an aspect, said stable nitroxyl radical compoundis selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1- 10piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radical compound is TEMPO. In afurther aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL- 15stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radical compound is selected from thegroups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid,Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl- 202,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL.In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably said molecule has theability to selectively oxidize primary alcohol in the presence of a nitroxyl radical compound. In anaspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide,Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 251,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the group consisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. Preferably said 30oxidant is N-Chlorosuccinimide.In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).In one embodiment, the quenching agent of step a’) is selected from vicinal diols, 1,2-aminoalcohols, amino acids, glutathione, sulfite, bisulfate, dithionite, metabisulfite, thiosulfate, 35phosphites, hypophosphites or phosphorous acid.In one embodiment, the quenching agent is a 1,2-aminoalcohols of formula (I): (I)wherein R is selected from H, methyl, ethyl, propyl or isopropyl.In one embodiment, the quenching agent is selected from sodium and potassium salts ofsulfite, bisulfate, dithionite, metabisulfite, thiosulfate, phosphites, hypophosphites or phosphorousacid. 5In one embodiment, the quenching agent is an amino acid. In such embodiments, saidamino acid may be selected from serine, threonine, cysteine, cystine, methionine, proline,hydroxyproline, tryptophan, tyrosine, and histidine.In one embodiment, the quenching agent is a sulfite such as bisulfate, dithionite,metabisulfite, thiosulfate. 10In one embodiment, the quenching agent is a compound comprising two vicinal hydroxylgroups (vicinal diols), i.e., two hydroxyl groups covalently linked to two adjacent carbon atoms.Preferably, the quenching agent is a compound of formula (II): OH O H RR (II)wherein R and R are each independently selected from H, methyl, ethyl, propyl or isopropyl. 15In a preferred embodiment, the quenching agent is glycerol, ethylene glycol, propan-1,2-diol,butan-1,2-diol or butan-2,3-diol, or ascorbic acid. In an even preferred embodiment, thequenching agent is butan-2,3-diol.In a preferred embodiment the (also named "degree of activation" in the presentdocument) of the activated serotype 38 saccharide is between 2 and 30. In an embodiment the 20degree of oxidation (DO) of the activated serotype 38 polysaccharide is between 10 and 25.In one embodiment the activated saccharide and the carrier protein are lyophilised beforestep b).In an embodiment the initial input ratio (weight by weight) of activated serotype 38saccharide to carrier protein at step b) is between 4:1 and 0.1:1. In an embodiment the initial input 25ratio (weight by weight) of activated serotype 38 saccharide to carrier protein at step b) is between1.5:1 and 0.5:1.In an embodiment, the reduction reaction (c) is carried out in aqueous solvent. In anotherembodiment, the reduction reaction (c) is carried out in aprotic solvent.In an embodiment, the reduction reaction (c) is carried out in the presence of dimethylsulphoxide 30(DMSO) or dimethylformamide (DMF). In an embodiment, the reduction reaction (c) is carried outin the presence of dimethylformamide (DMF). In an embodiment, the reduction reaction (c) iscarried out in the presence of dimethylsulphoxide (DMSO).
N HOH R1 38In one embodiment the reduction reaction (c) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment thereduction reaction (c) is carried out in a solution consisting essentially of dimethylformamide(DMF). In one embodiment the reduction reaction (c) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO). 5In an embodiment, the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide)or in DMF (dimethylformamide)) solvent. In an embodiment, the reduction reaction (c) is carriedout in DMSO (dimethylsulfoxide) solvent.In an embodiment, the reducing agent is sodium cyanoborohydride, sodiumtriacetoxyborohydride, sodium or zinc borohydride in the presence of Bronsted or Lewis acids, 10amine boranes such as pyridine borane, 2-Picoline Borane, 2,6-diborane-methanol,dimethylamine-borane, t-BuMeiPrN-BH3, benzylamine-BH3 or 5-ethyl-2-methylpyridine borane(PEMB). In an embodiment, the reducing agent is sodium triacetoxyborohydride. In a preferredembodiment, the reducing agent is sodium cyanoborohydride. In an embodiment, the reducingagent is sodium cyanoborohydride in the present of nickel (see WO2018144439). 15In one embodiment between 0.2 and 20 molar equivalents of reducing agent is used atstep c). In one embodiment between 0.5 and 10 molar equivalents of reducing agent is used atstep c). In one embodiment between 1.0 and 5 molar equivalents of reducing agent is used atstep c).At the end of the reduction reaction, there may be unreacted aldehyde groups remaining 20in the conjugates, these may be capped using a suitable capping agent. In one embodiment thiscapping agent is sodium borohydride (NaBH4). In an embodiment capping is achieved by mixingthe product of step c) with 1 to 20 molar equivalents of sodium borohydride. In an embodimentcapping is achieved by mixing the product of step c) with 1 to 10 molar equivalents of sodiumborohydride. In an embodiment capping is achieved by mixing the product of step c) with 1 to 5 25molar equivalents of sodium borohydride.
CDI and/or CDT chemistryIn an embodiment, the serotype 38 glycoconjugate of the present invention is prepared byCDI and/or CDT chemistry as disclosed in WO2022249107. 30CDI and/or CDT chemistry involves two steps, (1) reacting the serotype 38 saccharidewith CDI and/or CDT in an aprotic solvent to produce an activated saccharide (activation), (2)reacting the activated saccharide with a carrier protein (e.g. CRM 197, TT or SCP) to form aglycoconjugate.In an embodiment, the activating agent of step (1) is 1,1’-carbonyldiimidazole (CDI). In an 35embodiment, the activating agent of step (1) is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT).As mentioned above, before activation with CDI and/or CDT, sizing of the serotype 38saccharide to a target molecular weight (MW) range can be performed. 39Therefore, in an embodiment, the serotype 38 saccharide is sized before activation with CDI. Inan embodiment, the isolated polysaccharide is sized before activation with CDT. In anembodiment, the serotype 38 saccharide is sized to any of the target molecular weight (MW)range defined above.Therefore, in an embodiment, the serotype 38 saccharide is conjugated to a carrier protein 5by a process comprising the step of:(a) reacting said isolated polysaccharide with CDI and/or CDT in an aprotic solvent;(b) reacting the activated polysaccharide of step (a) with a carrier protein in an aprotic solvent toform a glycoconjugate.Following step (a) the polysaccharide is said to be activated and is referred to as "activated 10polysaccharide".In one embodiment step a) comprises reacting the serotype 38 saccharide with CDI.In one embodiment step a) comprises reacting the serotype 38 saccharide with an amountof CDI that is between 0.5-10 molar equivalent to the amount of serotype 38 saccharide presentin the reaction mixture. 15In one embodiment step a) comprises reacting the serotype 38 saccharide with CDT.In one embodiment step a) comprises reacting the serotype 38 saccharide with an amountof CDT hat is between 0.5-10 molar equivalent to the amount of serotype 38 saccharide presentin the reaction mixture.In an embodiment, the activating reaction a) is carried out in the presence of 20dimethylsulphoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphoramide (HMPA). In an embodiment, the activating reaction a)is carried out in the presence of dimethylsulphoxide (DMSO).In one embodiment the activating reaction a) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment the 25activating reaction a) is carried out in a solution consisting essentially of dimethylsulphoxide(DMSO).In an embodiment, the conjugation reaction b) is carried out in the presence ofdimethylsulphoxide (DMSO), dimethylformamide (DMF), dimethylacetamide, N-methyl-2-pyrrolidone or hexamethylphosphoramide (HMPA). 30In an embodiment, the conjugation reaction b) is carried out in the presence of dimethylsulphoxide(DMSO).In one embodiment the conjugation reaction b) is carried out in a solution consistingessentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment theconjugation reaction b) is carried out in a solution consisting essentially of dimethylsulphoxide 35(DMSO).In one embodiment, weak organic base can be added to the reaction mixture after theactivating reaction a) but before the conjugation reaction b). The weak organic base can be added 40before or after the carrier protein is introduced the reaction mixture. Therefore, in oneembodiment, the weak organic base is added to the reaction mixture before the carrier protein isintroduced. In another embodiment, the weak organic base is added to the reaction mixture afterthe carrier protein is introduced. Weak organic base can be selected from alkanamines, imidazole,triazole, pyridine, histidine and guanidine. Alkanamines include alkyl primary amines such as 5methyl amine, ethylamine, propylamine, isopropylamine; alkyl secondary amines such asdimethyl amine, diethylamine, dipropylamine, diisopropylamine; alkyl tertially amines such astrimethyl amine, triethylamine, tri-isopropylamine, di-N,N’-isopropylethylamine, et al. In anembodiment, the weak organic base is an alkanamine. In an embodiment, the weak organic baseis an imidazole. In an embodiment, the weak organic base is a triazole. In an embodiment, the 10weak organic base is pyridine. In an embodiment, the weak organic base is histidine. In anembodiment, the weak organic base is guanidine.In one embodiment following the conjugation reaction b) unconjugated reactive sites ofthe activated polysaccharide are hydrolyzed. In one embodiment unconjugated reactive sites arehydrolyzed by addition to the conjugation solution of an aqueous solution. In one embodiment 15unconjugated reactive sites are hydrolyzed by addition to the conjugation solution of an aqueousbuffered solution. In one embodiment unconjugated reactive sites are hydrolyzed by addition tothe conjugation solution of an aqueous buffered solution and adjustment of the pH to betweenabout 3.0 to about 10.0. In one embodiment unconjugated reactive sites are hydrolyzed byaddition to the conjugation solution of an aqueous buffered solution and adjustment of the pH to 20between about 7.0 to about 10.0. In one embodiment unconjugated reactive sites are hydrolyzedby addition to the conjugation solution of an aqueous buffered solution and adjustment of the pHto between about 3.0 to about 7.0. In one embodiment unconjugated reactive sites are hydrolyzedby addition to the conjugation solution of an aqueous buffered solution and adjustment of the pHto about 4.0. In one embodiment unconjugated reactive sites are hydrolyzed by addition to the 25conjugation solution of an aqueous buffered solution and adjustment of the pH to about 9.0. eTEC chemistryIn an embodiment, the serotype 38 glycoconjugate of the present invention is prepared byeTEC chemistry as disclosed WO2014027302 30The eTEC spacer includes seven linear atoms (i.e., –C(O)NH(CH2)2SCH2C(O)- ) andprovides stable thioether and amide bonds between the saccharide and carrier protein. Synthesisof the eTEC linked glycoconjugate involves reaction of an activated hydroxyl group of thesaccharide with the amino group of a thioalkylamine reagent, e.g., cystamine or cysteinamine ora salt thereof, forming a carbamate linkage to the saccharide to provide a thiolated saccharide. 35Generation of one or more free sulfhydryl groups is accomplished by reaction with a reducingagent to provide an activated thiolated saccharide. Reaction of the free sulfhydryl groups of theactivated thiolated saccharide with an activated carrier protein having one or more α- 41haloacetamide groups on amine containing residues generates a thioether bond to form theconjugate, wherein the carrier protein is attached to the eTEC spacer through an amide bond.
Therefore, in an embodiment, the serotype 38 glycoconjugate of the present invention comprisesa serotype 38 saccharide covalently conjugated to a carrier protein through a (2-((2- 5oxoethyl)thio)ethyl)carbamate (eTEC) spacer.In an embodiment, the serotype 38 glycoconjugate of the present invention comprises aserotype 38 saccharide conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, wherein the saccharide is covalently linked to theeTEC spacer through a carbamate linkage, and wherein the carrier protein is covalently linked to 10the eTEC spacer through an amide linkage.The eTEC linked glycoconjugates of the invention may be represented by the generalformula (III): (III), where (saccharide)represents the serotype 38 saccharide. 15Formula (III) is a schematic representation of glycoconjugates of the invention. It shouldnot be understood that only one linkage is present between the saccharide and the carrier protein.Rather, an individual carrier protein (CP) molecule may be linked to more than one serotype 38saccharide molecule and an individual saccharide molecule can be linked to more than oneindividual carrier protein (CP) molecule. Additionally, a majority of the saccharide repeating unit 20remains unmodified and covalent linkages between the carrier protein and the saccharide is for aminority of the saccharide repeat units.
Click chemistryIn a preferred embodiment, the serotype 38 glycoconjugate of the present invention is 25prepared by click chemistry (see e.g. PCT/IB2023/050202).Therefore, in an embodiment, the serotype 38 glycoconjugate of the present inventioncomprises a serotype 38 saccharide covalently conjugated to a carrier protein (CP) through aspacer and having the general formula (IV): (IV), 30 42wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0 5to 4,wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units.
In a particular aspect, the invention is directed to a serotype 38 glycoconjugate comprisinga serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 10having the general formula (IV), wherein X is CH2(CH2) n’, where n’ is 2 and wherein X' isCH2O(CH 2)n’’CH 2C=O where n’’ is 1.In a particular aspect, the invention pertains to a serotype 38 glycoconjugate comprisinga serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (V), 15 (V)wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units.Formulas (IV), (V) are schematic representations of glycoconjugates of the invention. Itshould not be understood that a linkage is present at every repeating unit of the saccharide (the 20structure in square brackets). Rather, a majority of the saccharide repeating unit remainsunmodified and covalent linkages between the carrier protein and the saccharide is for a minorityof the saccharide repeat units. Additionally, an individual carrier protein (CP) molecule may belinked to more than one saccharide molecule and an individual saccharide molecule can be linkedto more than one individual carrier protein (CP) molecule. The structure in square brackets 25represents a repeat unit of the serotype 38 saccharide.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is CH 2(CH2)n’, where n’ is selected from 1 to 10 andwerein X' is CH2O(CH 2) n’’CH 2C=O where n’’ is selected from 0 to 10. In an embodiment, n’ is 30selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selectedfrom 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a 43particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yetanother embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet afurther embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In aparticular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a 5further embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet 10another embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a 15particular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a 20further embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is CH 2(CH2)n’, where n’ is selected from 1 to 10 andwerein CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected 25from 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 and 30n’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’ 35is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0. 44In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1 10and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1. 15In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment, 20n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1 25and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2. 30In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment, 35n’ is 4, m’ is 3 and n" is 2. 45In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’ 5is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1 10and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’ 20is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 25 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4. 30In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’ 35is 1, m’ is 3 and n’’ is 5. 46In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment, 5n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is 10 and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 to 15and werein X' is CH2O(CH 2) n’’CH2C=O, where n’’ is selected from 0 to 10. In an embodiment, mis selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 toand n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yet 20another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In a 25particular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yet 30another embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 35having the general formula (IV), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1 toand werein X' is CH2O(CH 2CH2O) m’(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4. 47In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1. 5In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3 10and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ is 15and n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1. 20In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, m 25is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1 30and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2. 35In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2. 48In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, m 5is 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1 10and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3. 15In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ is 20and n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is 25 and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5. 30In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment, 35m is 3, m’ is 3 and n’’ is 5. 49In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 5having the general formula (IV), wherein X is NHCO(CH 2) n’, where n’ is selected from 1 to 10 andwerein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10. In an embodiment, n’ isselected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selectedfrom 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a 10particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yetanother embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet afurther embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In aparticular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a 15further embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet 20another embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a 25particular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a 30further embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2) n’, where n’ is selected from 1 to 10 andwerein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is 35selected from 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected 50from 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3 5and n’’ is 0.In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1 10and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0. 15In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ isand n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’ 20is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1 25and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1. 30In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’ 35is 1, m’ is 3 and n’’ is 2. 51In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’ 5is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ is 10and n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is 25 and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment, 35n’ is 3, m’ is 3 and n’’ is 4. 52In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 and 10n’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and werein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10. In an 25embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 300. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yet 35another embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 53particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 5serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and werein X' is CH2O(CH 2CH2O) m’(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10and m’ is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0 10to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 and 15n’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0. 20In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment, 25m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’ 30is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1. 35In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1. 54In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3 5and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ is 10and n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3. 15In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 20is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is 25 and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment,m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4. 30In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment, 35m is 4, m’ is 3 and n" is 4. 55In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 5 and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is 10 and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is OCH 2(CH2)n’, where n’ is selected from 1 to 10 and 15werein X' is CH2O(CH 2) n’’CH2C=O, where n’’ is selected from 0 to 10.In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ 20is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a 25particular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yetanother embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a 30further embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In aparticular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet 35another embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet afurther embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yet 56another embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is OCH 2(CH2)n’, where n’ is selected from 1 to 10 and 5werein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ is 10selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ is 25and n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’ 35is 3, m’ is 3 and n’’ is 1. 57In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’ 10is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’ 25is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 3. 58In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is 5 and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 10 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4. 15In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 20 and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 25 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5. 30In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (IV), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2)n’’CH2C=O, where n’’ is selected from 0 to 10.In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, 35m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ 59is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In a 5particular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yet 10another embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 15having the general formula (IV), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 andm’ is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selected 20from 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ is 25and n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1 30and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0. 35In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1. 60In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, m 5is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1 10and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’ 25is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, 35m is 1, m’ is 3 and n’’ is 4. 61In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment, 5m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is 10 and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is and n’’ is 5. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 5.In a very preferred embodiment of the present invention, the serotype 38 glycoconjugateof the present invention are prepared using click chemistry. The invention also relates to a methodof making serotype 38 glycoconjugate, as disclosed herein above.In an embodiment, click chemistry may comprise three steps, (a) reacting an isolated 25serotype 38 saccharide with a carbonic acid derivative and an azido linker in an aprotic solventto produce an activated azido saccharide (activation of the saccharide), (b) reacting a carrierprotein with an agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group wherethe NHS moiety reacts with the amino groups to form an amide linkage thereby obtaining analkyne functionalized carrier protein (activation of the carrier protein), (c) reacting the activated 30azido saccharide of step (a) with the activated alkyne-carrier protein of step (b) by Cu+1 mediatedazide-alkyne cycloaddition reaction to form a glycoconjugate.Following step (a) the saccharide is said to be activated and is referred to herein as"activated saccharide" or "activated azido saccharide".Following step (b) the carrier is said to be activated and is referred to as "activated carrier". 35As mentioned above, before the activation (a), sizing of the saccharide to a targetmolecular weight (MW) range may be performed. Therefore, in an embodiment, the isolatedserotype 38 saccharide is sized before activation with a carbonic acid derivative and an azido 62linker. In an embodiment, the isolated serotype 38 saccharide is sized to any of the targetmolecular weight (MW) range defined above. In an embodiment, the isolated serotype 38saccharide is not sized before activation with a carbonic acid derivative and an azido linker.In an embodiment, said carbonic acid derivative is selected from the group consisting of1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), N,N′-Disuccinimidyl 5carbonate (DSC) and N-hydroxysuccinimidyl chloroformate.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Inanother embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). Inanother embodiment, said carbonic acid derivative is N,N′-Disuccinimidyl carbonate (DSC). In yeta further embodiment, said carbonic acid derivative is N-hydroxysuccinimidyl chloroformate. 10In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI) or 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Preferably, said carbonic acid derivative N,N ′-Disuccinimidylcarbonate (DSC).In an embodiment, said azido linker is a compound of formula (VI), 15 (VI)wherein X is selected from the group consisting of CH2(CH2) n, (CH 2CH2O)mCH 2CH2, NHCO(CH2)n,NHCO(CH2CH2O)mCH 2CH2, OCH 2(CH 2)n and O(CH2CH2O)mCH2CH2; where n is selected from 1to 10 and m is selected from 1 to 4.In an embodiment, said azido linker is a compound of formula (VI), wherein X is CH2(CH2)n, 20and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In an embodiment, nis selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In an embodiment, n isselected from 1 to 2. In a particular embodiment, n is 1. In another embodiment, n is 2. In yetanother embodiment, n is 3. In yet a further embodiment, n is 4. In yet a further embodiment, n is5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yet a further 25embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, n is 10.In an embodiment, said azido linker is a compound of formula (VI), wherein X is(CH2CH2O)mCH 2CH2, wherein m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4. 30In an embodiment, said azido linker is a compound of formula (VI), wherein X isNHCO(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a further 35embodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yet 63a further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10.In an embodiment, said azido linker is a compound of formula (VI), wherein X isNHCO(CH2CH2O)mCH 2CH2, where m is selected from 1 to 4. In an embodiment, m is selectedfrom 1 to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In 5another embodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, mis 4.In an embodiment, said azido linker is a compound of formula (VI), wherein X isOCH 2(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In an 10embodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10. 15In an embodiment, said azido linker is a compound of formula (VI), wherein X isO(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4.In an embodiment, said azido linker is a compound of formula (VII), 20 (VII) In a preferred embodiment, said azido linker is 3-azido-propylamine.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a terminal alkyne. 25In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (VIII), (VIII)where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O andCH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to 354.
X 64In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (VIII), wherein X is CH2O(CH 2)nCH2C=O, where n isselected from 0 to 10. In an embodiment, n is selected from 0 to 5. In an embodiment, n isselected from 0 to 4. In an embodiment, n is selected from 0 to 3. In an embodiment, n isselected from 0 to 2. In a particular embodiment, n is 0. In a particular embodiment, n is 1. In 5another embodiment, n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is4. In yet a further embodiment, n is 5. In yet a further embodiment, n is 6. In yet a furtherembodiment, n is 7. In yet a further embodiment, n is 8. In yet a further embodiment, n is 9. Inyet a further embodiment, n is 10.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an 10alkyne group is a compound of formula (VIII), wherein X is CH2O(CH 2CH2O)m(CH2) nCH2C=O,where n is selected from 0 to 10 and m is selected from 0 to 4. In an embodiment, n is selectedfrom 0 to 5. In an embodiment, n is selected from 0 to 4. In an embodiment, n is selected from 0to 3. In an embodiment, n is selected from 0 to 2. In a particular embodiment, n is 0. In a particularembodiment, n is 1. In another embodiment, n is 2. In yet another embodiment, n is 3. In yet a 15further embodiment, n is 4. In yet a further embodiment, n is 5. In yet a further embodiment, n is6. In yet a further embodiment, n is 7. In yet a further embodiment, n is 8. In yet a furtherembodiment, n is 9. In yet a further embodiment, n is 10. In an embodiment, m is selected from 0to 3. In an embodiment, m is selected from 0 to 2. In a particular embodiment, m is 1. In a particularembodiment, m is 1. In another embodiment, m is 2. In yet another embodiment, m is 3. In yet a 20further embodiment, m is 4.In an embodiment, n is selected from 0 to 5 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 5 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 4 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 4 and m is selected from 0 to 2. 25In an embodiment, n is selected from 0 to 3 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 3 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 2 and m is selected from 0 to 3. In an embodiment, nis selected from 0 to 2 and m is selected from 0 to 2.In an embodiment, n is selected from 0 to 1 and m is selected from 0 to 3. In an embodiment, n 30is selected from 0 to 1 and m is selected from 0 to 2.In an embodiment, n is 0 and m is 0. In an embodiment, n is 1 and m is 0. In an embodiment, nis 2 and m is 0. In an embodiment, n is 3 and m is 0. In an embodiment, n is 4 and m is 0. In anembodiment, n is 5 and m is 0. In an embodiment, n is 6 and m is 0. In an embodiment, n is 7and m is 0. In an embodiment, n is 8 and m is 0. In an embodiment, n is 9 and m is 0. In an 35embodiment, n is 10 and m is 0.In an embodiment, n is 0 and m is 1. In an embodiment, n is 1 and m is 1. In an embodiment, nis 2 and m is 1. In an embodiment, n is 3 and m is 1. In an embodiment, n is 4 and m is 1. In an 65embodiment, n is 5 and m is 1. In an embodiment, n is 6 and m is 1. In an embodiment, n is 7and m is 1. In an embodiment, n is 8 and m is 1. In an embodiment, n is 9 and m is 1. In anembodiment, n is 10 and m is 1.In an embodiment, n is 0 and m is 2. In an embodiment, n is 1 and m is 2. In an embodiment, nis 2 and m is 2. In an embodiment, n is 3 and m is 2. In an embodiment, n is 4 and m is 2. In an 5embodiment, n is 5 and m is 2. In an embodiment, n is 6 and m is 2. In an embodiment, n is 7and m is 2. In an embodiment, n is 8 and m is 2. In an embodiment, n is 9 and m is 2. In anembodiment, n is 10 and m is 2.In an embodiment, n is 0 and m is 3. In an embodiment, n is 1 and m is 3. In an embodiment, nis 2 and m is 3. In an embodiment, n is 3 and m is 3. In an embodiment, n is 4 and m is 3. In an 10embodiment, n is 5 and m is 3. In an embodiment, n is 6 and m is 3. In an embodiment, n is 7and m is 3. In an embodiment, n is 8 and m is 3. In an embodiment, n is 9 and m is 3. In anembodiment, n is 10 and m is 3.In an embodiment, n is 0 and m is 4. In an embodiment, n is 1 and m is 4. In an embodiment, nis 2 and m is 4. In an embodiment, n is 3 and m is 4. In an embodiment, n is 4 and m is 4. In an 15embodiment, n is 5 and m is 4. In an embodiment, n is 6 and m is 4. In an embodiment, n is 7and m is 4. In an embodiment, n is 8 and m is 4. In an embodiment, n is 9 and m is 4. In anembodiment, n is 10 and m is 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and analkyne group is a compound of formula (IX): 20 (IX) In an embodiment, step a) comprises reacting the saccharide with a carbonic acidderivative followed by reacting the carbonic acid derivative-activated saccharide with an azidolinker in an aprotic solvent to produce an activated azido saccharide. 25In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.01-10 molar equivalent to the amount of saccharide present inthe reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.1-10 molar equivalent to the amount of saccharide present in the 30reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-5 molar equivalent to the amount of saccharide present in thereaction mixture. 66In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 2-5 molar equivalent to the amount of saccharide present in the 5reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 5-10 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 10acid derivative that is between 0.1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-2 molar equivalent to the amount of saccharide present in thereaction mixture. 15In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.01 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.1 molar equivalent to the amount of saccharide present in the reaction 20mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.2 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 25acid derivative of about 0.5 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 1 molar equivalent to the amount of saccharide present in the reactionmixture. 30In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 2 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 5 molar equivalent to the amount of saccharide present in the reaction 35mixture. 67In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 10 molar equivalent to the amount of saccharide present in the reactionmixture.In an embodiment, at step a) the isolated saccharide is reacted with a carbonic acidderivative in an aprotic solvent. 5In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). Inone embodiment the isolated saccharide is reacted with a carbonic acid derivative in a solutionconsisting essentially of dimethylformamide (DMF). In one embodiment the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of dimethylsulphoxide 10(DMSO).In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylacetamide. In an embodiment, the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative 15in a solution consisting essentially of hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution consisting essentially of dimethylsulphoxide (DMSO).In one embodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment the isolated 20saccharide is reacted with a carbonic acid derivative in dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO).In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative indimethylacetamide. In an embodiment, the isolated saccharide is reacted with a carbonic acid 25derivative in N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted witha carbonic acid derivative in hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with CDI indimethylsulphoxide (DMSO). In an embodiment the isolated saccharide is reacted with CDI inanhydrous DMSO. 30It has been surprisingly found that reacting the isolated saccharide with CDI in anenvironment with a moisture level of about 0.1% to 1% (v/v) allows to avoid side reactions.Therefore, in one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.1% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.1% to 0.5% (v/v) water. In one embodiment the isolated 35saccharide is reacted with CDI in an aprotic solvent comprising 0.1% to 0.2% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising about 0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with 68CDI in an aprotic solvent comprising about 0.2% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.3% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted 5with CDI in an aprotic solvent comprising about 0.6% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.7% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.9% (v/v) water. 10In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.1%to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.1% to 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.1% to 0.2% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about 150.1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.2% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising about 0.3% (v/v) water. In one embodiment the isolated saccharide isreacted with CDI in DMSO comprising about 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising about 0.5% (v/v) water. In one embodiment 20the isolated saccharide is reacted with CDI in DMSO comprising about 0.6% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in DMSO comprising about 0.7% (v/v)water. In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.9% (v/v) water. 25In one embodiment the free carbonic acid derivative is then quenched by the addition ofwater before the addition of the azido linker. Water can inactivate free CDI.Therefore, in an embodiment, carbonic acid derivative activation is followed by the addition ofwater. In an embodiment, water is added to bring the total water content in the mixture to betweenabout 1% to about 10% (v/v). In an embodiment, water is added to bring the total water content 30in the mixture to between about 1% to about 5% (v/v). In an embodiment, water is added to bringthe total water content in the mixture to about 1 % (v/v). In an embodiment, water is added tobring the total water content in the mixture to about 2% (v/v). In an embodiment, water is addedto bring the total water content in the mixture to about 5% (v/v).Once the saccharide has been reacted with carbonic acid derivative and following an 35eventual quenching of carbonic acid derivative with water, the carbonic acid derivative-activatedsaccharide is reacted with an azido linker. 69In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 0.01-10 molar equivalent tothe amount of polysaccharide Repeat Unit of the activated saccharide (molar equivalent of RU).In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 0.1-5 molar equivalent to the 5amount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of azido linker that is between 0.5-2 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative- 10activated saccharide with an amount of azido linker that is between 1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In the above embodiements, said carbonic acid derivative may be CDI. In anotherembodiment, said carbonic acid derivative is CDT. In a preferred embodiment, said carbonic acidderivative is DSC (N,N′-Disuccinimidyl carbonate). 15In one embodiment the degree of activation of the activated saccharide following step a)is between 1.0 to 100%. The degree of activation of the azido saccharide being defined as thepercentage of Repeating Unit linked to an azido linker.In one embodiment the degree of activation of the activated saccharide following step a)is between 5 to 70%. In another embodiment the degree of activation of the activated saccharide 20following step a) is between 5 to 50%.In a preferred embodiment the degree of activation of the activated saccharide followingstep a) is between 15 to 50%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 10 to 40%. 25In another embodiment the degree of activation of the activated saccharide following stepa) is between 5 to 15%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 15 to 35%.In a preferred embodiment the degree of activation of the activated saccharide following 30step a) is between 15 to 50%.In an embodiment the degree of activation of the activated saccharide following step a) isabout 25%.In an embodiment the degree of activation of the activated saccharide following step a) isabout 30%. 35In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 0.1-10 molarequivalents to the lysines on the carrier. 70In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 0.5-10 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 1-5 molar equivalents 5to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 2-5 molar equivalentsto the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 10bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 5-10 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is 1-5 molar equivalentsto the lysines on the carrier. 15In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 10 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 5 molar 20equivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 2 molarequivalents to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 25bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 1 molarequivalent to the lysines on the carrier.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 0.5 molarequivalents to the lysines on the carrier. 30In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group that is about 0.1 molarequivalents to the lysines on the carrier.In one embodiment the degree of activation of the activated carrier following step b) isbetween 1 and 50. The degree of activation of the activated carrier being defined as the number 35of lysine residues in the carrier protein that become linked to the agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group . 71In an embodiment, the carrier protein is CRM 197, which contains 39 lysine residues. In saidembodiment the degree of activation of the activated carrier following step b) may be between 1to 30. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is between 5 to 20. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is between 9 to 18. In another embodiment the degree of activation of 5the activated carrier (CRM 197) following step b) is between 8 to 11. In another embodiment thedegree of activation of the activated carrier (CRM 197) following step b) is between 15 to 20. Inanother embodiment the degree of activation of the activated carrier (CRM 197) following step b) isabout 5. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 6. In another embodiment the degree of activation of the activated carrier 10(CRM 197) following step b) is about 7. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 8. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 9. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 10. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about 1511. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 12. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 13. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 14. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 15. In another embodiment 20the degree of activation of the activated carrier (CRM 197) following step b) is about 16. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about17. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 18. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 19. In another embodiment the degree of activation of the 25activated carrier (CRM 197) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 21. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 22. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about23. In another embodiment the degree of activation of the activated carrier (CRM 197) following 30step b) is about 24. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 25.In an embodiment, the carrier protein is SCP or a fragment thereof. In said embodimentthe degree of activation of the activated carrier following step b) may be between 1 to 50. Inanother embodiment the degree of activation of the activated carrier (SCP) following step b) is 35between 5 to 50. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is between 7 to 45. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is between 5 to 25. In another embodiment the degree 72of activation of the activated carrier (SCP) following step b) is between 10 to 25. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is betweento 22. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 5. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 7. In another embodiment the degree of activation of the activated carrier 5(SCP) following step b) is about 10. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is about 13. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 15. In another embodiment thedegree of activation of the activated carrier (SCP) following step b) is about 20. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is about 26. 10In another embodiment the degree of activation of the activated carrier (SCP) following step b) isabout 30. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 35. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 37. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is about 40. In another embodiment the degree of activation of the 15activated carrier (SCP) following step b) is about 45. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 50.In an embodiment, the carrier protein is TT or a fragment thereof. In said embodiment thedegree of activation of the activated carrier following step b) may be between 1 to 30. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is between 5 20to 25. In another embodiment the degree of activation of the activated carrier (TT) following stepb) is between 7 to 25. In another embodiment the degree of activation of the activated carrier (TT)following step b) is between 10 to 20. In another embodiment the degree of activation of theactivated carrier (TT) following step b) is about 5. In another embodiment the degree of activationof the activated carrier (TT) following step b) is about 7. In another embodiment the degree of 25activation of the activated carrier (TT) following step b) is about 10. In another embodiment thedegree of activation of the activated carrier (TT) following step b) is about 12. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is about 15. Inanother embodiment the degree of activation of the activated carrier (TT) following step b) is about20. In another embodiment the degree of activation of the activated carrier (TT) following step b) 30is about 25. In another embodiment the degree of activation of the activated carrier (TT) followingstep b) is about 30.In an embodiment, the conjugation reaction c) is carried out in aqueous buffer. In anembodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence of copper(I) as catalyst. In an embodiment, the conjugation reaction c) is carried out in aqueous buffer in 35the presence an oxidant and of copper (I) as catalyst. In a preferred embodiment, the conjugationreaction c) is carried out in aqueous buffer in the presence of copper (I) as catalyst and ascorbateas oxidant. In an embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and 73aminoguanidine may be further added to protect the protein from side reactions. Therefore, in apreferred embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presenceof copper (I) as catalyst and ascorbate as oxidant, wherein the reaction mixture further comprisesTHPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.In an embodiment the initial input ratio (weight by weight) of activated azido saccharide to 5activated alkyne-carrier at setp c) is between 0.1 and 3. In an embodiment the initial input ratio(weight by weight) of activated azido saccharide to activated alkyne-carrier at setp c) is between0.5 and 2. In an embodiment the initial input ratio (weight by weight) of activated azido saccharideto activated alkyne-carrier at setp c) is between 0.6 and 1.5. In a preferred embodiment the initialinput ratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at setp c) 10is between 0.8 and 1. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at setp c) is about 0.5. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at setp c) is about0.6. In an embodiment the initial input ratio (weight by weight) of activated azido saccharide toactivated alkyne-carrier at setp c) is about 0.7. In an embodiment the initial input ratio (weight by 15weight) of activated azido saccharide to activated alkyne-carrier at setp c) is about 0.8. In anembodiment the initial input ratio (weight by weight) of activated azido saccharide to activatedalkyne-carrier at setp c) is about 0.9. In an embodiment the initial input ratio (weight by weight) ofactivated azido saccharide to activated alkyne-carrier at setp c) is about 1. In an embodiment theinitial input ratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at 20setp c) is about 1.1. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at setp c) is about 1.2. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at setp c) is about1.3. In an embodiment the initial input ratio (weight by weight) of activated azido saccharide toactivated alkyne-carrier at setp c) is about 1.4. In an embodiment the initial input ratio (weight by 25weight) of activated azido saccharide to activated alkyne-carrier at setp c) is about 1.5. In anembodiment the initial input ratio (weight by weight) of activated azido saccharide to activatedalkyne-carrier at setp c) is about 1.6. In an embodiment the initial input ratio (weight by weight) ofactivated azido saccharide to activated alkyne-carrier at setp c) is about 1.7. In an embodimentthe initial input ratio (weight by weight) of activated azido saccharide to activated alkyne-carrier 30at setp c) is about 1.8. In an embodiment the initial input ratio (weight by weight) of activated azidosaccharide to activated alkyne-carrier at setp c) is about 1.9. In an embodiment the initial inputratio (weight by weight) of activated azido saccharide to activated alkyne-carrier at setp c) is about2.Following the click conjugation reaction, there may remain unreacted azido groups in the 35conjugates, these may be capped using a suitable azido group capping agent. Therefore, in anembodiment, following step c), unreacted azido groups in the conjugates, are capped using asuitable azido group capping agent. In one embodiment this azido group capping agent is an 74agent bearing an alkyne group. In one embodiment this azido group capping agent is an agentbearing a terminal alkyne. In one embodiment this azido group capping agent is an agent bearinga cycloalkyne.In an embodiment, said azido group capping agent is a compound of formula (X), (X) 5wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this azido group capping agent is propargyl alcohol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted azido groups remained in the conjugates with an azido group cappingagent. 10In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.05 to 20 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.1 to 15 molar equivalents to the amount of polysaccharide 15repeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 10 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 20of capping agent that is between 0.5 to 5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 2 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 25In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 1 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide repeat 30unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.75 to 1.5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 35of capping agent that is about 1 molar equivalent to the amount of polysaccharide repeat unit ofthe activated saccharide. 75In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1.5 molar equivalent to the amount of polysaccharide repeat unitof the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 0.5 molar equivalent to the amount of polysaccharide repeat unit 5of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 2 molar equivalents to the amount of polysaccharide repeat unit ofthe activated saccharide.Following the click conjugation reaction, unreacted alkyne groups may remain present in 10the conjugates, these may be capped using a suitable alkyne group capping agent. In oneembodiment this alkyne group capping agent is an agent bearing an azido group.In an embodiment, said alkyne group capping agent is a compound of formula (XI), (XI)wherein X is (CH2)n wherein n is selected from 1 to 15. 15In one embodiment this alkyne group capping agent is 3-azido-1-propanol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted alkyne groups remained in the conjugates with an alkyne group cappingagent.In an embodiment the capping of the unreacted alkyne groups is performed with an 20amount of capping agent that is between 0.05 to 20 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.1 to 15 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 25In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 10 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 5 molar equivalents to the amount of 30polysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 2 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 35amount of capping agent that is between 0.5 to 1 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 76In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide 5repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1.5 to 2.5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 10amount of capping agent that about 0.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide. 15In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2 molar equivalents to the amount of polysaccharide repeat 20unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2.5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 25amount of capping agent that about 5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.Following conjugation to the carrier protein, the glycoconjugate can be purified (enrichedwith respect to the amount of saccharide-protein conjugate) by a variety of techniques known tothe skilled person. These techniques include dialysis, concentration/diafiltration operations, 30tangential flow filtration precipitation/elution, column chromatography (DEAE or hydrophobicinteraction chromatography), and depth filtration. Therefore, in one embodiment the process forproducing the glycoconjugate of the present invention comprises the step of purifying theglycoconjugate after it is produced.In an aspect, the invention provides a serotype 38 glycoconjugate produced according to 35any of the methods disclosed herein. 77Alternative click chemistryIn an embodiment of the present invention, the serotype 38 glycoconjugate of the presentinvention is prepared by alternative click chemistry as disclosed e.g. in application No.PCT/IB2024/051122 (filed on February 07, 2024).Therefore, in an embodiment, the serotype 38 glycoconjugate of the present invention 5comprises a serotype 38 saccharide covalently conjugated to a carrier protein (CP) through aspacer and having the general formula (XII): (XII),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ is 10selected from 0 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2(CH2)n", CH2O(CH 2)n’’CH2,CH2O(CH 2CH2O)m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selected from 0 to 4and wherein the structure in square backet represents a repeat unit of the serotype 38 saccharideand wherein n represents the number of repeating units. 15In a particular aspect, the invention is directed to a serotype 38 glycoconjugate comprisinga serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is CH2(CH2) n’, where n’ is 0 and wherein X' isCH2(CH2) n" where n’’ is 0.In a particular aspect, the invention pertains to a serotype 38 glycoconjugate comprising 20a serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XIII), (XIII) 78wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units.Formulas (XII) and (XIII) are schematic representations of glycoconjugates of theinvention. It should not be understood that a linkage is present at every repeating unit of thesaccharide (the structure in square brackets). Rather, a majority of the saccharide repeating unit 5remains unmodified and covalent linkages between the carrier protein and the saccharide is for aminority of the saccharide repeat units. Additionally, an individual carrier protein (CP) moleculemay be linked to more than one saccharide molecule and an individual saccharide molecule canbe linked to more than one individual carrier protein (CP) molecule. The structure in squarebrackets represents a repeat unit of the serotype 38 saccharide. 10In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 andwherein X' is CH2(CH2) n" where n’’ is selected from 0 to 10. In an embodiment, n’ is selected fromto 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 0 to 5 and n’’ is 15selected from 0 to 5. In an embodiment, n’ is selected from 0 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 0 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 0 and n’’ is 0. In a particular embodiment, n’ is 1 and n’’ is 0. In anotherembodiment, n’ is 2 and n’’ is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a furtherembodiment, n’ is 4 and n" is 0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further 20embodiment, n’ is 6 and n" is 0. In a particular embodiment, n’ is à and n’’ is 1. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1 and n’’ is 2. In another 25embodiment, n’ is 2 and n’’ is 2. In yet another embodiment, n’ is 3 and n’’ is 2. In yet a furtherembodiment, n’ is 4 and n" is 2. In yet a further embodiment, n’ is 5 and n" is 2. In yet a furtherembodiment, n’ is 6 and n" is 2. In a particular embodiment, n’ is 0 and n’’ is 3. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a further 30embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particularembodiment, n’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1 and n’’ is 4. In anotherembodiment, n’ is 2 and n’’ is 4. In yet another embodiment, n’ is 3 and n’’ is 4. In yet a furtherembodiment, n’ is 4 and n" is 4. In yet a further embodiment, n’ is 5 and n" is 4. In yet a furtherembodiment, n’ is 6 and n" is 4. In a particular embodiment, n’ is 0 and n’’ is 5. In a particular 35embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet anotherembodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a furtherembodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particular 79embodiment, n’ is 0 and n’’ is 6. In a particular embodiment, n’ is 1 and n’’ is 6. In anotherembodiment, n’ is 2 and n’’ is 6. In yet another embodiment, n’ is 3 and n’’ is 6. In yet a furtherembodiment, n’ is 4 and n" is 6. In yet a further embodiment, n’ is 5 and n" is 6. In yet a furtherembodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 5serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 andwherein X' is CH2O(CH 2) n’’CH2 where n’’ is selected from 0 to 10. In an embodiment, n’ is selectedfrom 0 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 0 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 0 to 3 and n’’ is selected from 0 to 3. 10In an embodiment, n’ is selected from 0 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 0 and n’’ is 0. In a particular embodiment, n’ is 1 and n’’ is 0. In anotherembodiment, n’ is 2 and n’’ is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a furtherembodiment, n’ is 4 and n" is 0. In yet a further embodiment, n’ is 5 and n" is 0. In yet a furtherembodiment, n’ is 6 and n" is 0. In a particular embodiment, n’ is à and n’’ is 1. In a particular 15embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1 and n’’ is 2. In anotherembodiment, n’ is 2 and n’’ is 2. In yet another embodiment, n’ is 3 and n’’ is 2. In yet a further 20embodiment, n’ is 4 and n" is 2. In yet a further embodiment, n’ is 5 and n" is 2. In yet a furtherembodiment, n’ is 6 and n" is 2. In a particular embodiment, n’ is 0 and n’’ is 3. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a furtherembodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particular 25embodiment, n’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1 and n’’ is 4. In anotherembodiment, n’ is 2 and n’’ is 4. In yet another embodiment, n’ is 3 and n’’ is 4. In yet a furtherembodiment, n’ is 4 and n" is 4. In yet a further embodiment, n’ is 5 and n" is 4. In yet a furtherembodiment, n’ is 6 and n" is 4. In a particular embodiment, n’ is 0 and n’’ is 5. In a particularembodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet another 30embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a furtherembodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particularembodiment, n’ is 0 and n’’ is 6. In a particular embodiment, n’ is 1 and n’’ is 6. In anotherembodiment, n’ is 2 and n’’ is 6. In yet another embodiment, n’ is 3 and n’’ is 6. In yet a furtherembodiment, n’ is 4 and n" is 6. In yet a further embodiment, n’ is 5 and n" is 6. In yet a further 35embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 80having the general formula (XII), wherein X is CH 2(CH2)n’, where n’ is selected from 0 to 10 andwherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 0 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 0 to 5, m’ is selected from 0 to 4 and n’’ is selected 5from 0 to 5. In an embodiment, n’ is selected from 0 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 0 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1. In an embodiment, n’ is selected from 0 to 1, m’ is selected from 0 to 1and n’’ is selected from 0 to 1.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 0. In another embodiment, n’ is 0, m’ is 1 and 10n’’ is 0. In another embodiment, n’ is 0, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ is 25and n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 1. 30In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1.In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3 35and n’’ is 1. 81In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 0, m’ is 1 10and n’’ is 2. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 2.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ is 25and n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 3. 30In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3 35and n’’ is 3. 82In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ isand n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 0, m’ is 1 10and n’’ is 4. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 4.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment, 20n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is 25and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4.In a particular embodiment, n’ is 0, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 0, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 0, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 0, m’ is 3 and n’’ is 5. 30In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 and n’’is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 3 35and n’’ is 5. 83In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment, 5n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ isand n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 10serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 to 3and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selected 15from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yetanother embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In a 20particular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yet 25another embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6. 30In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2) n’’CH2, where n’’ is selected from 0 to 10. In an embodiment, mis selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 to 35and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yet 84another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In a 5particular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yet 10another embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 15having the general formula (XII), wherein X is (CH 2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2) n’’CH2, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selected 20from 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ is 25and n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1 30and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0. 35In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1. 85In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, m 5is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1 10and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’ 25is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is 1and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, m 35is 1, m’ is 3 and n’’ is 4. 86In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 and n’’is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ is 3and n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is 1and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment, m 5is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ isand n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4.In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is 1 10and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment, mis 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 and n’’is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 3and n’’ is 5. 15In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is 1and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment, mis 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ isand n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment, 20m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 andwherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 25to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yet anotherembodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet a further 30embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet another 35embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet a furtherembodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet another 87embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a furtherembodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particularembodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yet anotherembodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet a furtherembodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a particular 5embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet anotherembodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a furtherembodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particularembodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yet anotherembodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a further 10embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (VII), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2)n’’CH2, where n’’ is selected from 0 to 10. In an embodiment, n’ is selected 15from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment, n’ is selected from 1 to 5 and n’’ isselected from 0 to 5. In an embodiment, n’ is selected from 1 to 3 and n’’ is selected from 0 to 3.In an embodiment, n’ is selected from 1 to 2 and n’’ is selected from 0 to 2. In a particularembodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’ is 0. In yet anotherembodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 0. In yet a further 20embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0. In a particularembodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yet anotherembodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet a furtherembodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In a particularembodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet another 25embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet a furtherembodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In a particularembodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yet anotherembodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet a furtherembodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a particular 30embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yet anotherembodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet a furtherembodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In a particularembodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yet anotherembodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a further 35embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In a particularembodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yet another 88embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet a furtherembodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is NHCO(CH2) n’, where n’ is selected from 1 to 10 and 5wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ is 10selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 andn’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ is 25and n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’ 35is 3, m’ is 3 and n’’ is 1. 89In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ isand n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2.In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’ 10is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 2. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’ 25is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 3. 90In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 andn’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is 5 and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 10 and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 4. 15In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 20 and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 25 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5. 30In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. In an embodiment, mis selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m is selected from 1 to 35and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected from 0 to 2. In aparticular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’ is 0. In yet 91another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is 0. In aparticular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In yetanother embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In a 5particular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yet 10another embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 15having the general formula (XII), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selectedfrom 1 to 4 and wherein X' is CH2O(CH 2) n’’CH 2, where n’’ is selected from 0 to 10. In anembodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, m isselected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1 to 2and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected 20from 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 25another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 30particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 35serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is NHCO(CH 2CH2O)mCH2CH2, where m is selected 92from 1 to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10and m’ is selected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ is 5selected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 andn’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0. 10In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0.In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, m 15is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1 20and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, mis 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1. 25In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment, 30m is 4, m’ is 3 and n" is 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’ 35is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3and n’’ is 2. 93In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ isand n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment, 5m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3.In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’ 10is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, mis 3, m’ is 3 and n’’ is 3. 15In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, 20m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is 25 and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4. 30In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 35 and n’’ is 5. 94In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment, 5m is 4, m’ is 3 and n" is 5.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10. 10In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 150. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet 20another embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a 25particular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a 30further embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 35serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2) n’’CH 2, where n’’ is selected from 0 to 10. 95In an embodiment, n’ is selected from 1 to 5 and n’’ is selected from 0 to 10. In an embodiment,n’ is selected from 1 to 5 and n’’ is selected from 0 to 5. In an embodiment, n’ is selected from 1to 3 and n’’ is selected from 0 to 3. In an embodiment, n’ is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, n’ is 1 and n’’ is 0. In another embodiment, n’ is 2 and n’’is 0. In yet another embodiment, n’ is 3 and n’’ is 0. In yet a further embodiment, n’ is 4 and n" is 50. In yet a further embodiment, n’ is 5 and n" is 0. In yet a further embodiment, n’ is 6 and n" is 0.In a particular embodiment, n’ is 1 and n’’ is 1. In another embodiment, n’ is 2 and n’’ is 1. In yetanother embodiment, n’ is 3 and n’’ is 1. In yet a further embodiment, n’ is 4 and n" is 1. In yet afurther embodiment, n’ is 5 and n" is 1. In yet a further embodiment, n’ is 6 and n" is 1. In aparticular embodiment, n’ is 1 and n’’ is 2. In another embodiment, n’ is 2 and n’’ is 2. In yet 10another embodiment, n’ is 3 and n’’ is 2. In yet a further embodiment, n’ is 4 and n" is 2. In yet afurther embodiment, n’ is 5 and n" is 2. In yet a further embodiment, n’ is 6 and n" is 2. In aparticular embodiment, n’ is 1 and n’’ is 3. In another embodiment, n’ is 2 and n’’ is 3. In yetanother embodiment, n’ is 3 and n’’ is 3. In yet a further embodiment, n’ is 4 and n" is 3. In yet afurther embodiment, n’ is 5 and n" is 3. In yet a further embodiment, n’ is 6 and n" is 3. In a 15particular embodiment, n’ is 1 and n’’ is 4. In another embodiment, n’ is 2 and n’’ is 4. In yetanother embodiment, n’ is 3 and n’’ is 4. In yet a further embodiment, n’ is 4 and n" is 4. In yet afurther embodiment, n’ is 5 and n" is 4. In yet a further embodiment, n’ is 6 and n" is 4. In aparticular embodiment, n’ is 1 and n’’ is 5. In another embodiment, n’ is 2 and n’’ is 5. In yetanother embodiment, n’ is 3 and n’’ is 5. In yet a further embodiment, n’ is 4 and n" is 5. In yet a 20further embodiment, n’ is 5 and n" is 5. In yet a further embodiment, n’ is 6 and n" is 5. In aparticular embodiment, n’ is 1 and n’’ is 6. In another embodiment, n’ is 2 and n’’ is 6. In yetanother embodiment, n’ is 3 and n’’ is 6. In yet a further embodiment, n’ is 4 and n" is 6. In yet afurther embodiment, n’ is 5 and n" is 6. In yet a further embodiment, n’ is 6 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 25serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is OCH2(CH2)n’, where n’ is selected from 1 to 10 andwherein X' is CH2O(CH 2CH2O) m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selectedfrom 0 to 4.In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selected from 0 30to 10. In an embodiment, n’ is selected from 1 to 5, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, n’ is selected from 1 to 3, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, n’ is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 0. In another embodiment, n’ is 1, m’ is 1 and 35n’’ is 0. In another embodiment, n’ is 1, m’ is 2 and n’’ is 0. In another embodiment, n’ is 1, m’ is 3and n’’ is 0. 96In another embodiment, n’ is 2, m’ is 0 and n’’ is 0. In another embodiment, n’ is 2, m’ is 1 and n’’is 0. In another embodiment, n’ is 2, m’ is 2 and n’’ is 0. In another embodiment, n’ is 2, m’ is 3and n’’ is 0.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 0. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 0. In yet another embodiment, n’ 5is 3, m’ is 3 and n’’ is 0.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 4, m’ isand n" is 0. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 0.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 0. In yet a further embodiment, n’ is 5, m’ is 10and n" is 0.In yet a further embodiment, n’ is 5, m’ is 2 and n" is 0. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 0.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 1. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 1. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 1. 15In another embodiment, n’ is 2, m’ is 0 and n’’ is 1. In another embodiment, n’ is 2, m’ is 1 and n’’is 1. In another embodiment, n’ is 2, m’ is 2 and n’’ is 1. In another embodiment, n’ is 2, m’ is 3and n’’ is 1.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 1. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 1. In yet another embodiment, n’ 20is 3, m’ is 3 and n’’ is 1.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 4, m’ isand n" is 1. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 1.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 1. In yet a further embodiment, n’ is 5, m’ is 25and n" is 1. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 1. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 1.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 2. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 2. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 2. 30In another embodiment, n’ is 2, m’ is 0 and n’’ is 2. In another embodiment, n’ is 2, m’ is 1 and n’’is 2. In another embodiment, n’ is 2, m’ is 2 and n’’ is 2. In another embodiment, n’ is 2, m’ is 3and n’’ is 2.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 2. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 2. In yet another embodiment, n’ 35is 3, m’ is 3 and n’’ is 2. 97In yet a further embodiment, n’ is 4, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 4, m’ isand n" is 2. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 2. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 2.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 2. In yet a further embodiment, n’ is 5, m’ isand n" is 2. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 2. In yet a further embodiment, 5n’ is 5, m’ is 3 and n" is 2.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 3. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 3. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 3.In another embodiment, n’ is 2, m’ is 0 and n’’ is 3. In another embodiment, n’ is 2, m’ is 1 and n’’ 10is 3. In another embodiment, n’ is 2, m’ is 2 and n’’ is 3. In another embodiment, n’ is 2, m’ is 3and n’’ is 3.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 1and n’’ is 3. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 3. In yet another embodiment, n’is 3, m’ is 3 and n’’ is 3. 15In yet a further embodiment, n’ is 4, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 4, m’ isand n" is 3. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 3. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 3.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 3. In yet a further embodiment, n’ is 5, m’ is and n" is 3. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 3. In yet a further embodiment, 20n’ is 5, m’ is 3 and n" is 3.In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 4. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 4. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 4.In another embodiment, n’ is 2, m’ is 0 and n’’ is 4. In another embodiment, n’ is 2, m’ is 1 and 25n’’ is 4. In another embodiment, n’ is 2, m’ is 2 and n’’ is 4. In another embodiment, n’ is 2, m’ is and n’’ is 4.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 4. In yet another embodiment, n’ is 3, m’ is and n’’ is 4. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 4. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 4. 30In yet a further embodiment, n’ is 4, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 4, m’ is and n" is 4. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 4. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 4.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 4. In yet a further embodiment, n’ is 5, m’ is and n" is 4. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 4. In yet a further embodiment, 35n’ is 5, m’ is 3 and n" is 4. 98In a particular embodiment, n’ is 1, m’ is 0 and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 1and n’’ is 5. In a particular embodiment, n’ is 1, m’ is 2 and n’’ is 5. In a particular embodiment, n’is 1, m’ is 3 and n’’ is 5.In another embodiment, n’ is 2, m’ is 0 and n’’ is 5. In another embodiment, n’ is 2, m’ is 1 andn’’ is 5. In another embodiment, n’ is 2, m’ is 2 and n’’ is 5. In another embodiment, n’ is 2, m’ is 5 and n’’ is 5.In yet another embodiment, n’ is 3, m’ is 0 and n’’ is 5. In yet another embodiment, n’ is 3, m’ is and n’’ is 5. In yet another embodiment, n’ is 3, m’ is 2 and n’’ is 5. In yet another embodiment,n’ is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, n’ is 4, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 10 and n" is 5. In yet a further embodiment, n’ is 4, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 4, m’ is 3 and n" is 5.In yet a further embodiment, n’ is 5, m’ is 0 and n" is 5. In yet a further embodiment, n’ is 5, m’ is and n" is 5. In yet a further embodiment, n’ is 5, m’ is 2 and n" is 5. In yet a further embodiment,n’ is 5, m’ is 3 and n" is 5. 15In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2(CH2) n", where n’’ is selected from 0 to 10.In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment, 20m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selectedfrom 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. In 25yet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yetanother embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In a 30particular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In aparticular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yet 35another embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising aserotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer and 99having the general formula (XII), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2)n’’CH2, where n’’ is selected from 0 to 10.In an embodiment, m is selected from 1 to 3 and n’’ is selected from 0 to 10. In an embodiment,m is selected from 1 to 3 and n’’ is selected from 0 to 5. In an embodiment, m is selected from 1to 2 and n’’ is selected from 0 to 3. In an embodiment, m is selected from 1 to 2 and n’’ is selected 5from 0 to 2. In a particular embodiment, m is 1 and n’’ is 0. In another embodiment, m is 2 and n’’is 0. In yet another embodiment, m is 3 and n’’ is 0. In yet a further embodiment, m is 4 and n" is0. In a particular embodiment, m is 1 and n’’ is 1. In another embodiment, m is 2 and n’’ is 1. Inyet another embodiment, m is 3 and n’’ is 1. In yet a further embodiment, m is 4 and n" is 1. In aparticular embodiment, m is 1 and n’’ is 2. In another embodiment, m is 2 and n’’ is 2. In yet 10another embodiment, m is 3 and n’’ is 2. In yet a further embodiment, m is 4 and n" is 2. In aparticular embodiment, m is 1 and n’’ is 3. In another embodiment, m is 2 and n’’ is 3. In yetanother embodiment, m is 3 and n’’ is 3. In yet a further embodiment, m is 4 and n" is 3. In aparticular embodiment, m is 1 and n’’ is 4. In another embodiment, m is 2 and n’’ is 4. In yetanother embodiment, m is 3 and n’’ is 4. In yet a further embodiment, m is 4 and n" is 4. In a 15particular embodiment, m is 1 and n’’ is 5. In another embodiment, m is 2 and n’’ is 5. In yetanother embodiment, m is 3 and n’’ is 5. In yet a further embodiment, m is 4 and n" is 5. In aparticular embodiment, m is 1 and n’’ is 6. In another embodiment, m is 2 and n’’ is 6. In yetanother embodiment, m is 3 and n’’ is 6. In yet a further embodiment, m is 4 and n" is 6.In an embodiment, the invention provides a serotype 38 glycoconjugate comprising a 20serotype 38 saccharide covalently conjugated to a carrier protein (CP) through a spacer andhaving the general formula (XII), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1to 4 and wherein X' is CH2O(CH 2CH2O) m’(CH2) n’’CH2, where n’’ is selected from 0 to 10 and m’ isselected from 0 to 4.In an embodiment, m is selected from 1 to 3, m’ is selected from 0 to 4 and n’’ is selected from 0 25to 10. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 4 and n’’ is selectedfrom 0 to 5. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 and n’’ isselected from 0 to 3. In an embodiment, m is selected from 1 to 2, m’ is selected from 0 to 2 andn’’ is selected from 0 to 1.In a particular embodiment, m is 1, m’ is 0 and n’’ is 0. In another embodiment, m is 1, m’ is 1 and 30n’’ is 0. In another embodiment, m is 1, m’ is 2 and n’’ is 0. In another embodiment, m is 1, m’ isand n’’ is 0.In another embodiment, m is 2, m’ is 0 and n’’ is 0. In another embodiment, m is 2, m’ is 1 and n’’is 0. In another embodiment, m is 2, m’ is 2 and n’’ is 0. In another embodiment, m is 2, m’ is 3and n’’ is 0. 35In yet another embodiment, m is 3, m’ is 0 and n’’ is 0. In yet another embodiment, m is 3, m’ is 1and n’’ is 0. In yet another embodiment, m is 3, m’ is 2 and n’’ is 0. In yet another embodiment, mis 3, m’ is 3 and n’’ is 0. 100In yet a further embodiment, m is 4, m’ is 0 and n" is 0. In yet a further embodiment, m is 4, m’ isand n" is 0. In yet a further embodiment, m is 4, m’ is 2 and n" is 0. In yet a further embodiment,m is 4, m’ is 3 and n" is 0.In a particular embodiment, m is 1, m’ is 0 and n’’ is 1. In a particular embodiment, m is 1, m’ is 1and n’’ is 1. In a particular embodiment, m is 1, m’ is 2 and n’’ is 1. In a particular embodiment, m 5is 1, m’ is 3 and n’’ is 1.In another embodiment, m is 2, m’ is 0 and n’’ is 1. In another embodiment, m is 2, m’ is 1 and n’’is 1. In another embodiment, m is 2, m’ is 2 and n’’ is 1. In another embodiment, m is 2, m’ is 3and n’’ is 1.In yet another embodiment, m is 3, m’ is 0 and n’’ is 1. In yet another embodiment, m is 3, m’ is 1 10and n’’ is 1. In yet another embodiment, m is 3, m’ is 2 and n’’ is 1. In yet another embodiment, mis 3, m’ is 3 and n’’ is 1.In yet a further embodiment, m is 4, m’ is 0 and n" is 1. In yet a further embodiment, m is 4, m’ isand n" is 1. In yet a further embodiment, m is 4, m’ is 2 and n" is 1. In yet a further embodiment,m is 4, m’ is 3 and n" is 1. 15In a particular embodiment, m is 1, m’ is 0 and n’’ is 2. In a particular embodiment, m is 1, m’ is 1and n’’ is 2. In a particular embodiment, m is 1, m’ is 2 and n’’ is 2. In a particular embodiment, mis 1, m’ is 3 and n’’ is 2.In another embodiment, m is 2, m’ is 0 and n’’ is 2. In another embodiment, m is 2, m’ is 1 and n’’is 2. In another embodiment, m is 2, m’ is 2 and n’’ is 2. In another embodiment, m is 2, m’ is 3 20and n’’ is 2.In yet another embodiment, m is 3, m’ is 0 and n’’ is 2. In yet another embodiment, m is 3, m’ is 1and n’’ is 2. In yet another embodiment, m is 3, m’ is 2 and n’’ is 2. In yet another embodiment, mis 3, m’ is 3 and n’’ is 2.In yet a further embodiment, m is 4, m’ is 0 and n" is 2. In yet a further embodiment, m is 4, m’ is 25and n" is 2. In yet a further embodiment, m is 4, m’ is 2 and n" is 2. In yet a further embodiment,m is 4, m’ is 3 and n" is 2.In a particular embodiment, m is 1, m’ is 0 and n’’ is 3. In a particular embodiment, m is 1, m’ is 1and n’’ is 3. In a particular embodiment, m is 1, m’ is 2 and n’’ is 3. In a particular embodiment, mis 1, m’ is 3 and n’’ is 3. 30In another embodiment, m is 2, m’ is 0 and n’’ is 3. In another embodiment, m is 2, m’ is 1 and n’’is 3. In another embodiment, m is 2, m’ is 2 and n’’ is 3. In another embodiment, m is 2, m’ is 3and n’’ is 3.In yet another embodiment, m is 3, m’ is 0 and n’’ is 3. In yet another embodiment, m is 3, m’ is 1and n’’ is 3. In yet another embodiment, m is 3, m’ is 2 and n’’ is 3. In yet another embodiment, m 35is 3, m’ is 3 and n’’ is 3. 101In yet a further embodiment, m is 4, m’ is 0 and n" is 3. In yet a further embodiment, m is 4, m’ isand n" is 3. In yet a further embodiment, m is 4, m’ is 2 and n" is 3. In yet a further embodiment,m is 4, m’ is 3 and n" is 3.In a particular embodiment, m is 1, m’ is 0 and n’’ is 4. In a particular embodiment, m is 1, m’ is and n’’ is 4. In a particular embodiment, m is 1, m’ is 2 and n’’ is 4. In a particular embodiment, 5m is 1, m’ is 3 and n’’ is 4.In another embodiment, m is 2, m’ is 0 and n’’ is 4. In another embodiment, m is 2, m’ is 1 andn’’ is 4. In another embodiment, m is 2, m’ is 2 and n’’ is 4. In another embodiment, m is 2, m’ isand n’’ is 4.In yet another embodiment, m is 3, m’ is 0 and n’’ is 4. In yet another embodiment, m is 3, m’ is 10 and n’’ is 4. In yet another embodiment, m is 3, m’ is 2 and n’’ is 4. In yet another embodiment,m is 3, m’ is 3 and n’’ is 4.In yet a further embodiment, m is 4, m’ is 0 and n" is 4. In yet a further embodiment, m is 4, m’ is and n" is 4. In yet a further embodiment, m is 4, m’ is 2 and n" is 4. In yet a further embodiment,m is 4, m’ is 3 and n" is 4. 15In a particular embodiment, m is 1, m’ is 0 and n’’ is 5. In a particular embodiment, m is 1, m’ is and n’’ is 5. In a particular embodiment, m is 1, m’ is 2 and n’’ is 5. In a particular embodiment,m is 1, m’ is 3 and n’’ is 5.In another embodiment, m is 2, m’ is 0 and n’’ is 5. In another embodiment, m is 2, m’ is 1 andn’’ is 5. In another embodiment, m is 2, m’ is 2 and n’’ is 5. In another embodiment, m is 2, m’ is 20 and n’’ is 5.In yet another embodiment, m is 3, m’ is 0 and n’’ is 5. In yet another embodiment, m is 3, m’ is and n’’ is 5. In yet another embodiment, m is 3, m’ is 2 and n’’ is 5. In yet another embodiment,m is 3, m’ is 3 and n’’ is 5.In yet a further embodiment, m is 4, m’ is 0 and n" is 5. In yet a further embodiment, m is 4, m’ is 25 and n" is 5. In yet a further embodiment, m is 4, m’ is 2 and n" is 5. In yet a further embodiment,m is 4, m’ is 3 and n" is 5.In an embodiment of the present invention, the serotype 38 glycoconjugate of the presentinvention are prepared using the alternative click chemistry of the present section. The inventionalso relates to a method of making serotype 38 glycoconjugate, as disclosed herein above. 30In an embodiment, click chemistry may comprise three steps, (a) reacting an isolatedserotype 38 saccharide with a carbonic acid derivative and an alkyne linker in an aprotic solventto produce an activated alkynyl saccharide (activation of the saccharide), (b) reacting a carrierprotein with an agent bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group wherethe NHS moiety reacts with the amino groups to form an amide linkage thereby obtaining an azido 35functionalized carrier protein (activation of the carrier protein), (c) reacting the activated alkynylsaccharide of step (a) with the activated azido-carrier protein of step (b) by Cu+1 mediated azide-alkyne cycloaddition reaction to form a glycoconjugate. 102Following step (a) the saccharide is said to be activated and is referred to herein as"activated saccharide" or "activated alkynyl saccharide".Following step (b) the carrier is said to be activated and is referred to as "activated carrier"or "activated azido-carrier".As mentioned above, before the activation (a), sizing of the serotype 38 saccharide to a 5target molecular weight (MW) range may be performed. Therefore, in an embodiment, the isolatedserotype 38 saccharide is sized before activation with a carbonic acid derivative and an alkynelinker. In an embodiment, the isolated serotype 38 saccharide is sized to any of the targetmolecular weight (MW) range defined above. In an embodiment, the isolated serotype 38saccharide is not sized before activation with a carbonic acid derivative and an alkyne linker. 10In an embodiment, said carbonic acid derivative is selected from the group consisting of1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), disuccinimidyl carbonate(DSC) and N-hydroxysuccinimidyl chloroformate.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). Inanother embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). In 15another embodiment, said carbonic acid derivative is disuccinimidyl carbonate (DSC). In yet afurther embodiment, said carbonic acid derivative is N-hydroxysuccinimidyl chloroformate.In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI) or 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). In an embodiment, said carbonic acid derivative is 1,1’-carbonyldiimidazole (CDI). In an embodiment, said carbonic acid derivative is 1,1'-Carbonyl-di- 20(1,2,4-triazole) (CDT). Preferably, said carbonic acid derivative N,N′-Disuccinimidyl carbonate(DSC).In an embodiment, said alkyne linker is a compound of formula (XIV), (XIV) 25wherein X is selected from the group consisting of CH2, CH2(CH2)n, (CH2CH2O)mCH 2CH2,NHCO(CH2)n, NHCO(CH2CH2O)mCH2CH2, OCH 2(CH2)n and O(CH2CH2O)mCH2CH2; where n isselected from 1 to 10 and m is selected from 1 to 4.In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X is CH2.In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X is 30CH2(CH2) n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yet 35a further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10.
HN X 103In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X is(CH2CH2O)mCH 2CH2, wherein m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4.In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X is 5NHCO(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In anembodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yet 10a further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10.In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X isNHCO(CH2CH2O)mCH 2CH2, where m is selected from 1 to 4. In an embodiment, m is selectedfrom 1 to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In 15another embodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, mis 4.In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X isOCH 2(CH2)n, and n is selected from 1 to 10. In an embodiment, n is selected from 1 to 5. In anembodiment, n is selected from 1 to 4. In an embodiment, n is selected from 1 to 3. In an 20embodiment, n is selected from 1 to 2. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. In yeta further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further embodiment, nis 10. 25In an embodiment, said alkyne linker is a compound of formula (XIV), wherein X isO(CH 2CH2O)mCH2CH2, where m is selected from 1 to 4. In an embodiment, m is selected from 1to 3. In an embodiment, m is selected from 1 to 2. In a particular embodiment, m is 1. In anotherembodiment, m is 2. In yet another embodiment, m is 3. In yet a further embodiment, m is 4.In an embodiment, said alkyne linker is a compound of formula (XV), 30( XV) Hence in a preferred embodiment, said alkyne linker is propargylamine. In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XVI), 35 (XVI) HN X N3 104where X is selected from the group consisting of (CH 2)nCH2C=O and (CH2CH2O)mCH2CH2=Owhere n is selected from 0 to 10 and m is selected from 0 to 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XVI), wherein X is (CH 2)nCH2C=O, where n is selectedfrom 0 to 10. In an embodiment, n is selected from 0 to 5. In an embodiment, n is selected from 5to 4. In an embodiment, n is selected from 0 to 3. In an embodiment, n is selected from 0 to2. In a particular embodiment, n is 0. In a particular embodiment, n is 1. In another embodiment,n is 2. In yet another embodiment, n is 3. In yet a further embodiment, n is 4. In yet a furtherembodiment, n is 5. In yet a further embodiment, n is 6. In yet a further embodiment, n is 7. Inyet a further embodiment, n is 8. In yet a further embodiment, n is 9. In yet a further 10embodiment, n is 10.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XVI), wherein X is (CH 2CH2O)mCH2CH2=O, where m isselected from 0 to 4. In an embodiment, m is selected from 0 to 3. In an embodiment, m is selectedfrom 0 to 2. In an embodiment, m is selected from 0 to 1. In a particular embodiment, m is 0. In a 15particular embodiment, m is 1. In another embodiment, m is 2. In yet another embodiment, m is3. In yet a further embodiment, m is 4.In an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety and anazido group is a compound of formula (XVII): (XVII) 20Hence in an embodiment, said agent bearing an N-Hydroxysuccinimide (NHS) moiety andan azido group is (2,5-Dioxopyrrolidin-1-yl) 2-azidoacetate.In an embodiment, step a) comprises reacting the saccharide with a carbonic acidderivative followed by reacting the carbonic acid derivative-activated saccharide with an alkynelinker in an aprotic solvent to produce an activated alkynyl saccharide. 25In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.01-10 molar equivalent to the amount of saccharide present inthe reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.1-10 molar equivalent to the amount of saccharide present in the 30reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-5 molar equivalent to the amount of saccharide present in thereaction mixture. 105In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 2-5 molar equivalent to the amount of saccharide present in the 5reaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 5-10 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 10acid derivative that is between 0.1-5 molar equivalent to the amount of saccharide present in thereaction mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative that is between 0.5-2 molar equivalent to the amount of saccharide present in thereaction mixture. 15In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.01 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.1 molar equivalent to the amount of saccharide present in the reaction 20mixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 0.2 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonic 25acid derivative of about 0.5 molar equivalent to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 1 molar equivalent to the amount of saccharide present in the reactionmixture. 30In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 2 molar equivalents to the amount of saccharide present in the reactionmixture.In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 5 molar equivalents to the amount of saccharide present in the reaction 35mixture. 106In one embodiment step a) comprises reacting the saccharide with an amount of carbonicacid derivative of about 10 molar equivalents to the amount of saccharide present in the reactionmixture.In an embodiment, at step a) the isolated saccharide is reacted with a carbonic acidderivative in an aprotic solvent. 5In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in asolution comprising dimethylsulphoxide (DMSO) or dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative in a solutioncomprising dimethylformamide (DMF). In one embodiment the isolated saccharide is reacted witha carbonic acid derivative in a solution comprising dimethylsulphoxide (DMSO). 10In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution comprising dimethylsulphoxide (DMSO).In one embodiment the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylsulphoxide (DMSO) or dimethylformamide (DMF). Inone embodiment the isolated saccharide is reacted with a carbonic acid derivative in a solution 15consisting essentially of dimethylformamide (DMF). In one embodiment the isolated saccharideis reacted with a carbonic acid derivative in a solution consisting essentially of dimethylsulphoxide(DMSO).In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative in asolution consisting essentially of dimethylacetamide. In an embodiment, the isolated saccharide 20is reacted with a carbonic acid derivative in a solution consisting essentially of N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted with a carbonic acid derivativein a solution consisting essentially of hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with a carbonic acidderivative in a solution consisting essentially of dimethylsulphoxide (DMSO). 25In one embodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO) or dimethylformamide (DMF). In one embodiment the isolatedsaccharide is reacted with a carbonic acid derivative in dimethylformamide (DMF). In oneembodiment the isolated saccharide is reacted with a carbonic acid derivative indimethylsulphoxide (DMSO). 30In an embodiment, the isolated saccharide is reacted with a carbonic acid derivative indimethylacetamide. In an embodiment, the isolated saccharide is reacted with a carbonic acidderivative in N-methyl-2-pyrrolidone. In an embodiment, the isolated saccharide is reacted witha carbonic acid derivative in hexamethylphosphoramide (HMPA).In a preferred embodiment the isolated saccharide is reacted with CDI in 35dimethylsulphoxide (DMSO). In an embodiment the isolated saccharide is reacted with CDI inanhydrous DMSO. 107It has been surprisingly found that reacting the isolated saccharide with CDI in anenvironment with a moisture level of about 0.1% to 1% (v/v) allows to avoid side reactions.Therefore, in one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.1% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.1% to 0.8% (v/v) water. In one embodiment the isolated 5saccharide is reacted with CDI in an aprotic solvent comprising 0.1% to 0.5% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising 0.1% to0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising 0.1% to 0.3% (v/v) water. In one embodiment the isolated saccharide isreacted with CDI in an aprotic solvent comprising 0.1% to 0.2% (v/v) water. 10In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.2% to 1% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.2% to 0.8% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising 0.2% to 0.5% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising 0.2% to 150.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising 0.2% to 0.3% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising 0.3% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in an aprotic solvent comprising 0.3% to 0.5% (v/v) water. In one embodiment the isolated 20saccharide is reacted with CDI in an aprotic solvent comprising 0.3% to 0.4% (v/v) water.Preferably, in one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising 0.1% to 0.5% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in an aprotic solventcomprising about 0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with 25CDI in an aprotic solvent comprising about 0.2% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.3% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.4% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted 30with CDI in an aprotic solvent comprising about 0.6% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in an aprotic solvent comprising about 0.7% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in an aprotic solvent comprising about0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in an aproticsolvent comprising about 0.9% (v/v) water. 35In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.1%to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.1% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with 108CDI in DMSO comprising 0.1% to 0.5% (v/v) water. In one embodiment the isolated saccharideis reacted with CDI in DMSO comprising 0.1% to 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising 0.1% to 0.3% (v/v) water. In one embodimentthe isolated saccharide is reacted with CDI in DMSO comprising 0.1% to 0.2% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.2% 5to 1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.2% to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.2% to 0.5% (v/v) water. In one embodiment the isolated saccharideis reacted with CDI in DMSO comprising 0.2% to 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising 0.2% to 0.3% (v/v) water. 10In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising 0.3%to 0.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising 0.3% to 0.5% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising 0.3% to 0.4% (v/v) water.Preferably, in one embodiment the isolated saccharide is reacted with CDI in DMSO 15comprising 0.1% to 0.5% (v/v) water.In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about0.1% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.2% (v/v) water. In one embodiment the isolated saccharide is reacted withCDI in DMSO comprising about 0.3% (v/v) water. In one embodiment the isolated saccharide is 20reacted with CDI in DMSO comprising about 0.4% (v/v) water. In one embodiment the isolatedsaccharide is reacted with CDI in DMSO comprising about 0.5% (v/v) water. In one embodimentthe isolated saccharide is reacted with CDI in DMSO comprising about 0.6% (v/v) water. In oneembodiment the isolated saccharide is reacted with CDI in DMSO comprising about 0.7% (v/v)water. In one embodiment the isolated saccharide is reacted with CDI in DMSO comprising about 250.8% (v/v) water. In one embodiment the isolated saccharide is reacted with CDI in DMSOcomprising about 0.9% (v/v) water.In one embodiment the free carbonic acid derivative is then quenched by the addition ofwater before the addition of the alkyne linker. Water can inactivate free CDI.Therefore, in an embodiment, carbonic acid derivative activation is followed by the addition of 30water. In an embodiment, water is added to bring the total water content in the mixture to betweenabout 1% to about 10% (v/v). In an embodiment, water is added to bring the total water contentin the mixture to between about 1% to about 5% (v/v). In an embodiment, water is added to bringthe total water content in the mixture to about 1 % (v/v). In an embodiment, water is added tobring the total water content in the mixture to about 2% (v/v). In an embodiment, water is added 35to bring the total water content in the mixture to about 5% (v/v). 109Once the saccharide has been reacted with carbonic acid derivative and following aneventual quenching of carbonic acid derivative with water, the carbonic acid derivative-activatedsaccharide is reacted with an alkyne linker.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.01-10 molar equivalent to 5the amount of polysaccharide Repeat Unit of the activated saccharide (molar equivalent of RU).In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative- 10activated saccharide with an amount of alkyne linker that is between 0.1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 0.5-2 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide. 15In one embodiment step a) further comprises reacting the carbonic acid derivative-activated saccharide with an amount of alkyne linker that is between 1-5 molar equivalent to theamount of polysaccharide repeat unit of the activated saccharide.In the above embodiments, said carbonic acid derivative is CDI. In another embodiment,said carbonic acid derivative is CDT. In the above embodiments, said carbonic acid derivative is 20preferably DSC.In one embodiment the degree of activation of the activated saccharide following step a)is between 0.5 to 50%. The degree of activation of the alkynyl saccharide being defined as thepercentage of Repeating Unit linked to an alkyne linker.In one embodiment the degree of activation of the activated saccharide following step a) 25is between 1 to 30%. In another embodiment the degree of activation of the activated saccharidefollowing step a) is between 2 to 25%. In another embodiment the degree of activation of theactivated saccharide following step a) is between 3 to 20%.In another embodiment the degree of activation of the activated saccharide following stepa) is between 3 to 15%. In another embodiment the degree of activation of the activated 30saccharide following step a) is between 4 to 15%. In an embodiment the degree of activation ofthe activated saccharide following step a) is between 1 to 6%.In an embodiment the degree of activation of the activated saccharide following step a) isbetween 3 to 6%. In an embodiment the degree of activation of the activated saccharide followingstep a) is between 10 to 15%. In a preferred embodiment the degree of activation of the activated 35saccharide following step a) is between 15 to 50%.In an embodiment the degree of activation of the activated saccharide following step a) isabout 1%. In an embodiment the degree of activation of the activated saccharide following step 110a) is about 2%. In an embodiment the degree of activation of the activated saccharide followingstep a) is about 3%. In an embodiment the degree of activation of the activated saccharidefollowing step a) is about 4%. In an embodiment the degree of activation of the activatedsaccharide following step a) is about 5%. In an embodiment the degree of activation of theactivated saccharide following step a) is about 6%. In an embodiment the degree of activation of 5the activated saccharide following step a) is about 7%. In an embodiment the degree of activationof the activated saccharide following step a) is about 8%. In an embodiment the degree ofactivation of the activated saccharide following step a) is about 9%. In an embodiment the degreeof activation of the activated saccharide following step a) is about 10%. In an embodiment thedegree of activation of the activated saccharide following step a) is about 11%. In an embodiment 10the degree of activation of the activated saccharide following step a) is about 12%. In anembodiment the degree of activation of the activated saccharide following step a) is about 13%.In an embodiment the degree of activation of the activated saccharide following step a) is about14%. In an embodiment the degree of activation of the activated saccharide following step a) isabout 15%. In an embodiment the degree of activation of the activated saccharide following step 15a) is about 16%. In an embodiment the degree of activation of the activated saccharide followingstep a) is about 17%. In an embodiment the degree of activation of the activated saccharidefollowing step a) is about 18%. In an embodiment the degree of activation of the activatedsaccharide following step a) is about 19%. In an embodiment the degree of activation of theactivated saccharide following step a) is about 20%. 20In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 0.1-10 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 0.5-10 molar 25equivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 1-5 molar equivalentsto the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 30bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is 2-5 molar equivalentsto the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 10 molarequivalents to the lysines on the carrier protein. 35In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 7.5 molarequivalents to the lysines on the carrier protein. 111In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 5 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 2 molar 5equivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 1 molarequivalent to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agent 10bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 0.5 molarequivalents to the lysines on the carrier protein.In one embodiment step b) comprises reacting the carrier protein with an amount of agentbearing an N-Hydroxysuccinimide (NHS) moiety and an azido group that is about 0.1 molarequivalents to the lysines on the carrier protein. 15In one embodiment the degree of activation of the activated carrier following step b) isbetween 1 and 50. The degree of activation of the activated carrier being defined as the numberof lysine residues in the carrier protein that become linked to the agent bearing an N-Hydroxysuccinimide (NHS) moiety and an azido group.In an embodiment, the carrier protein is CRM 197, which contains 39 lysine residues. In said 20embodiment the degree of activation of the activated carrier following step b) may be between 1to 30. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is between 5 to 20. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is between 9 to 18. In another embodiment the degree of activation ofthe activated carrier (CRM 197) following step b) is between 8 to 11. In another embodiment the 25degree of activation of the activated carrier (CRM 197) following step b) is between 15 to 20. Inanother embodiment the degree of activation of the activated carrier (CRM 197) following step b) isabout 5. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 6. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 7. In another embodiment the degree of activation of the 30activated carrier (CRM 197) following step b) is about 8. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 9. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 10. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about11. In another embodiment the degree of activation of the activated carrier (CRM 197) following 35step b) is about 12. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 13. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 14. In another embodiment the degree of 112activation of the activated carrier (CRM 197) following step b) is about 15. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 16. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about17. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 18. In another embodiment the degree of activation of the activated carrier 5(CRM 197) following step b) is about 19. In another embodiment the degree of activation of theactivated carrier (CRM 197) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (CRM 197) following step b) is about 21. In another embodimentthe degree of activation of the activated carrier (CRM 197) following step b) is about 22. In anotherembodiment the degree of activation of the activated carrier (CRM 197) following step b) is about 1023. In another embodiment the degree of activation of the activated carrier (CRM 197) followingstep b) is about 24. In another embodiment the degree of activation of the activated carrier(CRM 197) following step b) is about 25.In an embodiment, the carrier protein is SCP or a fragment thereof. In said embodimentthe degree of activation of the activated carrier following step b) may be between 1 to 50. In 15another embodiment the degree of activation of the activated carrier (SCP) following step b) isbetween 5 to 50. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is between 7 to 45. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is between 5 to 15. In another embodiment the degreeof activation of the activated carrier (SCP) following step b) is between 20 to 30. In another 20embodiment the degree of activation of the activated carrier (SCP) following step b) is betweento 50. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is between 30 to 40. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is between 10 to 40. In a preferred embodiment the degree ofactivation of the activated carrier (SCP) following step b) is between 15 to 25. In another 25embodiment the degree of activation of the activated carrier (SCP) following step b) is about 5. Inanother embodiment the degree of activation of the activated carrier (SCP) following step b) isabout 7. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 10. In another embodiment the degree of activation of the activated carrier (SCP)following step b) is about 13. In another embodiment the degree of activation of the activated 30carrier (SCP) following step b) is about 15. In another embodiment the degree of activation of theactivated carrier (SCP) following step b) is about 20. In another embodiment the degree ofactivation of the activated carrier (SCP) following step b) is about 26. In another embodiment thedegree of activation of the activated carrier (SCP) following step b) is about 30. In anotherembodiment the degree of activation of the activated carrier (SCP) following step b) is about 35. 35In another embodiment the degree of activation of the activated carrier (SCP) following step b) isabout 37. In another embodiment the degree of activation of the activated carrier (SCP) followingstep b) is about 40. In another embodiment the degree of activation of the activated carrier (SCP) 113following step b) is about 45. In another embodiment the degree of activation of the activatedcarrier (SCP) following step b) is about 50.In an embodiment, the carrier protein is TT or a fragment thereof. In said embodiment thedegree of activation of the activated carrier following step b) may be between 1 to 30. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is between 5 5to 25. In another embodiment the degree of activation of the activated carrier (TT) following stepb) is between 7 to 25. In another embodiment the degree of activation of the activated carrier (TT)following step b) is between 10 to 20. In another embodiment the degree of activation of theactivated carrier (TT) following step b) is about 5. In another embodiment the degree of activationof the activated carrier (TT) following step b) is about 7. In another embodiment the degree of 10activation of the activated carrier (TT) following step b) is about 10. In another embodiment thedegree of activation of the activated carrier (TT) following step b) is about 12. In anotherembodiment the degree of activation of the activated carrier (TT) following step b) is about 15. Inanother embodiment the degree of activation of the activated carrier (TT) following step b) is about20. In another embodiment the degree of activation of the activated carrier (TT) following step b) 15is about 25. In another embodiment the degree of activation of the activated carrier (TT) followingstep b) is about 30.In an embodiment, the conjugation reaction c) is carried out in aqueous buffer. In anembodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence of copper(I) as catalyst. In an embodiment, the conjugation reaction c) is carried out in aqueous buffer in 20the presence an oxidant and of copper (I) as catalyst. In a preferred embodiment, the conjugationreaction c) is carried out in aqueous buffer in the presence of copper (I) as catalyst and ascorbateas oxidant. In an embodiment, THPTA (tris(3-hydroxypropyltriazolylmethyl)amine) andaminoguanidine may be further added to protect the protein from side reactions. Therefore, in apreferred embodiment, the conjugation reaction c) is carried out in aqueous buffer in the presence 25of copper (I) as catalyst and ascorbate as oxidant, wherein the reaction mixture further comprisesTHPTA (tris(3-hydroxypropyltriazolylmethyl)amine) and aminoguanidine.In an embodiment the initial input ratio (weight by weight) of activated alkynyl saccharideto activated azido-carrier at step c) is between 0.1 and 3. In an embodiment the initial input ratio(weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) is between 300.5 and 2. In an embodiment the initial input ratio (weight by weight) of activated alkynylsaccharide to activated azido-carrier at step c) is between 0.6 and 1.5. In an embodiment theinitial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier atstep c) is between 0.8 and 1. In a preferred embodiment the initial input ratio (weight by weight)of activated alkynyl saccharide to activated azido-carrier at step c) is between 0.8 and 1.2 In an 35embodiment the initial input ratio (weight by weight) of activated alkynyl saccharide to activatedazido-carrier at step c) is about 0.5. In an embodiment the initial input ratio (weight by weight) ofactivated alkynyl saccharide to activated azido-carrier at step c) is about 0.6. In an embodiment 114the initial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrierat step c) is about 0.7. In an embodiment the initial input ratio (weight by weight) of activatedalkynyl saccharide to activated azido-carrier at step c) is about 0.8. In an embodiment the initialinput ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c)is about 0.9. In an embodiment the initial input ratio (weight by weight) of activated alkynyl 5saccharide to activated azido-carrier at step c) is about 1. In an embodiment the initial input ratio(weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) is about1.1. In an embodiment the initial input ratio (weight by weight) of activated alkynyl saccharide toactivated azido-carrier at step c) is about 1.2. In an embodiment the initial input ratio (weight byweight) of activated alkynyl saccharide to activated azido-carrier at step c) is about 1.3. In an 10embodiment the initial input ratio (weight by weight) of activated alkynyl saccharide to activatedazido-carrier at step c) is about 1.4. In an embodiment the initial input ratio (weight by weight) ofactivated alkynyl saccharide to activated azido-carrier at step c) is about 1.5. In an embodimentthe initial input ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrierat step c) is about 1.6. In an embodiment the initial input ratio (weight by weight) of activated 15alkynyl saccharide to activated azido-carrier at step c) is about 1.7. In an embodiment the initialinput ratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c)is about 1.8. In an embodiment the initial input ratio (weight by weight) of activated alkynylsaccharide to activated azido-carrier at step c) is about 1.9. In an embodiment the initial inputratio (weight by weight) of activated alkynyl saccharide to activated azido-carrier at step c) is 20about 2.Following the click conjugation reaction, unreacted alkyne groups may remain present inthe conjugates, these may be capped using a suitable alkyne group capping agent. In oneembodiment this alkyne group capping agent is an agent bearing an azido group.In an embodiment, said alkyne group capping agent is a compound of formula (XVIII), 25 ( XVIII)wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this alkyne group capping agent is 3-azido-1-propanol.Therefore, in an embodiment, following step (c) the process further comprises a step ofcapping the unreacted alkyne groups remained in the conjugates with an alkyne group capping 30agent.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.05 to 20 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 35amount of capping agent that is between 0.1 to 15 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide. 115In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 10 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 5 molar equivalents to the amount of 5polysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 0.5 to 2 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 10amount of capping agent that is between 0.5 to 1 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1 to 2 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 15In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that is between 1.5 to 2.5 molar equivalents to the amount ofpolysaccharide repeat unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 0.5 molar equivalent to the amount of polysaccharide repeat 20unit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 1 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with an 25amount of capping agent that about 1.5 molar equivalent to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide. 30In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 2.5 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide.In an embodiment the capping of the unreacted alkyne groups is performed with anamount of capping agent that about 5 molar equivalents to the amount of polysaccharide repeat 35unit of the activated saccharide.Following the click conjugation reaction, there may remain unreacted azido groups in theconjugates, these may be capped using a suitable azido group capping agent. Therefore, in an 116embodiment, following step c), unreacted azido groups in the conjugates, are capped using asuitable azido group capping agent. In one embodiment this azido group capping agent is anagent bearing an alkyne group. In one embodiment this azido group capping agent is an agentbearing a terminal alkyne. In one embodiment this azido group capping agent is an agent bearinga cycloalkyne. 5In an embodiment, said azido group capping agent is a compound of formula (XIX), (XIX)wherein X is (CH2)n wherein n is selected from 1 to 15.In one embodiment this azido group capping agent is propargyl alcohol.Therefore, in an embodiment, following step (c) the process further comprises a step of 10capping the unreacted azido groups remained in the conjugates with an azido group cappingagent.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.05 to 20 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide. 15In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 10 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 5 molar equivalents to the amount of polysaccharide 20repeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.5 to 2 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amount 25of capping agent that is between 0.5 to 1 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 1 to 2 molar equivalents to the amount of polysaccharide repeatunit of the activated saccharide. 30In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is between 0.75 to 1.5 molar equivalents to the amount of polysacchariderepeat unit of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1 molar equivalent to the amount of polysaccharide repeat unit of 35the activated saccharide. 117In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 1.5 molar equivalent to the amount of polysaccharide repeat unitof the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 0.5 molar equivalent to the amount of polysaccharide repeat unit 5of the activated saccharide.In an embodiment the capping of the unreacted azido groups is performed with an amountof capping agent that is about 2 molar equivalents to the amount of polysaccharide repeat unit ofthe activated saccharide.Following conjugation to the carrier protein, the serotype 38 glycoconjugate can be purified 10(enriched with respect to the amount of saccharide-protein conjugate) by a variety of techniquesknown to the skilled person. These techniques include dialysis, concentration/diafiltrationoperations, tangential flow filtration precipitation/elution, column chromatography (DEAE orhydrophobic interaction chromatography), and depth filtration. Therefore, in one embodiment theprocess for producing the glycoconjugate of the present invention comprises the step of purifying 15the glycoconjugate after it is produced.In an aspect, the invention provides a a serotype 38 glycoconjugate produced accordingto any of the methods disclosed herein. 2.4 Carrier Proteins 20A component of the glycoconjugate is a carrier protein to which the serotype 38 saccharideis conjugated. The terms "protein carrier" or "carrier protein" or "carrier" may be usedinterchangeably herein. Carrier proteins should be amenable to standard conjugationprocedures.In a preferred embodiment, the carrier protein of the serotype 38 saccharide 25glycoconjugate is selected in the group consisting of: DT (Diphtheria Toxoid), TT (Tetanus Toxoid)or fragment C of TT, CRM 197 (a nontoxic but antigenically identical variant of diphtheria toxin),other DT mutants (such as CRM 176, CRM 228, CRM45 (Uchida et al. (1973) J. Biol. Chem. 218:3838-3844), CRM 9, CRM 102, CRM 103 or CRM 107; and other mutations described by Nicholls and Youlein Genetically Engineered Toxins, Ed: Frankel, Maecel Dekker Inc. (1992); deletion or mutation 30of Glu-148 to Asp, Gln or Ser and/or Ala 158 to GIy and other mutations disclosed in U.S. PatentNos. 4,709,017 and 4,950,740; mutation of at least one or more residues Lys 516, Lys 526, Phe530 and/or Lys 534 and other mutations disclosed in U.S. Patent Nos. 5,917,017 and 6,455,673;or fragment disclosed in U.S. Patent No. 5,843,711, pneumococcal pneumolysin (ply) (Kuo et al.(1995) Infect lmmun 63:2706-2713) including ply detoxified in some fashion, for example dPLY- 35GMBS (WO 2004/081515, WO 2006/032499) or dPLY-formol, PhtX, including PhtA, PhtB, PhtD,PhtE (sequences of PhtA, PhtB, PhtD or PhtE are disclosed in WO 00/37105 and WO 00/39299)and fusions of Pht proteins, for example PhtDE fusions, PhtBE fusions, Pht A-E (WO 01/98334, 118WO 03/054007, WO 2009/000826), OMPC (meningococcal outer membrane protein), which isusually extracted from Neisseria meningitidis serogroup B (EP0372501), PorB (from N.meningitidis), PD (Haemophilus influenzae protein D; see, e.g., EP0594610 B), orimmunologically functional equivalents thereof, synthetic peptides (EP0378881, EP0427347),heat shock proteins (WO 93/17712, WO 94/03208), pertussis proteins (WO 98/58668, 5EP0471177), cytokines, lymphokines, growth factors or hormones (WO 91/01146), artificialproteins comprising multiple human CD4+ T cell epitopes from various pathogen derived antigens(Falugi et al. (2001) Eur J Immunol 31:3816-3824) such as N19 protein (Baraldoi et al. (2004)Infect lmmun 72:4884-4887) pneumococcal surface protein PspA (WO 02/091998), iron uptakeproteins (WO 01/72337), toxin A or B of Clostridium difficile (WO 00/61761), transferrin binding 10proteins, pneumococcal adhesion protein (PsaA), recombinant Pseudomonas aeruginosaexotoxin A (in particular non-toxic mutants thereof (such as exotoxin A bearing a substution atglutamic acid 553 (Douglas et al. (1987) J. Bacteriol. 169(11):4967-4971)). Other proteins, suchas ovalbumin, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or purified proteinderivative of tuberculin (PPD) also can be used as carrier proteins. Other suitable carrier proteins 15include inactivated bacterial toxins such as cholera toxoid (e.g., as described in WO2004/083251), Escherichia coli LT, E. coli ST, and exotoxin A from P. aeruginosa. Anothersuitable carrier protein is a C5a peptidase from Streptococcus (SCP). Another suitable carrierprotein is rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1) (WO2020056202).Another suitable carrier protein is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] fusion 20protein (SPP2), see WO2023039223. WO2020/056202 and WO2023/039223 are incorporatedby reference. SPP2 is described in particular at sections [0245] to [250] of WO2023/039223.In a preferred embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is selected from the group consisting of TT, DT, DT mutants (suchas CRM 197), and a C5a peptidase from Streptococcus (SCP). 25In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate is DT(Diphtheria Toxoid). In another embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate is TT (Tetanus Toxoid).In another embodiment, the carrier protein of the serotype 38 saccharide glycoconjugateis PD (H. influenzae protein D; see, e.g., EP0594610 B). 30In a preferred embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate is CRM 197 or a C5a peptidase from Streptococcus (SCP).In another embodiment, the carrier protein of the serotype 38 saccharide glycoconjugateis rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1).In another embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate 35is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185] fusion protein (SPP2). In an embodiment,said SPP2 has the amino acid sequence as set forth at SEQ ID NO: 19 of WO2023/039223. 119In a preferred embodiment, the serotype 38 saccharide is conjugated to CRM 197 protein.The CRM 197 protein is a nontoxic form of diphtheria toxin but is immunologically indistinguishablefrom the diphtheria toxin. CRM 197 is produced by Corynebacterium diphtheriae infected by thenontoxigenic phage β197tox-created by nitrosoguanidine mutagenesis of the toxigeniccorynephage beta (Uchida et al. (1971) Nature New Biology 233:8-11). The CRM 197 protein has 5the same molecular weight as the diphtheria toxin but differs therefrom by a single base change(guanine to adenine) in the structural gene. This single base change causes an amino acidsubstitution (glutamic acid for glycine) in the mature protein and eliminates the toxic properties ofdiphtheria toxin. The CRM 197 protein is a safe and effective T-cell dependent carrier forsaccharides. Further details about CRM 197 and production thereof can be found, e.g., in U.S. 10Patent No. 5,614,382.In an embodiment, the serotype 38 saccharide is conjugated to CRM 197 protein. In anembodiment, the serotype 38 saccharide is conjugated to CRM 197 protein or the A chain of CRM 197(see CN103495161). In an embodiment, the serotype 38 saccharide is conjugated the A chain ofCRM 197 obtained via expression by genetically recombinant E. coli (see CN103495161). 15In other preferred embodiments, the carrier protein of the serotype 38 saccharide glycoconjugateof the invention is SCP (Streptococcal C5a Peptidase).Two important species of β-hemolytic streptococci, Streptococcus pyogenes (group AStreptococcus, GAS) and Streptococcus agalactiae (group B Streptococcus, GBS), which causea variety of serious human infections that range from mild cases of pharyngitis and impetigo to 20serious invasive diseases such as necrotizing fasciitis (GAS) and neonatalsepsis (GBS) have developed a way to defeat this immune response. All human isolates of β-hemolytic streptococci, including GAS and GBS, produce a highly conserved cell-wall proteinSCP (Streptococcal C5a Peptidase) that specifically inactivates C5a. The scp genes from GASand GBS encode a polypeptide containing between 1,134 and 1,181 amino acids (Brown et al., 25PNAS, 2005, vol. 102, no. 51 pages 18391–18396). The first 31 residues are the export signalpresequence and are removed upon passing through the cytoplasmic membrane. The next 68residues serve as a pro-sequence and must be removed to produce active SCP. The next 10residues can be removed without loss of protease activity. At the other end, starting with Lys-1034, are four consecutive 17-residue motifs followed by a cell sorting and cell-wall attachment 30signal. This combined signal is composed of a 20-residue hydrophilic sequence containing anLPTTND sequence, a 17-residue hydrophobic sequence, and a short basic carboxyl terminus.SCP can be divided in domains (see figure 1B of Brown et al., PNAS, 2005, vol. 102, no. 51 pages18391–18396). These domains are the Pre/Pro domain (which comprises the export signalpresequence (commonly the first 31 residues) and the pro-sequence (commonly the next 68 35residues)), the protease domain (which is splitted in two part (protease part 1 commonly residues89–333/334 and protease domain part 2 and commonly residues 467/468–583/584), theprotease-associated domain (PA domain) (commonly residues 333/334–467/468), three 120fibronectin type III (Fn) domains (Fn1, commonly residues 583/584–712/713; Fn2, commonlyresidues 712/713–928/929/930; commonly Fn3, residues 929/930-1029/1030/1031) and a cellwall anchor domain (commonly redisues 1029/1030/1031 to the C-terminus).In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an SCP from GBS (SCPB). An exemple of SCPB is provided at SEQ. ID.NO: 3 of 5WO97/26008. See also SEQ ID NO: 3 of WO00/34487.In another preferred embodiments, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an SCP from GAS (SCPA).Examples of SCPA can be found at SEQ.ID.No.1 and SEQ.ID.No.2 of WO97/26008. See alsoSEQ ID NO: 1, 2 and 23 of WO00/34487. 10In a preferred embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive SCP.In other preferred embodiments, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive SCP from GBS (SCPB).In another preferred embodiments, the carrier protein of the serotype 38 saccharide 15glycoconjugate of the invention is an enzymatically inactive SCP from GAS (SCPA).In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is a fragment of an SCP. In an embodiment, the carrier protein of the serotype 38saccharide glycoconjugate of the invention is a fragment of an SCPA. Preferably, the carrierprotein of the serotype 38 saccharide glycoconjugate of the invention is a fragment of an SCPB. 20In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is a fragment of an SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 25invention is a fragment of an SCP which comprises the protease domain, the protease-associateddomain (PA domain) and the three fibronectin type III (Fn) domains but does not comprise theexport signal presequence, the pro-sequence and the cell wall anchor domain.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP which comprises the protease domain, 30the protease-associated domain (PA domain) and two of the three fibronectin type III (Fn)domains but does not comprise the export signal presequence, the pro-sequence and the cellwall anchor domain.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP. In an embodiment, said enzymatically 35inactive fragment of SCP comprises the protease domain, the protease-associated domain (PAdomain) and the three fibronectin type III (Fn) domains but does not comprise the export signalpresequence, the pro-sequence and the cell wall anchor domain. 121In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCPA. In an embodiment, said enzymaticallyinactive fragment of an SCPA comprises the protease domain, the protease-associated domain(PA domain) and the three fibronectin type III (Fn) domains but does not comprise the exportsignal presequence, the pro-sequence and the cell wall anchor domain. 5In a preferred embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCPB. Preferably, saidenzymatically inactive fragment of SCPB comprises the protease domain, the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does notcomprise the export signal presequence, the pro-sequence and the cell wall anchor domain. 10In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least oneamino acid of the wild type sequence. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. The numbers indicate the amino acidresidue position in the peptidase according to the numbering of SEQ ID NO: 1 of WO00/34487.Therefore, in an embodiment, the carrier protein of the serotype 38 saccharide 15glycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least one amino acid of the wild type sequence. Preferably, saidreplacement of at least one amino acid is in the protease domain. In an embodiment, saidreplacement of at least one amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least one amino acid is in part 2 of the protease domain. In an embodiment, 20said replacement is selected from the group consisting of D130A, H193A, N295A and S512A. Inan embodiment, said replacement is D130A. In another embodiment, said replacement is H193A.In another embodiment, said replacement is N295A. In yet another embodiment, saidreplacement is S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 25invention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least one amino acid of the wild type sequence. Preferably, said replacement of at least oneamino acid is in the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 1 of the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 2 of the protease domain. In an embodiment, said replacement is selected from the 30group consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement isD130A. In another embodiment, said replacement is H193A. In another embodiment, saidreplacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacing 35at least one amino acid of the wild type sequence. Preferably, said replacement of at least oneamino acid is in the protease domain. In an embodiment, said replacement of at least one aminoacid is in part 1 of the protease domain. In an embodiment, said replacement of at least one amino 122acid is in part 2 of the protease domain. In an embodiment, said replacement is selected from thegroup consisting of D130A, H193A, N295A and S512A. In an embodiment, said replacement isD130A. In another embodiment, said replacement is H193A. In another embodiment, saidreplacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 5invention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least one amino acid of the wild type sequence. Preferably, said replacement ofat least one amino acid is in the protease domain. In an embodiment, said replacement of at leastone amino acid is in part 1 of the protease domain. In an embodiment, said replacement of atleast one amino acid is in part 2 of the protease domain. In an embodiment, said replacement is 10selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidreplacement is D130A. In another embodiment, said replacement is H193A. In anotherembodiment, said replacement is N295A. In yet another embodiment, said replacement is S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, the 15protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least one amino acid of the wild typesequence. Preferably, said replacement of at least one amino acid is in the protease domain. Inan embodiment, said replacement of at least one amino acid is in part 1 of the protease domain. 20In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, saidreplacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A. 25In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least one amino acid of the wild 30type sequence. Preferably, said replacement of at least one amino acid is in the protease domain.In an embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, said 35replacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A. 123In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least one amino acid of the wild 5type sequence. Preferably, said replacement of at least one amino acid is in the protease domain.In an embodiment, said replacement of at least one amino acid is in part 1 of the protease domain.In an embodiment, said replacement of at least one amino acid is in part 2 of the protease domain.In an embodiment, said replacement is selected from the group consisting of D130A, H193A,N295A and S512A. In an embodiment, said replacement is D130A. In another embodiment, said 10replacement is H193A. In another embodiment, said replacement is N295A. In yet anotherembodiment, said replacement is S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least twoamino acids of the wild type sequence. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In an 15embodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. In anembodiment, said at least two amino acids replacements are D130A and S512A. In anembodiment, said at least two amino acids replacements are H193A and N295A. In anembodiment, said at least two amino acids replacements are H193A and S512A. In an 20embodiment, said at least two amino acids replacements are N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive SCP where said inactivation isaccomplished by replacing at least two amino acids of the wild type sequence. Preferably, saidreplacement of at least two amino acids is in the protease domain. In an embodiment, said 25replacement of at least two amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least two amino acid is in part 2 of the protease domain. In an embodiment,said at least two amino acids replacements are selected from the group consisting of D130A,H193A, N295A and S512A. In an embodiment, said at least two amino acids replacements areD130A and H193A. In an embodiment, said at least two amino acids replacements are D130A 30and N295A. Preferably, said at least two amino acids replacements are D130A and S512A. In anembodiment, said at least two amino acids replacements are H193A and N295A. In anembodiment, said at least two amino acids replacements are H193A and S512A. In anembodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 35invention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least two amino acids of the wild type sequence. Preferably, said replacement of at least twoamino acids is in the protease domain. In an embodiment, said replacement of at least two amino 124acids is in part 1 of the protease domain. In an embodiment, said replacement of at least twoamino acid is in part 2 of the protease domain. In an embodiment, said at least two amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. Preferably, said 5at least two amino acids replacements are D130A and S512A. In an embodiment, said at leasttwo amino acids replacements are H193A and N295A. In an embodiment, said at least two aminoacids replacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 10invention is an enzymatically inactive SCPB where said inactivation is accomplished by replacingat least two amino acids of the wild type sequence. Preferably, said replacement of at least twoamino acids is in the protease domain. In an embodiment, said replacement of at least two aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least twoamino acid is in part 2 of the protease domain. In an embodiment, said at least two amino acids 15replacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least two amino acids replacements are D130A and H193A. In anembodiment, said at least two amino acids replacements are D130A and N295A. Preferably, saidat least two amino acids replacements are D130A and S512A. In an embodiment, said at leasttwo amino acids replacements are H193A and N295A. In an embodiment, said at least two amino 20acids replacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least two amino acids of the wild type sequence. Preferably, said replacement of 25at least two amino acids is in the protease domain. In an embodiment, said replacement of atleast two amino acids is in part 1 of the protease domain. In an embodiment, said replacement ofat least two amino acid is in part 2 of the protease domain. In an embodiment, said at least twoamino acids replacements are selected from the group consisting of D130A, H193A, N295A andS512A. In an embodiment, said at least two amino acids replacements are D130A and H193A. 30In an embodiment, said at least two amino acids replacements are D130A and N295A. Preferably,said at least two amino acids replacements are D130A and S512A. In an embodiment, said atleast two amino acids replacements are H193A and N295A. In an embodiment, said at least twoamino acids replacements are H193A and S512A. In an embodiment, said at least two aminoacids replacements are N295A and S512A. 35In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but does 125not comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least two amino acids of the wild typesequence. Preferably, said replacement of at least two amino acids is in the protease domain. Inan embodiment, said replacement of at least two amino acids is in part 1 of the protease domain.In an embodiment, said replacement of at least two amino acid is in part 2 of the protease domain. 5In an embodiment, said at least two amino acids replacements are selected from the groupconsisting of D130A, H193A, N295A and S512A. In an embodiment, said at least two amino acidsreplacements are D130A and H193A. In an embodiment, said at least two amino acidsreplacements are D130A and N295A. Preferably, said at least two amino acids replacements areD130A and S512A. In an embodiment, said at least two amino acids replacements are H193A 10and N295A. In an embodiment, said at least two amino acids replacements are H193A andS512A. In an embodiment, said at least two amino acids replacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but 15does not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least two amino acids of the wildtype sequence. Preferably, said replacement of at least two amino acids is in the proteasedomain. In an embodiment, said replacement of at least two amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least one amino acids is in part 2 of 20the protease domain. In an embodiment, said at least two amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leasttwo amino acids replacements are D130A and H193A. In an embodiment, said at least two aminoacids replacements are D130A and N295A. Preferably, said at least two amino acidsreplacements are D130A and S512A. In an embodiment, said at least two amino acids 25replacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acidsreplacements are N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain, 30the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least two amino acids of the wildtype sequence. Preferably, said replacement of at least two amino acids is in the proteasedomain. In an embodiment, said replacement of at least two amino acids is in part 1 of the 35protease domain. In an embodiment, said replacement of at least two amino acids is in part 2 ofthe protease domain. In an embodiment, said at least two amino acids replacements are selectedfrom the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at least 126two amino acids replacements are D130A and H193A. In an embodiment, said at least two aminoacids replacements are D130A and N295A. Preferably, said at least two amino acidsreplacements are D130A and S512A. In an embodiment, said at least two amino acidsreplacements are H193A and N295A. In an embodiment, said at least two amino acidsreplacements are H193A and S512A. In an embodiment, said at least two amino acids 5replacements are N295A and S512A.In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least threeamino acids of the wild type sequence. In an embodiment, said at least three amino acidsreplacements are selected from the group consisting of D130A, H193A, N295A and S512A. In anembodiment, said at least three amino acids replacements are D130A, H193A and N295A. In an 10embodiment, said at least three amino acids replacements are D130A, H193A and S512A. In anembodiment, said at least three amino acids replacements are D130A, N295A and S512A. In anembodiment, said at least three amino acids replacements are H193A, N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive SCP where said inactivation is 15accomplished by replacing at least three amino acids of the wild type sequence. Preferably, saidreplacement of at least three amino acids is in the protease domain. In an embodiment, saidreplacement of at least three amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least three amino acid is in part 2 of the protease domain. In anembodiment, said at least three amino acids replacements are selected from the group consisting 20of D130A, H193A, N295A and S512A. In an embodiment, said at least three amino acidsreplacements are D130A, H193A and N295A. In an embodiment, said at least three amino acidsreplacements are D130A, H193A and S512A. In an embodiment, said at least three amino acidsreplacements are D130A, N295A and S512A. In an embodiment, said at least three amino acidsreplacements are H193A, N295A and S512A. 25In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least three amino acids of the wild type sequence. Preferably, said replacement of at leastthree amino acids is in the protease domain. In an embodiment, said replacement of at least threeamino acids is in part 1 of the protease domain. In an embodiment, said replacement of at least 30three amino acid is in part 2 of the protease domain. In an embodiment, said at least three aminoacids replacements are selected from the group consisting of D130A, H193A, N295A and S512A.In an embodiment, said at least three amino acids replacements are D130A, H193A and N295A.In an embodiment, said at least three amino acids replacements are D130A, H193A and S512A.In an embodiment, said at least three amino acids replacements are D130A, N295A and S512A. 35In an embodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPB where said inactivation is accomplished by replacing 127at least three amino acids of the wild type sequence. Preferably, said replacement of at leastthree amino acids is in the protease domain. In an embodiment, said replacement of at least threeamino acids is in part 1 of the protease domain. In an embodiment, said replacement of at leastthree amino acid is in part 2 of the protease domain. In an embodiment, said at least three aminoacids replacements are selected from the group consisting of D130A, H193A, N295A and S512A. 5In an embodiment, said at least three amino acids replacements are D130A, H193A and N295A.In an embodiment, said at least three amino acids replacements are D130A, H193A and S512A.In an embodiment, said at least three amino acids replacements are D130A, N295A and S512A.In an embodiment, said at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 10invention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least three amino acids of the wild type sequence. Preferably, said replacementof at least three amino acids is in the protease domain. In an embodiment, said replacement ofat least three amino acids is in part 1 of the protease domain. In an embodiment, said replacementof at least three amino acid is in part 2 of the protease domain. In an embodiment, said at least 15three amino acids replacements are selected from the group consisting of D130A, H193A, N295Aand S512A. In an embodiment, said at least three amino acids replacements are D130A, H193Aand N295A. In an embodiment, said at least three amino acids replacements are D130A, H193Aand S512A. In an embodiment, said at least three amino acids replacements are D130A, N295Aand S512A. In an embodiment, said at least three amino acids replacements are H193A, N295A 20and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, theprotease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain, 25where said inactivation is accomplished by replacing at least three amino acids of the wild typesequence. Preferably, said replacement of at least three amino acids is in the protease domain.In an embodiment, said replacement of at least three amino acids is in part 1 of the proteasedomain. In an embodiment, said replacement of at least three amino acid is in part 2 of theprotease domain. In an embodiment, said at least three amino acids replacements are selected 30from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and N295A. In an embodiment, said at leastthree amino acids replacements are D130A, H193A and S512A. In an embodiment, said at leastthree amino acids replacements are D130A, N295A and S512A. In an embodiment, said at leastthree amino acids replacements are H193A, N295A and S512A. 35In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but 128does not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least three amino acids of thewild type sequence. Preferably, said replacement of at least three amino acids is in the proteasedomain. In an embodiment, said replacement of at least three amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least three amino acids is in part 2 5of the protease domain. In an embodiment, said at least three amino acids replacements areselected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and N295A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, N295A and S512A. In an embodiment, said 10at least three amino acids replacements are H193A, N295A and S512A.In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchor 15domain, where said inactivation is accomplished by replacing at least three amino acids of thewild type sequence. Preferably, said replacement of at least three amino acids is in the proteasedomain. In an embodiment, said replacement of at least three amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least three amino acids is in part 2of the protease domain. In an embodiment, said at least three amino acids replacements are 20selected from the group consisting of D130A, H193A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and N295A. In an embodiment, saidat least three amino acids replacements are D130A, H193A and S512A. In an embodiment, saidat least three amino acids replacements are D130A, N295A and S512A. In an embodiment, saidat least three amino acids replacements are H193A, N295A and S512A. 25In an embodiment, the enzymatic activity of SCP is inactivated by replacing at least fouramino acids of the wild type sequence. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512A.Therefore, in an embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive SCP where said inactivation is 30accomplished by replacing at least four amino acids of the wild type sequence. Preferably, saidreplacement of at least four amino acids is in the protease domain. In an embodiment, saidreplacement of at least four amino acid is in part 1 of the protease domain. In an embodiment,said replacement of at least four amino acid is in part 2 of the protease domain. In an embodiment,said at least four amino acids replacements are D130A, H193A, N295A and S512A 35In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive SCPA where said inactivation is accomplished by replacingat least four amino acids of the wild type sequence. Preferably, said replacement of at least four 129amino acids is in the protease domain. In an embodiment, said replacement of at least four aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least fouramino acid is in part 2 of the protease domain. In an embodiment, said at least four amino acidsreplacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of the 5invention is an enzymatically inactive SCPB where said inactivation is accomplished by replacingat least four amino acids of the wild type sequence. Preferably, said replacement of at least fouramino acids is in the protease domain. In an embodiment, said replacement of at least four aminoacids is in part 1 of the protease domain. In an embodiment, said replacement of at least fouramino acid is in part 2 of the protease domain. In an embodiment, said at least four amino acids 10replacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of an SCP where said inactivation is accomplishedby replacing at least four amino acids of the wild type sequence. Preferably, said replacement ofat least four amino acids is in the protease domain. In an embodiment, said replacement of at 15least four amino acids is in part 1 of the protease domain. In an embodiment, said replacementof at least four amino acid is in part 2 of the protease domain. In an embodiment, said at leastfour amino acids replacements are D130A, H193A, N295A and S512AIn an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCP which comprises the protease domain, the 20protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains but doesnot comprise the export signal presequence, the pro-sequence and the cell wall anchor domain,where said inactivation is accomplished by replacing at least four amino acids of the wild typesequence. Preferably, said replacement of at least four amino acids is in the protease domain. Inan embodiment, said replacement of at least four amino acids is in part 1 of the protease domain. 25In an embodiment, said replacement of at least four amino acid is in part 2 of the protease domain.In an embodiment, said at least four amino acids replacements are D130A, H193A, N295A andS512AIn an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPA which comprises the protease domain, 30the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least four amino acids of the wildtype sequence. Preferably, said replacement of at least four amino acids is in the proteasedomain. In an embodiment, said replacement of at least four amino acids is in part 1 of the 35protease domain. In an embodiment, said replacement of at least one amino acids is in part 2 ofthe protease domain. In an embodiment, said at least four amino acids replacements are D130A,H193A, N295A and S512A 130In an embodiment, the carrier protein of the serotype 38 saccharide glycoconjugate of theinvention is an enzymatically inactive fragment of SCPB which comprises the protease domain,the protease-associated domain (PA domain) and the three fibronectin type III (Fn) domains butdoes not comprise the export signal presequence, the pro-sequence and the cell wall anchordomain, where said inactivation is accomplished by replacing at least four amino acids of the wild 5type sequence. Preferably, said replacement of at least four amino acids is in the proteasedomain. In an embodiment, said replacement of at least four amino acids is in part 1 of theprotease domain. In an embodiment, said replacement of at least four amino acids is in part 2 ofthe protease domain. In an embodiment, said at least four amino acids replacements are D130A,H193A, N295A and S512A 10In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP which consists ofSEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP which consists of 15SEQ ID NO: 2.
SEQ ID NO: 1 : MAKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD 20 YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP 25 DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN 30 SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF 35 TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQ SEQ ID NO: 1 is 950 amino acids long. 131SEQ ID NO: 2 : AKTADTPATSKATIRDLNDPSQVKTLQEKAGKGAGTVVAVIAAGFDKNH EAWRLTDKAKARYQSKEDLEKAKKEHGITYGEWVNDKVAYYHDYSKDGKT AVDQEHGTHVSGILSGNAPSETKEPYRLEGAMPEAQLLLMRVEIVNGLAD YARNYAQAIRDAINLGAKVINMSFGNAALAYANLPDETKKAFDYAKSKGV 5 SIVTSAGNDSSFGGKTRLPLADHPDYGVVGTPAAADSTLTVASYSPDKQL TETVTVKTADQQDKEMPVLSTNRFEPNKAYDYAYANRGTKEDDFKDVKGK IALIERGDIDFKDKIAKAKKAGAVGVLIYDNQDKGFPIELPNVDQMPAAF ISRKDGLLLKDNPQKTITFNATPKVLPTASGTKLSRFSSWGLTADGNIKP DIAAPGQDILSSVANNKYAKLSGTAMSAPLVAGIMGLLQEQYETQYPDMT 10 PSERLDLAKKVLMSSATALYDEDEKAYFSPRQQGAGAVDAKKASAATMYV TDKDNTSSKVHLNNVSDKFEVTVTVHNKSDKPQELYYQATVQTDKVDGKH FALAPKALYETSWQKITIPANSSKQVTVPIDASRFSKDLLAQMKNGYFLE GFVRFKQDPKKEELMSIPYIGFRGDFGNLSALEKPIYDSKDGSSYYHEAN SDAKDQLDGDGLQFYALKNNFTALTTESNPWTIIKAVKEGVENIEDIESS 15 EITETIFAGTFAKQDDDSHYYIHRHANGKPYAAISPNGDGNRDYVQFQGT FLRNAKNLVAEVLDKEGNVVWTSEVTEQVVKNYNNDLASTLGSTRFEKTR WDGKDKDGKVVANGTYTYRVRYTPISSGAKEQHTDFDVIVDNTTPEVATS ATFSTEDRRLTLASKPKTSQPVYRERIAYTYMDEDLPTTEYISPNEDGTF TLPEEAETMEGATVPLKMSDFTYVVEDMAGNITYTPVTKLLEGHSNKPEQ 20 SEQ ID NO: 2 is 949 amino acids long.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 90% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 38 saccharide 25glycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 95% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99% identity with SEQ ID NO: 1. 30In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.5% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of a 35polypeptide having at least 99.8% identity with SEQ ID NO: 1. 132In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.85% identity with SEQ ID NO: 1.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of a 5polypeptide having at least 90% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 95% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 38 saccharide 10glycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.5% identity with SEQ ID NO: 2. 15In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of apolypeptide having at least 99.8% identity with SEQ ID NO: 2.In a particular embodiment, the carrier protein of the serotype 38 saccharideglycoconjugate of the invention is an enzymatically inactive fragment of SCP consisting of a 20polypeptide having at least 99.85% identity with SEQ ID NO: 2. 3. Immunogenic compositions In an embodiment the invention relates to an immunogenic composition comprising a S.pneumoniae serotype 38 saccharide of the invention. 25In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and comprising from 1to 45 different glycoconjugates. 30In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and comprising from 1to 45 glycoconjugates from different serotypes of S. pneumoniae (1 to 45 pneumococcalconjugates).In one embodiment the invention relates to an immunogenic composition comprising 35glycoconjugates from 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25different serotypes of S. pneumoniae. In one embodiment the immunogenic compositioncomprises glycoconjugates from 16 or 20 different serotypes of S. pneumoniae. 133In an embodiment the immunogenic composition is a 21, 22, 23, 24 or 25-valentpneumococcal conjugate composition.In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugatecomposition. In an embodiment the immunogenic composition is a 22-valent pneumococcalconjugate composition. In an embodiment the immunogenic composition is a 23-valent 5pneumococcal conjugate composition. In an embodiment the immunogenic composition is a 24-valent pneumococcal conjugate composition. In an embodiment the immunogenic composition isa 25-valent pneumococcal conjugate composition.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and comprising from 26 10to 45 glycoconjugates from different serotypes of S. pneumoniae (26 to 45 pneumococcalconjugates). In one embodiment the invention relates to an immunogenic composition comprisingglycoconjugates from 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 ordifferent serotypes of S. pneumoniae.In one embodiment the immunogenic composition comprises glycoconjugates from 35 or 15different serotypes of S. pneumoniae. In an embodiment the immunogenic composition is a35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45-valent pneumococcal conjugate compositions. In anembodiment the immunogenic composition is a 40, 41, 42, 43, 44 or 45-valent pneumococcalconjugate compositions. In an embodiment the immunogenic composition is a 40-valentpneumococcal conjugate composition. In an embodiment the immunogenic composition is a 41- 20valent pneumococcal conjugate composition. In an embodiment the immunogenic composition isa 42-valent pneumococcal conjugate composition. In an embodiment the immunogeniccomposition is a 43-valent pneumococcal conjugate composition. In an embodiment theimmunogenic composition is a 44-valent pneumococcal conjugate composition. In anembodiment the immunogenic composition is a 45-valent pneumococcal conjugate composition. 25In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.In an embodiment said immunogenic composition comprises in addition glycoconjugatesfrom S. pneumoniae serotypes 1, 5 and 7F. 30In an embodiment any of the immunogenic compositions above comprises in additionglycoconjugates from S. pneumoniae serotype 3.In an embodiment any of the immunogenic compositions above comprises in additionglycoconjugates from S. pneumoniae serotypes 6A and 19A.In an embodiment any of the immunogenic compositions above comprise in addition a 35glycoconjugates from S. pneumoniae serotype 22F and 33F.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotypes 8, 10A, 11A, 12F and 15B. 134In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 2.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 9N.In an embodiment any of the immunogenic compositions above comprise in addition a 5glycoconjugates from S. pneumoniae serotype 17F.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 20.In an embodiment any of the immunogenic compositions above comprise in addition aglycoconjugates from S. pneumoniae serotype 15C. 10In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. In anembodiment the immunogenic composition is an 8-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising a 15Streptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. In anembodiment the immunogenic composition is an 11-valent pneumococcal conjugatecompositions.In an embodiment the invention relates to an immunogenic composition comprising a S. 20pneumoniae serotype 38 glycoconjugate of the invention and further comprising glycoconjugatesfrom S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. In anembodiment the immunogenic composition is a 14-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprising 25glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,22F, 23F and 33F. In an embodiment the immunogenic composition is a 16-valent pneumococcalconjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprising 30glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprising 35glycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15C, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition is a 21-valent pneumococcal conjugate compositions. 135In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 5In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15C, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 10In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 15In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic compositionis a 23-valent pneumococcal conjugate compositions. 20In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogeniccomposition is a 24-valent pneumococcal conjugate compositions. 25In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. In an embodiment the immunogeniccomposition is a 25-valent pneumococcal conjugate compositions. 30In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions. 35In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 13615B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 515B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1015B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 1515B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. In an embodiment the immunogenic composition isa 22-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2015A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. In an embodiment the immunogeniccomposition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 2515A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. In one embodiment, the S.pneumoniae saccharides are conjugated to CRM 197. In one embodiment, the S. pneumoniaesaccharides from serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A,19F, 22F, 23A, 23B, 23F, 24F, 33F, 35B and 38 are conjugated to CRM 197 and the S. pneumoniaesaccharide from serotype 3 is conjugated to SCP. In an embodiment the immunogenic 30composition is a 26-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B, 24F, 27, 3529, 31, 33B, 34, 35B and 35F.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprising 137twenty one glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B, 24F, 27,29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic composition is a 22-valentpneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising a 5Streptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic composition is a 23-valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising a 10Streptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F.In an embodiment the invention relates to an immunogenic composition comprising a 15Streptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingtwenty two glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic composition is a 23-valent pneumococcal conjugate compositions. 20In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingtwenty three glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic composition is a 24- 25valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic composition is a 23- 30valent pneumococcal conjugate compositions.In an embodiment the invention relates to an immunogenic composition comprising aStreptococcus pneumoniae serotype 38 glycoconjugate of the invention and further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A,23B, 24B, 24F, 27, 29, 31, 33B, 34, 35B and 35F. In an embodiment the immunogenic 35composition is a 25-valent pneumococcal conjugate compositions. 138Compositions of the invention may include a small amount of free carrier. When a givencarrier protein is present in both free and conjugated form in a composition of the invention, theunconjugated form is preferably no more than 5% of the total amount of the carrier protein in thecomposition as a whole, and more preferably present at less than 2% by weight. 4 Adjuvant(s) In some embodiments, the immunogenic compositions disclosed herein may furthercomprise at least one, two or three adjuvants. In some embodiments, the immunogeniccompositions disclosed herein may further comprise at least one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may further 10comprise one adjuvant.In some embodiments, the immunogenic compositions disclosed herein may furthercomprise two adjuvants.The term "adjuvant" refers to a compound or mixture that enhances the immune responseto an antigen. Antigens may act primarily as a delivery system, primarily as an immune modulator 15or have strong features of both. Suitable adjuvants include those suitable for use in mammals,including humans.Examples of known suitable delivery-system type adjuvants that can be used in humansinclude, but are not limited to, alum (e.g., aluminum phosphate, aluminum sulfate or aluminumhydroxide), calcium phosphate, liposomes, oil-in-water emulsions such as MF59 (4.3% w/v 20squalene, 0.5% w/v polysorbate 80 (Tween 80), 0.5% w/v sorbitan trioleate (Span 85)), water-in-oil emulsions such as Montanide, and poly(D,L-lactide-co-glycolide) (PLG) microparticles ornanoparticles.In an embodiment, the immunogenic compositions disclosed herein comprise aluminumsalts (alum) as adjuvant (e.g., aluminum phosphate, aluminum sulfate or aluminum hydroxide). 25In a preferred embodiment, the immunogenic compositions disclosed herein comprisealuminum phosphate or aluminum hydroxide as adjuvant. In an even preferred embodiment, theimmunogenic compositions disclosed herein comprise aluminum phosphate as adjuvant.Further exemplary adjuvants to enhance effectiveness of the immunogenic compositionsas disclosed herein include, but are not limited to: (1) oil-in-water emulsion formulations (with or 30without other specific immunostimulating agents such as muramyl peptides (see below) orbacterial cell wall components), such as for example (a) SAF, containing 10% Squalene, 0.4%Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP either microfluidized into a submicronemulsion or vortexed to generate a larger particle size emulsion, and (b) RIBI™ adjuvant system(RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or 35more bacterial cell wall components such as monophosphorylipid A (MPL), trehalose dimycolate(TDM), and cell wall skeleton (CWS), preferably MPL + CWS (DETOX™); (2) saponin adjuvants,such as QS21, STIMULON™ (Cambridge Bioscience, Worcester, MA), ABISCO® (Isconova, 139Sweden), or ISCOMATRIX® (Commonwealth Serum Laboratories, Australia), may be used orparticles generated therefrom such as ISCOMs (immunostimulating complexes), which ISCOMSmay be devoid of additional detergent (e.g., WO 00/07621); (3) Complete Freund's Adjuvant(CFA) and Incomplete Freund's Adjuvant (IFA); (4) cytokines, such as interleukins (e.g., IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12 (e.g., WO 99/44636)), interferons (e.g., gamma interferon), 5macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc.; (5)monophosphoryl lipid A (MPL) or 3-O-deacylated MPL (3dMPL) (see, e.g., GB-2220221,EP0689454), optionally in the substantial absence of alum when used with pneumococcalsaccharides (see, e.g., WO 00/56358); (6) combinations of 3dMPL with, for example, QS21 and/oroil-in-water emulsions (see, e.g., EP0835318, EP0735898, EP0761231); (7) a polyoxyethylene 10ether or a polyoxyethylene ester (see, e.g., WO 99/52549); (8) a polyoxyethylene sorbitan estersurfactant in combination with an octoxynol (e.g., WO 01/21207) or a polyoxyethylene alkyl etheror ester surfactant in combination with at least one additional non-ionic surfactant such as anoctoxynol (e.g., WO 01/21152); (9) a saponin and an immunostimulatory oligonucleotide (e.g., aCpG oligonucleotide) (e.g., WO 00/62800); (10) an immunostimulant and a particle of metal salt 15(see, e.g., WO 00/23105); (11) a saponin and an oil-in-water emulsion (e.g., WO 99/11241); (12)a saponin (e.g., QS21) + 3dMPL + IM2 (optionally + a sterol) (e.g., WO 98/57659); (13) othersubstances that act as immunostimulating agents to enhance the efficacy of the composition.Muramyl peptides include N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-25 acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutarninyl-L- 20alanine-2-(1'-2'-dipalmitoyl-sn-gIycero-3-hydroxyphosphoryloxy)-ethylamine MTP-PE), etc.In an embodiment of the present invention, the immunogenic compositions as disclosedherein comprise a CpG Oligonucleotide as adjuvant. A CpG oligonucleotide as used herein refersto an immunostimulatory CpG oligodeoxynucleotide (CpG ODN), and accordingly these termsare used interchangeably unless otherwise indicated. Immunostimulatory CpG 25oligodeoxynucleotides contain one or more immunostimulatory CpG motifs that are unmethylatedcytosine-guanine dinucleotides, optionally within certain preferred base contexts. The methylationstatus of the CpG immunostimulatory motif generally refers to the cytosine residue in thedinucleotide. An immunostimulatory oligonucleotide containing at least one unmethylated CpGdinucleotide is an oligonucleotide which contains a 5' unmethylated cytosine linked by a 30phosphate bond to a 3' guanine, and which activates the immune system through binding to Toll-like receptor 9 (TLR-9). In another embodiment the immunostimulatory oligonucleotide maycontain one or more methylated CpG dinucleotides, which will activate the immune systemthrough TLR9 but not as strongly as if the CpG motif(s) was/were unmethylated. CpGimmunostimulatory oligonucleotides may comprise one or more palindromes that in turn may 35encompass the CpG dinucleotide. CpG oligonucleotides have been described in a number ofissued patents, published patent applications, and other publications, including U.S. Patent Nos.6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. 140In an embodiment of the present invention, the immunogenic compositions as disclosed hereincomprise any of the CpG Oligonucleotide described at page 3, line 22, to page 12, line 36, of WO2010/125480.Different classes of CpG immunostimulatory oligonucleotides have been identified. Theseare referred to as A, B, C and P class, and are described in greater detail at page 3, line 22, to 5page 12, line 36, of WO 2010/125480. Methods of the invention embrace the use of these differentclasses of CpG immunostimulatory oligonucleotides.
Formulation The immunogenic compositions of the invention may be formulated in liquid form (i.e., 10solutions or suspensions) or in a lyophilized form. In an embodiment, the immunogeniccomposition of the invention is formulated in a liquid form. In an embodiment, the immunogeniccomposition of the invention is formulated in a lyophilized form. Liquid formulations mayadvantageously be administered directly from their packaged form and are thus ideal for injectionwithout the need for reconstitution in aqueous medium as otherwise required for lyophilized 15compositions of the invention.Formulation of the immunogenic composition of the present disclosure can be accomplishedusing art-recognized methods. For instance, the individual polysaccharides and/or conjugates canbe formulated with a physiologically acceptable vehicle to prepare the composition. Examples ofsuch vehicles include, but are not limited to, water, buffered saline, polyols (e.g., glycerol, 20propylene glycol, liquid polyethylene glycol) and dextrose solutions.The present disclosure provides an immunogenic composition comprising any ofcombination of glycoconjugates disclosed herein and a pharmaceutically acceptable excipient,carrier, or diluent.In an embodiment, the immunogenic composition of the disclosure is in liquid form, 25preferably in aqueous liquid form.Immunogenic compositions of the disclosure may comprise one or more of a buffer, a salt,a divalent cation, a non-ionic detergent, a cryoprotectant such as a sugar, and an anti-oxidantsuch as a free radical scavenger or chelating agent, or any multiple combinations thereof.In an embodiment, the immunogenic compositions of the disclosure comprise a buffer. In 30an embodiment, said buffer has a pKa of about 3.5 to about 7.5. In some embodiments, the bufferis phosphate, succinate, histidine or citrate. In some embodiments, the buffer is succinate. Insome embodiments, the buffer is histidine. In certain embodiments, the buffer is succinate at afinal concentration of 1 mM to 10 mM. In one particular embodiment, the final concentration of thesuccinate buffer is about 5 mM. 35In an embodiment, the immunogenic compositions of the disclosure comprise a salt. Insome embodiments, the salt is selected from the groups consisting of magnesium chloride,potassium chloride, sodium chloride and a combination thereof. In one particular embodiment, 141the salt is sodium chloride. In one particular embodiment, the immunogenic compositions of theinvention comprise sodium chloride at 150 mM.In an embodiment, the immunogenic compositions of the disclosure comprise a surfactant.In an embodiment, the surfactant is selected from the group consisting of polysorbate 20(TWEENTM20), polysorbate 40 (TWEENTM40), polysorbate 60 (TWEEN™60), polysorbate 65 5(TWEEN™65), polysorbate 80 (TWEEN™80), polysorbate 85 (TWEEN™85), TRITON™ N-101,TRITON™ X-100, oxtoxynol 40, nonoxynol-9, triethanolamine, triethanolamine polypeptideoleate, polyoxyethylene-660 hydroxystearate (PEG-15, Solutol H 15), polyoxyethylene-35-ricinoleate (CREMOPHOR® EL), soy lecithin and a poloxamer.In one particular embodiment, the surfactant is polysorbate 80. In some said embodiment, 10the final concentration of polysorbate 80 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 80in the formulation is at least 0.001% to 1% polysorbate 80 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 80 in the formulation is at least 0.01% to 1%polysorbate 80 weight to weight (w/w). In other embodiments, the final concentration of 15polysorbate 80 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 80 (w/w). In another embodiment, the final concentration of thepolysorbate 80 in the formulation is 0.02% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 0.01% polysorbate 80 (w/w). In anotherembodiment, the final concentration of the polysorbate 80 in the formulation is 0.03% polysorbate 20(w/w). In another embodiment, the final concentration of the polysorbate 80 in the formulationis 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbatein the formulation is 0.05% polysorbate 80 (w/w). In another embodiment, the finalconcentration of the polysorbate 80 in the formulation is 1% polysorbate 80 (w/w).In one particular embodiment, the surfactant is polysorbate 20. In some said embodiment, 25the final concentration of polysorbate 20 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 20in the formulation is at least 0.001% to 1% polysorbate 20 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 20 in the formulation is at least 0.01% to 1%polysorbate 20 weight to weight (w/w). In other embodiments, the final concentration of 30polysorbate 20 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 20 (w/w). In another embodiment, the final concentration of thepolysorbate 20 in the formulation is 0.02% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 0.01% polysorbate 20 (w/w). In anotherembodiment, the final concentration of the polysorbate 20 in the formulation is 0.03% polysorbate 35(w/w). In another embodiment, the final concentration of the polysorbate 20 in the formulationis 0.04% polysorbate 80 (w/w). In another embodiment, the final concentration of the polysorbate 142in the formulation is 0.05% polysorbate 20 (w/w). In another embodiment, the finalconcentration of the polysorbate 20 in the formulation is 1% polysorbate 20 (w/w).In one particular embodiment, the surfactant is polysorbate 40. In some said embodiment,the final concentration of polysorbate 40 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 40 5in the formulation is at least 0.001% to 1% polysorbate 40 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 40 in the formulation is at least 0.01% to 1%polysorbate 40 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 40 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 40 (w/w). In another embodiment, the final concentration of the 10polysorbate 40 in the formulation is 1% polysorbate 40 (w/w).In one particular embodiment, the surfactant is polysorbate 60. In some said embodiment,the final concentration of polysorbate 60 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 60in the formulation is at least 0.001% to 1% polysorbate 60 weight to weight (w/w). In some said 15embodiments, the final concentration of polysorbate 60 in the formulation is at least 0.01% to 1%polysorbate 60 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 60 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 60 (w/w). In another embodiment, the final concentration of thepolysorbate 60 in the formulation is 1% polysorbate 60 (w/w). 20In one particular embodiment, the surfactant is polysorbate 65. In some said embodiment,the final concentration of polysorbate 65 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 65in the formulation is at least 0.001% to 1% polysorbate 65 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 65 in the formulation is at least 0.01% to 1% 25polysorbate 65 weight to weight (w/w). In other embodiments, the final concentration ofpolysorbate 65 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 65 (w/w). In another embodiment, the final concentration of thepolysorbate 65 in the formulation is 1% polysorbate 65 (w/w).In one particular embodiment, the surfactant is polysorbate 85. In some said embodiment, 30the final concentration of polysorbate 85 in the formulation is at least 0.0001% to 10% polysorbateweight to weight (w/w). In some said embodiments, the final concentration of polysorbate 85in the formulation is at least 0.001% to 1% polysorbate 85 weight to weight (w/w). In some saidembodiments, the final concentration of polysorbate 85 in the formulation is at least 0.01% to 1%polysorbate 85 weight to weight (w/w). In other embodiments, the final concentration of 35polysorbate 85 in the formulation is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%,0.09% or 0.1% polysorbate 85 (w/w). In another embodiment, the final concentration of thepolysorbate 85 in the formulation is 1% polysorbate 85 (w/w). 143In certain embodiments, the immunogenic composition of the disclosure has a pH of 5.5to 7.5, more preferably a pH of 5.6 to 7.0, even more preferably a pH of 5.8 to 6.0.In one embodiment, the present disclosure provides a container filled with any of theimmunogenic compositions disclosed herein. In one embodiment, the container is selected fromthe group consisting of a vial, a syringe, a flask, a fermentor, a bioreactor, a bag, a jar, an 5ampoule, a cartridge and a disposable pen. In certain embodiments, the container is siliconized.In an embodiment, the container of the present disclosure is made of glass, metals (e.g.,steel, stainless steel, aluminum, etc.) and/or polymers (e.g., thermoplastics, elastomers,thermoplastic-elastomers). In an embodiment, the container of the present disclosure is made ofglass. 10In one embodiment, the present disclosure provides a syringe filled with any of theimmunogenic compositions disclosed herein. In certain embodiments, the syringe is siliconizedand/or is made of glass.A typical dose of the immunogenic composition of the invention for injection has a volumeof 0.1 mL to 2 mL. In an embodiment, the immunogenic composition of the invention for injection 15has a volume of 0.2 mL to 1 mL, even more preferably a volume of about 0.5 mL. 6 Uses of the glycoconjugate and immunogenic compositions of the invention The glycoconjugates disclosed herein may be use as antigens. For example, they may bepart of a vaccine. 20Therefore, in an embodiment, the immunogenic compositions of the invention are for useas a medicament.In an embodiment, the immunogenic compositions of the invention are for use as avaccine.Therefore, in an embodiment, the immunogenic compositions described herein are for use 25in generating an immune response in a subject. In one aspect, the subject is a mammal, such asa human, non-human primate, cat, sheep, pig, horse, bovine or dog. Preferably, the subject is ahuman.The immunogenic compositions described herein may be used in therapeutic orprophylactic methods for preventing, treating or ameliorating a bacterial infection, disease or 30condition in a subject. In particular, immunogenic compositions described herein may be used toprevent, treat or ameliorate a S. pneumoniae infection, disease or condition in a subject.Preferably, the immunogenic compositions described herein may be used to prevent, treat orameliorate S. pneumoniae infection, disease or condition by the serotypes contained in thecomposition in a subject. 35Thus, in one aspect, the disclosure provides a method of preventing, treating orameliorating an infection, disease or condition associated with S. pneumoniae serotype 38 in a 144subject, comprising administering to the subject an immunologically effective amount of animmunogenic composition of the disclosure.In some such embodiments, the infection, disease or condition is selected from the groupconsisting of pneumonia, sinusitis, otitis media, acute otitis media, meningitis, bacteremia, sepsis,pleural empyema, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, 5pericarditis, mastoiditis, cellulitis, soft tissue infection and brain abscess.In an embodiment, the disclosure provides a method of inducing an immune response toS. pneumoniae serotype 38 in a subject comprising administering to the subject animmunologically effective amount of an immunogenic composition of the invention. In one aspect,the subject is a mammal, such as a human, cat, sheep, pig, horse, bovine or dog. Preferably the 10subject is a human.In an embodiment, the immunogenic compositions disclosed herein are for use as avaccine. In such embodiments the immunogenic compositions described herein may be used toprevent S. pneumoniae serotype 38 infection in a subject. Thus, in one aspect, the inventionprovides a method of preventing an infection by S. pneumoniae 38 in a subject comprising 15administering to the subject an immunologically effective amount of an immunogenic compositionof the disclosure. In some such embodiments, the infection is selected from the group consistingof pneumonia, sinusitis, otitis media, acute otitis media, meningitis, bacteremia, sepsis, pleuralempyema, conjunctivitis, osteomyelitis, septic arthritis, endocarditis, peritonitis, pericarditis,mastoiditis, cellulitis, soft tissue infection and brain abscess. In one aspect, the subject is a 20mammal, such as a human, cat, sheep, pig, horse, bovine or dog. Preferably the subject is ahuman.The immunogenic composition of the present disclosure can be used to protect or treat ahuman susceptible to a S. pneumoniae serotype 38 infection, by means of administering theimmunogenic composition via a systemic or mucosal route. In an embodiment, the immunogenic 25composition of the invention is administered by intramuscular, intraperitoneal, intradermal orsubcutaneous routes. . In an embodiment, the immunogenic composition of the invention isadministered by intramuscular, intraperitoneal, intradermal or subcutaneous injection. In anembodiment, the immunogenic composition of the invention is administered by intramuscular orsubcutaneous injection. In an embodiment, the immunogenic composition of the invention is 30administered by intramuscular injection. In an embodiment, the immunogenic composition of theinvention is administered by subcutaneous injection. 7 Subject to be treated with the immunogenic compositions of the invention As disclosed herein, the immunogenic compositions described herein may be used in 35various therapeutic or prophylactic methods for preventing, treating or ameliorating a bacterialinfection, disease or condition in a subject. 145In a preferred embodiment, said subject is a human. In a most preferred embodiment, saidsubject is a newborn (i.e., under three months of age), an infant (i.e., from 3 months to one yearof age) or a toddler (i.e., from one year to four years of age). In an embodiment, the immunogeniccompositions disclosed herein are for use as a vaccine.In such embodiment, the subject to be vaccinated may be less than 1 year of age. For 5example, the subject to be vaccinated can be about 1, about 2, about 3, about 4, about 5, about6, about 7, about 8, about 9, about 10, about 11 or about 12 months of age. In an embodiment,the subject to be vaccinated is about 2, about 4 or about 6 months of age. In another embodiment,the subject to be vaccinated is less than 2 years of age. For example, the subject to be vaccinatedcan be about 12 to about 15 months of age. In some cases, as little as one dose of the 10immunogenic composition according to the invention is needed, but under some circumstances,a second, third or fourth dose may be given (see section 8 below).In an embodiment of the present invention, the subject to be vaccinated is a human adultyears of age or older, more preferably a human adult 55 years of age or older. In anembodiment, the subject to be vaccinated is a human adult 65 years of age or older, 70 years of 15age or older, 75 years of age or older or 80 years of age or older.In an embodiment the subject to be vaccinated is an immunocompromised individual, inparticular a human. An immunocompromised individual is generally defined as a person whoexhibits an attenuated or reduced ability to mount a normal humoral or cellular defense tochallenge by infectious agents. 20In an embodiment of the present invention, the immunocompromised subject to bevaccinated suffers from a disease or condition that impairs the immune system and results in anantibody response that is insufficient to protect against or treat pneumococcal disease.In an embodiment, said disease is a primary immunodeficiency disorder. Preferably, saidprimary immunodeficiency disorder is selected from the group consisting of: combined T- and B- 25cell immunodeficiencies, antibody deficiencies, well-defined syndromes, immune dysregulationdiseases, phagocyte disorders, innate immunity deficiencies, autoinflammatory disorders, andcomplement deficiencies. In an embodiment, said primary immunodeficiency disorder is selectedfrom the one disclosed on page 24, line 11, to page 25, line 19, of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject to 30be vaccinated suffers from a disease selected from the groups consisting of: HIV-infection,acquired immunodeficiency syndrome (AIDS), cancer, chronic heart or lung disorders, congestiveheart failure, diabetes mellitus, chronic liver disease, alcoholism, cirrhosis, spinal fluid leaks,cardiomyopathy, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD),spleen dysfunction (such as sickle cell disease), lack of spleen function (asplenia), blood 35malignancy, leukemia, multiple myeloma, Hodgkin’s disease, lymphoma, kidney failure, nephroticsyndrome and asthma. 146In an embodiment of the present invention, the immunocompromised subject to be vaccinatedsuffers from malnutrition.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated is taking a drug or treatment that lowers the body’s resistance to infection. In anembodiment, said drug is selected from the one disclosed on page 26, line 33, to page 26, line 4, 5of WO 2010/125480.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated is a smoker.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated has a white blood cell count (leukocyte count) below 5 x 10 cells per liter, or below 10x 10 cells per liter, or below 3 x 10 cells per liter, or below 2 x 10 cells per liter, or below 1 x9 cells per liter, or below 0.5 x 10 cells per liter, or below 0.3 x 10 cells per liter, or below 0.1x 10 cells per liter.White blood cell count (leukocyte count): The number of white blood cells (WBC) in theblood. The WBC is usually measured as part of the CBC (complete blood count). White blood 15cells are the infection-fighting cells in the blood and are distinct from the red (oxygen-carrying)blood cells known as erythrocytes. There are different types of white blood cells, includingneutrophils (polymorphonuclear leukocytes; PMN), band cells (slightly immature neutrophils), T-type lymphocytes (T-cells), B-type lymphocytes (B-cells), monocytes, eosinophils, and basophils.All the types of white blood cells are reflected in the white blood cell count. The normal range for 20the white blood cell count is usually between 4,300 and 10,800 cells per cubic millimeter of blood.This can also be referred to as the leukocyte count and can be expressed in international unitsas 4.3 - 10.8 x 10 cells per liter.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated suffers from neutropenia. In a particular embodiment of the present invention, the 25immunocompromised subject to be vaccinated has a neutrophil count below 2 x 10 cells per liter,or below 1 x 10 cells per liter, or below 0.5 x 10 cells per liter, or below 0.1 x 10 cells per liter,or below 0.05 x 10 cells per liter.A low white blood cell count or "neutropenia" is a condition characterized by abnormally low levelsof neutrophils in the circulating blood. Neutrophils are a specific kind of white blood cell that help 30to prevent and fight infections. The most common reason that cancer patients experienceneutropenia is as a side effect of chemotherapy. Chemotherapy-induced neutropenia increasesa patient’s risk of infection and disrupts cancer treatment.In a particular embodiment of the present invention, the immunocompromised subject tobe vaccinated has a CD4+ cell count below 500/mm, or CD4+ cell count below 300/mm, or 35CD4+ cell count below 200/mm, CD4+ cell count below 100/mm, CD4+ cell count below75/mm, or CD4+ cell count below 50/mm. 147CD4 cell tests are normally reported as the number of cells in mm. Normal CD4 counts arebetween 500 and 1,600, and CD8 counts are between 375 and 1,100. CD4 counts dropdramatically in people with HIV.In an embodiment of the invention, any of the immunocompromised subjects disclosedherein is a human male or a human female. 5 8 Regimen In some cases, as little as one dose of the immunogenic composition according to theinvention is needed, but under some circumstances, such as conditions of greater immunedeficiency, a second, third or fourth dose may be given. Following an initial vaccination, subjectscan receive one or several booster immunizations adequately spaced. 10In an embodiment, the schedule of vaccination of the immunogenic composition accordingto the invention is a single dose. In a particular embodiment, said single dose schedule is forhealthy persons being at least 2 years of age.In an embodiment, the schedule of vaccination of the immunogenic composition accordingto the invention is a multiple dose schedule. In a particular embodiment, said multiple dose 15schedule consists of a series of 2 doses separated by an interval of about 1 month to about 2months. In a particular embodiment, said multiple dose schedule consists of a series of 2 dosesseparated by an interval of about 1 month, or a series of 2 doses separated by an interval of aboutmonths.In another embodiment, said multiple dose schedule consists of a series of 3 doses 20separated by an interval of about 1 month to about 2 months. In another embodiment, saidmultiple dose schedule consists of a series of 3 doses separated by an interval of about 1 month,or a series of 3 doses separated by an interval of about 2 months.In another embodiment, said multiple dose schedule consists of a series of 3 dosesseparated by an interval of about 1 month to about 2 months followed by a fourth dose about 10 25months to about 13 months after the first dose. In another embodiment, said multiple doseschedule consists of a series of 3 doses separated by an interval of about 1 month followed by afourth dose about 10 months to about 13 months after the first dose, or a series of 3 dosesseparated by an interval of about 2 months followed by a fourth dose about 10 months to aboutmonths after the first dose. 30In an embodiment, the multiple dose schedule consists of at least one dose (e.g., 1, 2 ordoses) in the first year of age followed by at least one toddler dose.In an embodiment, the multiple dose schedule consists of a series of 2 or 3 dosesseparated by an interval of about 1 month to about 2 months (for example 28-56 days betweendoses), starting at 2 months of age, and followed by a toddler dose at 12-18 months of age. In an 35embodiment, said multiple dose schedule consists of a series of 3 doses separated by an intervalof about 1 month to about 2 months (for example 28-56 days between doses), starting at 2 months 148of age, and followed by a toddler dose at 12-15 months of age. In another embodiment, saidmultiple dose schedule consists of a series of 2 doses separated by an interval of about 2 months,starting at 2 months of age, and followed by a toddler dose at 12-18 months of age.In an embodiment, the multiple dose schedule consists of a 4-dose series of vaccine at 2,4, 6, and 12-15 months of age. 5In an embodiment, a prime dose is given at day 0 and one or more boosts are given atintervals that range from about 2 to about 24 weeks, preferably with a dosing interval of 4-8 weeks.In an embodiment, a prime dose is given at day 0 and a boost is given about 3 monthslater. 9. Analytical methods In an embodiment the invention relates to a method of detecting the presence of D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues in an isolated S. pneumoniaeserotype 38 polysaccharide, said method comprising the step of: a) isolating an S. pneumoniaeserotype 38 polysaccharide and b) detecting the presence of D-2-acetamido-2,6-dideoxy-xylo- 15hexos-4-ulose residues in said polysaccharide.In an embodiment the presence of D-Sug residues is detected by NMR or MassSpectrometry (MS). In an embodiment the presence of D-Sug residues is detected by NMR. Inan embodiment, the presence of D-Sug residues is detected by 1D NMR. In an embodiment, thepresence of D-Sug residues is detected by 1DH or 1DC NMR. In an embodiment, the presence 20of D-Sug residues is detected by 2D NMR. In an embodiment, the presence of D-Sug residues isdetected by Heteronuclear Single Quantum Coherence Spectroscopy (HSQC), Heteronuclearmultiple-bond correlation spectroscopy (HMBC), Nuclear Overhauser Effect Spectroscopy(NOESY), Correlation spectroscopy (COSY), Total Correlation Spectroscopy (TOCSY) orHeteronuclear Single Quantum Coherence Spectroscopy-Total Correlation Spectroscopy 25(HSQC-TOCSY).In an embodiment, the presence of D-Sug residues is detected by 1DH, 2DH-CHeteronuclear Single Quantum Coherence Spectroscopy (HSQC), 2DH-C Heteronuclearmultiple-bond correlation spectroscopy (HMBC), 2DH-C Nuclear Overhauser EffectSpectroscopy (NOESY), 2DH-C Correlation spectroscopy (COSY), 2DH-C Total Correlation 30Spectroscopy (TOCSY), 2DH-C Heteronuclear Single Quantum Coherence Spectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY) or 1DC NMR.In a preferred embodiment, the presence of D-Sug residues is detected by 1DH, 2DH-C Heteronuclear Single Quantum Coherence Spectroscopy (HSQC), or 1DC NMR.In an embodiment, the presence of D-Sug residues is detected by 2DH-C Heteronuclear Single 35Quantum Coherence Spectroscopy (HSQC).In an embodiment the presence of D-Sug residues is detected by Mass Spectrometry(MS). In an embodiment the presence of D-Sug residues is detected by Tandem Mass 149Spectrometry (MS/MS). In an embodiment the presence of D-Sug residues is detected by GasChromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry (CE-MS) or Ion Mobility Spectrometry-MassSpectrometry (IMS/MS or IMMS). In an embodiment the presence of D-Sug residues is detectedby Size-Exclusion Chromatography combined with Mass Spectrometry (SEC/MS). 5In an embodiment the presence of D-Sug residues is detected by Gas Chromatography-Mass Spectrometry (GC-MS). In an embodiment the presence of D-Sug residues is detected byLiquid Chromatography-Mass Spectrometry (LC-MS). In an embodiment the presence of D-Sugresidues is detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In anembodiment the presence of D-Sug residues is detected by Ion Mobility Spectrometry-Mass 10Spectrometry (IMS/MS). In an embodiment the presence of D-Sug residues is detected byHydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS).In an embodiment, the invention relates to a method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) residues in a reduced serotype 38 polysaccharide, said methodcomprising the step of: a) reacting an isolated S. pneumoniae serotype 38 polysaccharide with a 15reducing agent and b) detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) residues insaid reduced polysaccharide.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues isdetected by NMR. In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc)residues is detected by 2D NMR. 20In a preferred embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues isdetected by 2DH-C HSQC NMR.In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byMass Spectrometry (MS). In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc)residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment, the presence 25of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Gas Chromatography-MassSpectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), CapillaryElectrophoresis–Mass Spectrometry (CE-MS) or Ion Mobility Spectrometry-Mass Spectrometry(IMS/MS or IMMS). In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc)residues is detected by Size-Exclusion Chromatography combined with Mass Spectrometry 30(SEC/MS).In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byGas Chromatography-Mass Spectrometry (GC-MS). In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Liquid Chromatography-Mass Spectrometry(LC-MS). In an embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is 35detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In an embodiment, thepresence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS). In an embodiment, the presence of N-acetyl-D- 150fucosamine (D-FucNAc) residues is detected by Hydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS).In an embodiment, said reducing agent is sodium borohydride (NaBH4).In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previouslytreated with an oxidizing agent. In an embodiment, the oxidizing agent is any oxidizing agent 5which oxidizes a terminal hydroxyl group to an aldehyde. In an embodiment, the oxidizing agentis periodate. In an embodiment, the oxidizing agent is orthoperiodate. In a preferred embodiment,the oxidizing agent is sodium periodate. In an embodiment, the oxidizing agent is metaperiodate.In a preferred embodiment the oxidizing agent is sodium metaperiodate.In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previously 10treated with a stable nitroxyl radical compound and an oxidant. In an aspect, said stable nitroxylradical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without affecting secondaryhydroxyl groups. More preferably said molecule has the ability to selectively oxidize primary 15alcohol in the presence of an oxidant, to generate aldehyde groups, without over oxidation tocarboxyl groups. In an aspect, said stable nitroxyl radical compound is TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO,4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4- 20Amino-TEMPO or 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. In an aspect, said stablenitroxyl radical compound is selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino- 25TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radicalcompound is TEMPO. In a further aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or 3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radical 30compound is selected from the groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearicacid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably saidmolecule has the ability to selectively oxidize primary alcohol in the presence of a nitroxyl radical 35compound. In an aspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione,Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or 1511,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the groupconsisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuricacid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione.Preferably said oxidant is N-Chlorosuccinimide. 5In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).
In an embodiment, the invention relates to a method of detecting the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues in a reduced serotype 38 polysaccharide, said methodcomprising the step of: a) reacting an isolated S. pneumoniae serotype 38 polysaccharide with a 10reducing agent and b) detecting the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residuesin said reduced polysaccharide.In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby NMR. In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by 2D NMR. 15In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby Heteronuclear Single Quantum Coherence Spectroscopy (HSQC), Heteronuclear multiple-bond correlation spectroscopy (HMBC), Correlation spectroscopy (COSY), and/or HeteronuclearSingle Quantum Coherence Spectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY).In a preferred embodiment, the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is 20detected by 2DH-C HSQC NMR.In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby Mass Spectrometry (MS). In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment thepresence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Gas 25Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry (CE-MS) or Ion Mobility Spectrometry-MassSpectrometry (IMS/MS or IMMS). In an embodiment the presence of N-acetyl-D-quinovosamine(D-QuiNAc) residues is detected by Size-Exclusion Chromatography combined with MassSpectrometry (SEC/MS). 30In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby Gas Chromatography-Mass Spectrometry (GC-MS). In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Liquid Chromatography-MassSpectrometry (LC-MS). In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In an 35embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by IonMobility Spectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl- 152D-quinovosamine (D-QuiNAc) residues is detected by Hydrophilic Interaction LiquidChromatography -Mass Spectrometry (HILIC-LC/MS).In an embodiment, said reducing agent is sodium borohydride (NaBH4).In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previouslytreated with an oxidizing agent. In an embodiment, the oxidizing agent is any oxidizing agent 5which oxidizes a terminal hydroxyl group to an aldehyde. In an embodiment, the oxidizing agentis periodate. In an embodiment, the oxidizing agent is orthoperiodate. In a preferred embodiment,the oxidizing agent is sodium periodate. In an embodiment, the oxidizing agent is metaperiodate.In a preferred embodiment the oxidizing agent is sodium metaperiodate.In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previously 10treated with a stable nitroxyl radical compound and an oxidant. In an aspect, said stable nitroxylradical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1-pyrrolidinyloxy) moiety. Preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without affecting secondaryhydroxyl groups. More preferably said molecule has the ability to selectively oxidize primary 15alcohol in the presence of an oxidant, to generate aldehyde groups, without over oxidation tocarboxyl groups. In an aspect, said stable nitroxyl radical compound is TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO,4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4- 20Amino-TEMPO or 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. In an aspect, said stablenitroxyl radical compound is selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino- 25TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radicalcompound is TEMPO. In a further aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or 3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radical 30compound is selected from the groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearicacid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably saidmolecule has the ability to selectively oxidize primary alcohol in the presence of a nitroxyl radical 35compound. In an aspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione,Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or 1531,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the groupconsisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuricacid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione.Preferably said oxidant is N-Chlorosuccinimide. 5In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS).In an embodiment, the invention relates to a method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in a reducedserotype 38 polysaccharide, said method comprising the step of: a) reacting an isolated S. 10pneumoniae serotype 38 polysaccharide with a reducing agent and b) detecting the presence ofN-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in saidreduced polysaccharide.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. 15In a preferred embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by 2D-NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Mass Spectrometry (MS). In an embodimentthe presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) 20residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment the presenceof N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-MassSpectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry (CE-MS) or Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS or IMMS). In an embodiment the presence of N- 25acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by Size-Exclusion Chromatography combined with Mass Spectrometry (SEC/MS).In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Gas Chromatography-Mass Spectrometry(GC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl- 30D-quinovosamine (D-QuiNAc) residues is detected by Liquid Chromatography-MassSpectrometry (LC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc)and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Ion Mobility 35Spectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected byHydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS). 154In an embodiment, said reducing agent is sodium borohydride (NaBH4).In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previouslytreated with an oxidizing agent. In an embodiment, the oxidizing agent is any oxidizing agentwhich oxidizes a terminal hydroxyl group to an aldehyde. In an embodiment, the oxidizing agentis periodate. In an embodiment, the oxidizing agent is orthoperiodate. In a preferred embodiment, 5the oxidizing agent is sodium periodate. In an embodiment, the oxidizing agent is metaperiodate.In a preferred embodiment the oxidizing agent is sodium metaperiodate.In an embodiment, said isolated S. pneumoniae serotype 38 polysaccharide has been previouslytreated with a stable nitroxyl radical compound and an oxidant. In an aspect, said stable nitroxylradical compound is a molecule bearing a TEMPO or a PROXYL (2,2,5,5-tetramethyl-1- 10pyrrolidinyloxy) moiety. Preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without affecting secondaryhydroxyl groups. More preferably said molecule has the ability to selectively oxidize primaryalcohol in the presence of an oxidant, to generate aldehyde groups, without over oxidation tocarboxyl groups. In an aspect, said stable nitroxyl radical compound is TEMPO, 2,2,6,6- 15Tetramethyl-4-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO,4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO or 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. In an aspect, said stablenitroxyl radical compound is selected from the groups consisting of TEMPO, 2,2,6,6-Tetramethyl- 204-(methylsulfonyloxy)-1-piperidinooxy, 4-Phosphonooxy-TEMPO, 4-Oxo-TEMPO, 4-Methoxy-TEMPO, 4-Isothiocyanato-TEMPO, 4-(2-Iodoacetamido)-TEMPO free radical, 4-Hydroxy-TEMPO, 4-Cyano-TEMPO, 4-Carboxy-TEMPO, 4-(2-Bromoacetamido)-TEMPO, 4-Amino-TEMPO, 4-Acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl. Preferably said stable nitroxyl radicalcompound is TEMPO. In a further aspect, said stable nitroxyl radical compound is 3 β-DOXYL-5 α- 25cholestane, 5-DOXYL-stearic acid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3-Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL or 3-Cyano-PROXYL. In a further aspect, said stable nitroxyl radicalcompound is selected from the groups consisting of 3 β-DOXYL-5 α-cholestane, 5-DOXYL-stearicacid, 16-DOXYL-stearic acid, Methyl 5-DOXYL-stearate, 3-(Aminomethyl)-PROXYL, 3- 30Carbamoyl-PROXYL, 3-Carbamoyl-2,2,5,5-tetramethyl-3-pyrrolin-1-oxyl, 3-Carboxy-PROXYL, 3-Cyano-PROXYL. In an aspect, the oxidant is a molecule bearing a N-halo moiety. Preferably saidmolecule has the ability to selectively oxidize primary alcohol in the presence of a nitroxyl radicalcompound. In an aspect, said oxidant is N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, 35Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid or1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione. In an aspect, said oxidant is selected from the groupconsisting of N-Chlorosuccinimide, N-Bromosuccinimide, N-Iodosuccinimide, Dichloroisocyanuric 155acid, 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione, Dibromoisocyanuric acid, 1,3,5-tribromo-1,3,5-triazinane-2,4,6-trione, Diiodoisocyanuric acid and 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione.Preferably said oxidant is N-Chlorosuccinimide.In an aspect, said stable nitroxyl radical compound is 2,2,6,6-Tetramethyl-1-piperidinyloxy freeradical (TEMPO) and said oxidant is N-Chlorosuccinimide (NCS). 5In an embodiment the invention relates to a method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues in S.pneumoniae serotype 38 glycoconjugate, said method comprising the step of: a) preparing a S.pneumoniae serotype 38 glycoconjugate and b) detecting the presence of N-acetyl-D-fucosamine(D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues in said glycoconjugate. 10In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by 2D NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D- 15quinovosamine (D-QuiNAc) residues is detected by Heteronuclear Single Quantum CoherenceSpectroscopy (HSQC), Heteronuclear multiple-bond correlation spectroscopy (HMBC),Correlation spectroscopy (COSY), and/or Heteronuclear Single Quantum CoherenceSpectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY).In a preferred embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl- 20D-quinovosamine (D-QuiNAc) residues is detected by 2DH-C HSQC NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Mass Spectrometry (MS). In an embodimentthe presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment the 25presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc)residues is detected by Gas Chromatography-Mass Spectrometry (GC-MS), LiquidChromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry(CE-MS) or Ion Mobility Spectrometry-Mass Spectrometry (IMS/MS or IMMS). In an embodimentthe presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D- 30QuiNAc) residues is detected by Size-Exclusion Chromatography combined with MassSpectrometry (SEC/MS).In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Gas Chromatography-Mass Spectrometry(GC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl- 35D-quinovosamine (D-QuiNAc) residues is detected by Liquid Chromatography-MassSpectrometry (LC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc)and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Capillary Electrophoresis– 156Mass Spectrometry (CE-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected byHydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS). 5In an embodiment the invention relates to a method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in S. pneumoniaeserotype 38 glycoconjugate, said method comprising the step of: a) preparing a S. pneumoniaeserotype 38 glycoconjugate and b) detecting the presence of N-acetyl-D-fucosamine (D-FucNAc)and N-acetyl-D-quinovosamine (D-QuiNAc) residues in said glycoconjugate. 10In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by 2D NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D- 15quinovosamine (D-QuiNAc) residues is detected by Heteronuclear Single Quantum CoherenceSpectroscopy (HSQC), Heteronuclear multiple-bond correlation spectroscopy (HMBC),Correlation spectroscopy (COSY), and/or Heteronuclear Single Quantum CoherenceSpectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY).In a preferred embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D- 20quinovosamine (D-QuiNAc) residues is detected by 2DH-C HSQC NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Mass Spectrometry (MS). In an embodimentthe presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc)residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment the presence 25of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by Gas Chromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-MassSpectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry (CE-MS) or Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS or IMMS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is 30detected by Size-Exclusion Chromatography combined with Mass Spectrometry (SEC/MS).In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Gas Chromatography-Mass Spectrometry(GC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Liquid Chromatography-Mass 35Spectrometry (LC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc)and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D- 157FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected byHydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS).In an embodiment the invention relates to a method of detecting the presence of N-acetyl-D- 5fucosamine (D-FucNAc) residues in S. pneumoniae serotype 38 glycoconjugate, said methodcomprising the step of: a) preparing a S. pneumoniae serotype 38 glycoconjugate and b) detectingthe presence of N-acetyl-D-fucosamine (D-FucNAc) residues in said glycoconjugate.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byNMR. In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected 10by 2D NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byHeteronuclear Single Quantum Coherence Spectroscopy (HSQC), Heteronuclear multiple-bondcorrelation spectroscopy (HMBC), Correlation spectroscopy (COSY), and/or HeteronuclearSingle Quantum Coherence Spectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY). 15In a preferred embodiment, the presence of N-acetyl-D-fucosamine (D-FucNAc) residues isdetected by 2DH-C HSQC NMR.In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byMass Spectrometry (MS). the presence of N-acetyl-D-fucosamine (D-FucNAc) residues isdetected by Tandem Mass Spectrometry (MS/MS). In an embodiment the presence of N-acetyl- 20D-fucosamine (D-FucNAc) residues is detected by Gas Chromatography-Mass Spectrometry(GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis–MassSpectrometry (CE-MS) or Ion Mobility Spectrometry-Mass Spectrometry (IMS/MS or IMMS). Inan embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Size-Exclusion Chromatography combined with Mass Spectrometry (SEC/MS). 25In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected byGas Chromatography-Mass Spectrometry (GC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Liquid Chromatography-Mass Spectrometry(LC-MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues isdetected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In an embodiment the 30presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Ion MobilitySpectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Hydrophilic Interaction Liquid Chromatography -Mass Spectrometry (HILIC-LC/MS).In an embodiment the invention relates to a method of detecting the presence of N-acetyl-D- 35quinovosamine (D-QuiNAc) residues in S. pneumoniae serotype 38 glycoconjugate, said methodcomprising the step of: a) preparing a S. pneumoniae serotype 38 glycoconjugate and b) detectingthe presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues in said glycoconjugate. 158In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby NMR. In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by 2D NMR.In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby Heteronuclear Single Quantum Coherence Spectroscopy (HSQC), Heteronuclear multiple- 5bond correlation spectroscopy (HMBC), Correlation spectroscopy (COSY), and/or HeteronuclearSingle Quantum Coherence Spectroscopy-Total Correlation Spectroscopy (HSQC-TOCSY).In a preferred embodiment, the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues isdetected by 2DH-C HSQC NMR.In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected 10by Mass Spectrometry (MS). In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Tandem Mass Spectrometry (MS/MS). In an embodiment thepresence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by GasChromatography-Mass Spectrometry (GC-MS), Liquid Chromatography-Mass Spectrometry (LC-MS), Capillary Electrophoresis–Mass Spectrometry (CE-MS) or Ion Mobility Spectrometry-Mass 15Spectrometry (IMS/MS or IMMS). In an embodiment the presence of N-acetyl-D-quinovosamine(D-QuiNAc) residues is detected by Size-Exclusion Chromatography combined with MassSpectrometry (SEC/MS).In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detectedby Gas Chromatography-Mass Spectrometry (GC-MS). In an embodiment the presence of N- 20acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Liquid Chromatography-MassSpectrometry (LC-MS). In an embodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Capillary Electrophoresis–Mass Spectrometry (CE-MS). In anembodiment the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by IonMobility Spectrometry-Mass Spectrometry (IMS/MS). In an embodiment the presence of N-acetyl- 25D-quinovosamine (D-QuiNAc) residues is detected by Hydrophilic Interaction LiquidChromatography -Mass Spectrometry (HILIC-LC/MS).
Particular embodiments of the invention are set forth in the following numbered paragraphs 1 to 330: 301. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue and wherein all the repeating units comprise the same Y residue. [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 1592. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units. 3. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units. 4. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 0% to about 100% of the 20repeating units.
. The isolated S. pneumoniae serotype 38 saccharide of paragraph 4 wherein said O-acetyl group is present in about 50% to about 100% of the repeating units. 6. The isolated S. pneumoniae serotype 38 saccharide of paragraph 4 wherein said O-acetyl group is present in about 80% to about 100% of the repeating units 25 7. The isolated S. pneumoniae serotype 38 saccharide of paragraph 4 wherein said O-acetyl group is present in about 90% to about 100% of the repeating units. 8. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 100% of the repeating units. 35 [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n 2↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n 2↑β-D- Galf 1609. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: 5where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 95% of the repeating units.
. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Ser is present in about 0% to about 100% of the repeating units. 15 11. The isolated S. pneumoniae serotype 38 saccharide of paragraph 10 wherein said O-acetyl group is present in about 50% to about 100% of the repeating units. 12. The isolated S. pneumoniae serotype 38 saccharide of paragraph 10 wherein said O-acetyl group is present in about 80% to about 100% of the repeating units 13. The isolated S. pneumoniae serotype 38 saccharide of paragraph 10 wherein said O- 20acetyl group is present in about 90% to about 100% of the repeating units. 14. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Ser is present in about 100% of the repeating units.
. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit : where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Ser is present in about 95% of the repeating units. 35 [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n 2↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 16116. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Gly is present in about 0% to about 100% of the repeating units. 17. The isolated S. pneumoniae serotype 38 saccharide of paragraph 16 wherein said O-acetyl group is present in about 50% to about 100% of the repeating units. 18. The isolated S. pneumoniae serotype 38 saccharide of paragraph 16 wherein said O- 10acetyl group is present in about 80% to about 100% of the repeating units 19. The isolated S. pneumoniae serotype 38 saccharide of paragraph 16 wherein said O-acetyl group is present in about 90% to about 100% of the repeating units.
. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 of 20β-D-Galp4OAc,6Gly is present in about 100% of the repeating units. 21. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units and wherein the O-acetyl group at position 4 ofβ-D-Galp4OAc,6Gly is present in 95% of the repeating units. 22. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue and wherein all the repeating units comprise the same Y residue. 35 [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp,6 (Y) -(1→3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 16223. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units. 24. An isolated S. pneumoniae serotype 38 saccharide with the following repeating unit: where n represents the number of repeating units. 24. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having between 10 and 5,000 repeating units.
. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23 15having between 50 and 4,500 repeating units. 26. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having between 100 and 4,500 repeating units. 27. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having between 150 and 2,000 repeating units. 20 28. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 5 kDa and 5000 kDa. 29. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 5 kDa and 2000 kDa.
. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23 25having a weight average molecular weight between 50 kDa and 5000 kDa. 31. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 50 kDa and 1000 kDa. 32. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 100 kDa and 5000 kDa. 30 33. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 100 kDa and 1000 kDa. [→ 3)-β-D-Galp,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf 16334. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 100 kDa and 500 kDa.
. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 300 kDa and 5000 kDa. 36. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23 5having a weight average molecular weight between 300 kDa and 1000 kDa. 37. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 500 kDa and 3000 kDa. 38. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 500 kDa and 2000 kDa. 10 39. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23having a weight average molecular weight between 500 kDa and 1000 kDa. 40. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23sized to a weight average molecular weight between 10 kDa and 1000 kDa. 41. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23 15sized to a weight average molecular weight between 50 kDa and 500 kDa. 42. The isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-23sized to a weight average molecular weight between 100 kDa and 400 kDa. 43. A glycoconjugate comprising an isolated S. pneumoniae serotype 38 saccharide ofany one of paragraphs 1-42 conjugated to a carrier protein. 20 44. A glycoconjugate consisting of an isolated S. pneumoniae serotype 38 saccharide ofany one of paragraphs 1-42 conjugated to a carrier protein. 45. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues in every100 saccharide repeat units of the saccharide. 25 46. The serotype 38 glycoconjugate of paragraph 45 comprising between about 1 to aboutN-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of thesaccharide. 46. The serotype 38 glycoconjugate of paragraph 45 comprising between about 1 to aboutN-acetyl-D-fucosamine (D-FucNAc) residues in every 100 saccharide repeat units of the 30saccharide. 47. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising between about 0.5 to about 35 N-acetyl-D-quinovosamine (D-QuiNAc) residues inevery 100 saccharide repeat units of the saccharide. 16448. The serotype 38 glycoconjugate of paragraph 47 comprising between about 0.5 toabout 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units ofthe saccharide. 49. The serotype 38 glycoconjugate of paragraph 47 comprising between about 0.5 toabout 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of 5the saccharide. 50. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues andbetween about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. 10 51. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising between about 1 to about 68 N-acetyl-D-fucosamine (D-FucNAc) residues andbetween about 0.5 to about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. 52. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide 15comprising between about 1 to about 65 N-acetyl-D-fucosamine (D-FucNAc) residues andbetween about 0.5 to about 32.5 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. 53. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising between about 1 to about 60 N-acetyl-D-fucosamine (D-FucNAc) residues and 20between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100saccharide repeat units of the saccharide. 54. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharidecomprising about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the saccharide. 25 55. The serotype 38 glycoconjugate of any one of paragraphs 45-54 comprising a serotypecapsular saccharide comprising N-acetyl-D-fucosamine (D-FucNAc) residues and N-acetyl-D-quinovosamine (D-QuiNAc) residues where the number of D-FucNAc residues is about thedouble of the number of D-QuiNAc residues. 56. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide 30comprising N-acetyl-D-fucosamine (D-FucNAc), N-acetyl-D-quinovosamine (D-QuiNAc) and D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues. 57. The serotype 38 glycoconjugate of paragraph 56 comprising a serotype 38 capsularsaccharide comprising at the same position of the repeat unit either a N-acetyl-D-fucosamine (D- 165FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. 58. The serotype 38 glycoconjugate of paragraph 56 or 57 wherein the number of D-FucNAc residues is about the double of the number of D-QuiNAc residues. 59. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with the 5following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and where Xrepresents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine(D-QuiNAc) residue. 60. The serotype 38 glycoconjugate of paragraph 59 wherein said serotype 38 capsular 15saccharide comprises about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 61. The serotype 38 glycoconjugate of paragraph 59 wherein said serotype 38 capsularsaccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N- 20acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 62. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with thefollowing repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue wherein all the repeating units comprise the same Y residue and where X 30represents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine(D-QuiNAc) residue. 63. The serotype 38 glycoconjugate of paragraph 62 wherein said serotype 38 capsularsaccharide comprises about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of the 35saccharide. [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf 16664. The serotype 38 glycoconjugate of paragraph 62 wherein said serotype 38 capsularsaccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 65. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with the 5following repeating unit: where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. 66. The serotype 38 glycoconjugate of paragraph 65 wherein said serotype 38 capsularsaccharide comprises between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues, 15between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues and betweenabout 0 to about 98.5 D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues in every100 saccharide repeat units of the saccharide. 67. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with thefollowing repeating unit: 20 where n represents the number of repeating units and where X represents either a N-acetyl-D- 25fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine (D-QuiNAc) residue. 68. The serotype 38 glycoconjugate of paragraph 67 wherein said serotype 38 capsularsaccharide comprises about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 30 69. The serotype 38 glycoconjugate of paragraph 67 wherein said serotype 38 capsularsaccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 70. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with the 35following repeating unit: [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Ser-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf 167 where n represents the number of repeating units and where X represents either a N-acetyl-D- 5fucosamine (D-FucNAc) residue, a N-acetyl-D-quinovosamine (D-QuiNAc) residue or a D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residue. 71. The serotype 38 glycoconjugate of paragraph 70 wherein said serotype 38 capsularsaccharide comprises between about 1 to about 70 N-acetyl-D-fucosamine (D-FucNAc) residues,between about 0.5 to about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues and between 10about 0 to about 98.5 D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues in every100 saccharide repeat units of the saccharide. 72. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with thefollowing repeating unit: where n represents the number of repeating units and where X represents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine (D-QuiNAc) residue. 20 73. The serotype 38 glycoconjugate of paragraph 72 wherein said serotype 38 capsularsaccharide comprises about 70 N-acetyl-D-fucosamine (D-FucNAc) residues and about 30 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 74. The serotype 38 glycoconjugate of paragraph 72 wherein said serotype 38 capsular 25saccharide comprises about 68 N-acetyl-D-fucosamine (D-FucNAc) residues and about 32 N-acetyl-D-quinovosamine (D-QuiNAc) residues in every 100 saccharide repeat units of thesaccharide. 75. The serotype 38 glycoconjugate of paragraph 43 or 44 wherein said serotype 38glycoconjugate comprises a serotype 38 saccharide covalently conjugated to a carrier protein 30through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer. 75. The serotype 38 glycoconjugate of paragraph 43 or 44 wherein said serotype 38glycoconjugate is prepared by click chemistry. 76. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (IV): 35 [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6Gly-(1 →3)- α-D- GlcpNac-(1 →3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf 168 (IV),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O, 5CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4, wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units. 77. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalently 10conjugated to a carrier protein (CP) through a spacer and having the general formula (IV), whereinX is CH2(CH2) n’, where n’ is 2 and wherein X' is CH2O(CH 2)n’’CH2C=O where n’’ is 1. 78. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (V), (V) 15 wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units. 79. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (XII): 169 (XII),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 0 to 10 and m is selected from 1 to 4,wherein X' is selected from the group consisting of CH2(CH2)n", CH2O(CH 2)n’’CH2, 5CH2O(CH 2CH2O)m’(CH2)n’’CH2, where n’’ is selected from 0 to 10 and m’ is selected from 0 to 4and wherein the structure in square backet represents a repeat unit of the serotype 38 saccharideand wherein n represents the number of repeating units. 80. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (IV), wherein 10X is CH2(CH2) n’, where n’ is 0 and wherein X' is CH2(CH2) n" where n’’ is 0. 81. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (XIII), (XIII)wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide and 15wherein n represents the number of repeating units. 80. The glycoconjugate of any one of paragraphs 45 to 81 wherein said a serotype 38saccharide is an isolated S. pneumoniae serotype 38 saccharide of any one of paragraphs 1-42. 81. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is 20between 50 kDa and 1,000 kDa. 17082. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 100 kDa and 600 kDa. 83. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is 5between 100 kDa and 400 kDa. 84. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa. 85. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38 10glycoconjugate has a weight average molecular weight (Mw) of between 250 kDa and 20,000kDa. 86. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38glycoconjugate has a weight average molecular weight (Mw) of between 500 kDa and 15,000kDa. 15 87. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38glycoconjugate has a weight average molecular weight (Mw) of between 500 kDa and 10,000kDa. 87a. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa and 10,000 20kDa. 87b. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa and wherein said serotype 38 glycoconjugate has a weightaverage molecular weight (Mw) of between 1,000 kDa and 10,000 kDa. 25 88. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38glycoconjugate has a weight average molecular weight (Mw) of between 750 kDa and 7,500 kDa. 89. The glycoconjugate of any one of paragraphs 43 to 84 wherein said serotype 38glycoconjugate has a weight average molecular weight (Mw) of between 1,000 kDa and 5,000kDa. 30 90. The glycoconjugate of any one of paragraphs 43 to 89 wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 2 and 15. 91. The glycoconjugate of any one of paragraphs 43 to 89 wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 2 and 10. 17192. The glycoconjugate of any one of paragraphs 43 to 89 wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 3 and 5. 93. The glycoconjugate of any one of paragraphs 43 to 89 wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 2 and 6. 94. The glycoconjugate of any one of paragraphs 43 to 89 wherein the degree of 5conjugation of said serotype 38 glycoconjugate is between 4 and 10. 94a. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa and wherein the degree of 10conjugation of said serotype 38 glycoconjugate is between 2 and 10. 94b. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa and wherein the degree of 15conjugation of said serotype 38 glycoconjugate is between 4 and 10. 95. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 3.0. 97. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 2.0. 20 98. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5. 99. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.8 and 1.2. 100. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotype 25saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.0. 101. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 1.0 and 1.5. 102. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 1.0 and 2.0. 30 103. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.8 and 1.2. 104. The glycoconjugate of any one of paragraphs 43 to 94 wherein the ratio of serotypesaccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1. 172104a. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5 and wherein the 5degree of conjugation of said serotype 38 glycoconjugate is between 4 and 10. 104b. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 10saccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1 and wherein thedegree of conjugation of said serotype 38 glycoconjugate is between 4 and 10. 105. The glycoconjugate of any one of paragraphs 43 to 104 wherein said serotype 38glycoconjugate comprises less than about 50% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide. 15 106. The glycoconjugate of any one of paragraphs 43 to 104 wherein said serotype 38glycoconjugate comprises less than about 25% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide. 107. The glycoconjugate of any one of paragraphs 43 to 104 wherein said serotype 38glycoconjugate comprises less than about 20% of free serotype 38 saccharide compared to the 20total amount of serotype 38 saccharide. 108. The glycoconjugate of any one of paragraphs 43 to 104 wherein said serotype 38glycoconjugate comprises less than about 15% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide. 108a. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight average 25molecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5, wherein thedegree of conjugation of said serotype 38 glycoconjugate is between 4 and 10 and wherein said 30serotype 38 glycoconjugate comprises less than about 20% of free serotype 38 saccharidecompared to the total amount of serotype 38 saccharide. 108b. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average 35molecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 173saccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1, wherein thedegree of conjugation of said serotype 38 glycoconjugate is between 4 and 10 and wherein saidserotype 38 glycoconjugate comprises less than about 20% of free serotype 38 saccharidecompared to the total amount of serotype 38 saccharide. 109. The glycoconjugate of any one of paragraphs 43 to 108 wherein at least 30% of the 5serotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 110. The glycoconjugate of any one of paragraphs 43 to 108 wherein at least 40% of theglycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 111. The glycoconjugate of any one of paragraphs 43 to 108 wherein at least 60% of theserotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 10 112. The glycoconjugate of any one of paragraphs 43 to 108 wherein between 50% and80% of the serotype 38 glycoconjugate has a K d below or equal to 0.3 in a CL-4B column. 113. The glycoconjugate of any one of paragraphs 43 to 108 wherein between 65% and80% of the serotype 38 glycoconjugate has a K d below or equal to 0.3 in a CL-4B column. 113a. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight average 15molecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation isbetween 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5, wherein thedegree of conjugation of said serotype 38 glycoconjugate is between 4 and 10, wherein said 20serotype 38 glycoconjugate comprises less than about 20% of free serotype 38 saccharidecompared to the total amount of serotype 38 saccharide and wherein between 65% and 80% ofthe serotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 113b. The glycoconjugate of any one of paragraphs 43 to 81 wherein the weight averagemolecular weight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is 25between 150 kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight averagemolecular weight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1, wherein thedegree of conjugation of said serotype 38 glycoconjugate is between 4 and 10, wherein saidserotype 38 glycoconjugate comprises less than about 20% of free serotype 38 saccharide 30compared to the total amount of serotype 38 saccharide and wherein between 65% and 80% ofthe serotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column. 114. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is selected in the group consisting of: TT, DT, DTmutants and a C5a peptidase from Streptococcus (SCP). 35 174115. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is rhizavidin [aa 45-179J-GGGGSSS-SP1500-AAA-SP0785] (CP1). 115a. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62- 5185] fusion protein (SPP2). 116. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is DT. 117. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is TT. 10 118. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is PD. 119. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is CRM 197 or a C5a peptidase from Streptococcus(SCP). 15 120. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is CRM 197. 121. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is SCP. 122. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier protein 20of the serotype 38 saccharide glycoconjugate is an enzymatically inactive SCP. 123. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is an enzymatically inactive SCP from GBS (SCPB). 124. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is an enzymatically inactive SCP from GAS (SCPA). 25 125. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is a fragment of an SCPB. 126. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is an enzymatically inactive fragment of SCP whichconsists of SEQ ID NO: 1. 30 127. The glycoconjugate of any one of paragraphs 43 to 113 wherein the carrier proteinof the serotype 38 saccharide glycoconjugate is an enzymatically inactive fragment of SCP whichconsists of SEQ ID NO: 2. 175128. An immunogenic composition comprising a S. pneumoniae serotype 38 saccharideaccording to any one of paragraphs 1-42. 129. An immunogenic composition comprising a S. pneumoniae serotype 38 saccharideglycoconjugate according to any one of paragraphs 43-127. 130. The immunogenic composition of paragraph 129 comprising from 1 to 45 different 5glycoconjugates. 131. The immunogenic composition of paragraph 129 comprising from 1 to 45glycoconjugates from different serotypes of S. pneumoniae. 132. The immunogenic composition of paragraph 129 comprising glycoconjugates from 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 different serotypes of S. 10pneumoniae. 133. The immunogenic composition of paragraph 129 comprising glycoconjugates fromor 20 different serotypes of S. pneumoniae. 134. The immunogenic composition of paragraph 129 which is a 21, 22, 23, 24 or 25-valent pneumococcal conjugate composition. 15 135. The immunogenic composition of paragraph 129 which is a 21-valent pneumococcalconjugate composition. 136. The immunogenic composition of paragraph 129 which is a 22-valent pneumococcalconjugate composition. 137. The immunogenic composition of paragraph 129 which is a 23-valent pneumococcal 20conjugate composition. 138. The immunogenic composition of paragraph 129 which is a 24-valent pneumococcalconjugate composition. 139. The immunogenic composition of paragraph 129 which is a 25-valent pneumococcalconjugate composition. 25 140. The immunogenic composition of paragraph 129 comprising glycoconjugates fromto 45 glycoconjugates from different serotypes of S. pneumoniae. 141. The immunogenic composition of paragraph 129 comprising glycoconjugates from26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 different serotypesof S. pneumoniae. 30 142. The immunogenic composition of paragraph 129 comprising glycoconjugates fromor 45 different serotypes of S. pneumoniae. 176142a. The immunogenic composition of paragraph 129 comprising glycoconjugates fromdifferent serotypes of S. pneumoniae. 143. The immunogenic composition of paragraph 129 which is a 35, 36, 37, 38, 39, 40,41, 42, 43, 44 or 45-valent pneumococcal conjugate composition. 143a. The immunogenic composition of paragraph 129 which is a 35-valent pneumococcal 5conjugate composition. 144. The immunogenic composition of paragraph 129 which is a 40, 41, 42, 43, 44 or 45-valent pneumococcal conjugate composition. 145. The immunogenic composition of paragraph 129 which is a 40-valent pneumococcalconjugate composition. 10 146. The immunogenic composition of paragraph 129 which is a 41-valent pneumococcalconjugate composition. 147. The immunogenic composition of paragraph 129 which is a 42-valent pneumococcalconjugate composition. 148. The immunogenic composition of paragraph 129 which is a 43-valent pneumococcal 15conjugate composition. 149. The immunogenic composition of paragraph 129 which is a 44-valent pneumococcalconjugate composition. 150. The immunogenic composition of paragraph 129 which is a 45-valent pneumococcalconjugate composition. 20 151. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F. 152. The immunogenic composition of paragraph 151 further comprising glycoconjugatesfrom S. pneumoniae serotypes 1, 5 and 7F. 153. The immunogenic composition of paragraph 152 further comprising a glycoconjugate 25from S. pneumoniae serotype 3. 154. The immunogenic composition of paragraph 153 further comprising glycoconjugatesfrom S. pneumoniae serotypes 6A and 19A. 155. The immunogenic composition of paragraph 154 further comprising glycoconjugatesfrom S. pneumoniae serotype 22F and 33F. 30 156. The immunogenic composition of paragraph 155 further comprising glycoconjugatesfrom S. pneumoniae serotypes 8, 10A, 11A, 12F and 15B. 177157. The immunogenic composition of paragraph 156 further comprising a glycoconjugatefrom S. pneumoniae serotype 2. 158. The immunogenic composition of paragraph 157 further comprising a glycoconjugatefrom S. pneumoniae serotype 9N. 159. The immunogenic composition of paragraph 158 further comprising a glycoconjugate 5from S. pneumoniae serotype 17F. 160. The immunogenic composition of paragraph 159 further comprising a glycoconjugatefrom S. pneumoniae serotype 20. 161. The immunogenic composition of paragraph 160 further comprising a glycoconjugatefrom S. pneumoniae serotype 2. 10 162. The immunogenic composition of paragraph 161 further comprising a glycoconjugatefrom S. pneumoniae serotype 15C. 163. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F and whereinsaid immunogenic composition is an 8-valent pneumococcal conjugate composition. 15 164. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F andwherein said immunogenic composition is an 11-valent pneumococcal conjugate composition. 165. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 2023F and wherein said immunogenic composition is a 14-valent pneumococcal conjugatecomposition. 166. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F,22F, 23F and 33F and wherein said immunogenic composition is a 16-valent pneumococcal 25conjugate composition. 167. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F and wherein said immunogenic composition is a 21-valentpneumococcal conjugate composition. 30 168. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15C, 18C, 19A, 19F, 22F, 23F and 33F. 178169. The immunogenic composition of paragraph 168 which is a 21-valent pneumococcalconjugate composition. 170. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 5 171. The immunogenic composition of paragraph 170 which is a 22-valent pneumococcalconjugate composition. 172. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F,14, 15C, 18C, 19A, 19F, 22F, 23F and 33F. 10 173. The immunogenic composition of paragraph 172 which is a 22-valent pneumococcalconjugate composition. 174. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A, 12F,14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 15 175. The immunogenic composition of paragraph 174 which is a 22-valent pneumococcalconjugate composition. 176. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 20 177. The immunogenic composition of paragraph 176 which is a 23-valent pneumococcalconjugate composition. 178. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 22F, 23F and 33F. 25 179. The immunogenic composition of paragraph 178 which is a 24-valent pneumococcalconjugate composition. 180. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 9N, 10A, 11A,12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F. 30 181. The immunogenic composition of paragraph 180 which is a 25-valent pneumococcalconjugate composition. 179182. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23F and 33F. 183. The immunogenic composition of paragraph 182 which is a 22-valent pneumococcalconjugate composition. 5 184. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. 185. The immunogenic composition of paragraph 184 which is a 22-valent pneumococcalconjugate composition. 10 186. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23B, 23F and 33F. 187. The immunogenic composition of paragraph 186 which is a 22-valent pneumococcalconjugate composition. 15 188. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 24F and 33F. 189. The immunogenic composition of paragraph 188 which is a 22-valent pneumococcalconjugate composition. 20 190. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15B, 18C, 19A, 19F, 22F, 23F, 33F and 35B. 191. The immunogenic composition of paragraph 190 which is a 22-valent pneumococcalconjugate composition. 25 192. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23F and 33F. 193. The immunogenic composition of paragraph 192 which is a 23-valent pneumococcalconjugate composition. 30 194. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14,15A, 15B, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F and 35B. 180195. The immunogenic composition of paragraph 194 wherein the S. pneumoniaesaccharides are conjugated to CRM 197. 196. The immunogenic composition of paragraph 194 wherein the S. pneumoniaesaccharides from serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A,19F, 22F, 23A, 23B, 23F, 24F, 33F, 35B and 38 are conjugated to CRM 197 and the S. pneumoniae 5saccharide serotype 3 is conjugated to SCP. 197. The immunogenic composition of paragraph 196 which is a 26-valent pneumococcalconjugate composition. 198. The immunogenic composition of any one of paragraphs 129-150 further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S. 10pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B, 24F, 27,29, 31, 33B, 34, 35B and 35F. 199. The immunogenic composition of any one of paragraphs 129-150 further comprisingtwenty-one glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B, 24F, 27, 1529, 31, 33B, 34, 35B and 35F. 200. The immunogenic composition of paragraph 199 which is a 22-valent pneumococcalconjugate composition. 201. The immunogenic composition of any one of paragraphs 129-150 further comprisingglycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B, 2024F, 27, 29, 31, 33B, 34, 35B and 35. 202. The immunogenic composition of paragraph 201 which is a 23-valent pneumococcalconjugate composition. 203. The immunogenic composition of any one of paragraphs 129-150 further comprisingat least one glycoconjugate selected from the group consisting of glycoconjugates from S. 25pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. 204. The immunogenic composition of any one of paragraphs 129-150 further comprisingtwenty-two glycoconjugates selected from the group consisting of glycoconjugates from S.pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B, 3024F, 27, 29, 31, 33B, 34, 35B and 35F. 205. The immunogenic composition of paragraph 204 which is a 23-valent pneumococcalconjugate composition. 206. The immunogenic composition of any one of paragraphs 129-150 further comprisingtwenty-three glycoconjugates selected from the group consisting of glycoconjugates from S. 35 181pneumoniae serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. 207. The immunogenic composition of paragraph 206 which is a 24-valent pneumococcalconjugate composition. 208. The immunogenic composition of any one of paragraphs 129-150 further comprising 5glycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 20, 21, 22A, 23A, 23B, 24B,24F, 27, 29, 31, 33B, 34, 35B and 35F. 209. The immunogenic composition of paragraph 208 which is a 23-valent pneumococcalconjugate composition. 210. The immunogenic composition of any one of paragraphs 129-150 further comprising 10glycoconjugates from serotypes 2, 3, 7C, 9N, 10B, 15A, 16F, 17F, 19A, 19F, 20, 21, 22A, 23A,23B, 24B, 24F, 27, 29, 31, 33B, 34, 35B and 35F. 211. The immunogenic composition of paragraph 210 which is a 23-valent pneumococcalconjugate composition. 212. The immunogenic composition of any one of paragraphs 128-211 further comprising 15at least one, two or three adjuvants. 213. The immunogenic composition of any one of paragraphs 128-211 further comprisingone adjuvant. 214. The immunogenic composition of any one of paragraphs 128-211 further comprisingtwo adjuvants. 20 215. The immunogenic composition of any one of paragraphs 128-211 further comprisingaluminum salts (alum) as adjuvant. 216. The immunogenic composition of any one of paragraphs 128-211 further comprisingaluminum phosphate as adjuvant. 217. The immunogenic composition of any one of paragraphs 128-211 further comprising 25a saponin based adjuvant. 218. The immunogenic composition of any one of paragraphs 128-211 further comprisinga QS21 based adjuvant. 219. The immunogenic composition of any one of paragraphs 128-211 further comprisinga CpG Oligonucleotide as adjuvant. 30 220. The immunogenic composition of any one of paragraphs 128-219 for use as avaccine. 182221. The immunogenic composition of any one of paragraphs 128-219 for use in a methodof preventing, treating or ameliorating an infection, disease or condition associated with S.pneumoniae serotype 38 in a subject. 222. The immunogenic composition of any one of paragraphs 128-219 for use in a methodof inducing an immune response to S. pneumoniae serotype 38 in a subject said method 5comprising administering to the subject an immunologically effective amount of said immunogeniccomposition. 223. The immunogenic composition of any one of paragraphs 128-219 for use in a methodof preventing an infection by S. pneumoniae 38 in a subject said method comprisingadministering to the subject an immunologically effective amount of said immunogenic 10composition. 224. A method of detecting the presence of D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose (D-Sug) residues in an isolated S. pneumoniae serotype 38 polysaccharide, said methodcomprising the step of: a) isolating an S. pneumoniae serotype 38 polysaccharide and b)detecting the presence of D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose residues in said 15polysaccharide. 225. the method of paragraph 224 wherein the presence of D-Sug residues is detected byNMR or Mass Spectrometry (MS). 226. A method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) residuesin a reduced serotype 38 polysaccharide, said method comprising the step of: a) reacting an 20isolated S. pneumoniae serotype 38 polysaccharide with a reducing agent and b) detecting thepresence of N-acetyl-D-fucosamine (D-FucNAc) residues in said reduced polysaccharide. 226. the method of paragraph 225 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by NMR. 227. The method of any one of 225-226 wherein said reducing agent is sodium 25borohydride (NaBH4). 228. The method of any one of 225-227 wherein said isolated S. pneumoniae serotype 38polysaccharide has been previously treated with an oxidizing agent. 229. A method of detecting the presence of N-acetyl-D-quinovosamine (D-QuiNAc)residues in a reduced serotype 38 polysaccharide, said method comprising the step of: a) reacting 30an isolated S. pneumoniae serotype 38 polysaccharide with a reducing agent and b) detectingthe presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues in said reduced polysaccharide 230. The method of paragraph 229 wherein the presence of N-acetyl-D-quinovosamine(D-QuiNAc) residues is detected by NMR. 183231. The method of paragraph 229 wherein the presence of N-acetyl-D-quinovosamine(D-QuiNAc) residues is detected by Mass Spectrometry (MS). 232. The method of any one of 229-231 wherein said reducing agent is sodiumborohydride (NaBH4). 233. The method of any one of 229-232 wherein said isolated S. pneumoniae serotype 38 5polysaccharide has been previously treated with an oxidizing agent. 234. A method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in a reduced serotype 38 polysaccharide, saidmethod comprising the step of: a) reacting an isolated S. pneumoniae serotype 38 polysaccharidewith a reducing agent and b) detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and 10N-acetyl-D-quinovosamine (D-QuiNAc) residues in said reduced polysaccharide. 235. The method of paragraph 234 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. 236. The method of paragraph 234 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by Mass Spectrometry 15(MS). 237. The method of any one of 234-236 wherein said reducing agent is sodiumborohydride (NaBH4). 238. The method of any one of 234-237 wherein said isolated S. pneumoniae serotype 38polysaccharide has been previously treated with an oxidizing agent. 20 239. A method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues in S. pneumoniae serotype 38 glycoconjugate, saidmethod comprising the step of: a) preparing a S. pneumoniae serotype 38 glycoconjugate and b)detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine(D-QuiNAc) residues in said glycoconjugate. 25 240. The method of paragraph 239 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. 241. The method of paragraph 239 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) and/or N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by MassSpectrometry (MS). 30 242. A method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in S. pneumoniae serotype 38 glycoconjugate, saidmethod comprising the step of: a) preparing a S. pneumoniae serotype 38 glycoconjugate and b)detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues in said glycoconjugate. 35 184243. The method of paragraph 242 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected by NMR. 244. The method of paragraph 242 wherein the presence of presence of N-acetyl-D-fucosamine (D-FucNAc) and N-acetyl-D-quinovosamine (D-QuiNAc) residues is detected byMass Spectrometry (MS). 5 245. A method of detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) residuesin S. pneumoniae serotype 38 glycoconjugate, said method comprising the step of: a) preparinga S. pneumoniae serotype 38 glycoconjugate and b) detecting the presence of N-acetyl-D-fucosamine (D-FucNAc) residues in said glycoconjugate. 246. The method of paragraph 245 wherein the presence of N-acetyl-D-fucosamine (D- 10FucNAc) residues is detected by NMR. 247. The method of paragraph 245 wherein the presence of N-acetyl-D-fucosamine (D-FucNAc) residues is detected by Mass Spectrometry (MS). 248. A method of detecting the presence of N-acetyl-D-quinovosamine (D-QuiNAc)residues in S. pneumoniae serotype 38 glycoconjugate, said method comprising the step of: a) 15preparing a S. pneumoniae serotype 38 glycoconjugate and b) detecting the presence of N-acetyl-D-quinovosamine (D-QuiNAc) residues in said glycoconjugate. 249. The method of paragraph 248 wherein the presence of N-acetyl-D-quinovosamine(D-QuiNAc) residues is detected by NMR. 250. The method of paragraph 248 wherein the presence of N-acetyl-D-quinovosamine 20(D-QuiNAc) residues is detected by Mass Spectrometry (MS). 251. The glycoconjugate of any one of paragraphs 43-127 for use as an antigen. 252. The glycoconjugate of any one of paragraphs 43-127 for use as a medicament. 253. The glycoconjugate of any one of paragraphs 43-127 for use as a vaccine. 254 The glycoconjugate of any one of paragraphs 43-127 for use in generating an 25immune response in a subject. 255. The glycoconjugate for use of paragraph 254 wherein said subject is a human. 256. The immunogenic composition of any one of paragraphs 128-219 for use as amedicament. 257. The immunogenic composition of any one of paragraphs 128-219 for use as a 30vaccine. 258. The immunogenic composition for use of paragraph 257 wherein said subject is ahuman. 185259. The immunogenic composition of any one of paragraphs 128-219 for use is amethod of preventing, treating or ameliorating a bacterial infection, disease or condition in asubject. 260. The immunogenic composition of any one of paragraphs 128-219 for use is amethod of preventing, treating or ameliorating a S. pneumoniae serotype 38 infection, disease or 5condition in a subject. 261. The immunogenic composition of any one of paragraphs 128-219 for use is amethod of inducing an immune response to S. pneumoniae serotype 38 in a subject. 262. The immunogenic composition of any one of paragraphs 128-219 for use is amethod of preventing an infection by S. pneumoniae serotype 38 in a subject. 10 263. The immunogenic composition of any one of paragraphs 128-219 for use is amethod of protecting a human susceptible to a S. pneumoniae serotype 38 infection. 264. A method of making a Streptococcus pneumoniae serotype 38 glycoconjugate,using click chemistry said method comprising the steps of (a) reacting an isolated serotype 38saccharide with a carbonic acid derivative and an azido linker in an aprotic solvent to produce an 15activated azido saccharide (activation of the saccharide), (b) reacting a carrier protein with anagent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group where the NHSmoiety reacts with the amino groups to form an amide linkage thereby obtaining an alkynefunctionalized carrier protein (activation of the carrier protein), (c) reacting the activated azidosaccharide of step (a) with the activated alkyne-carrier protein of step (b) by Cu+1 mediated azide- 20alkyne cycloaddition reaction to form a glycoconjugate. 265. The method of paragraph 264 wherein before the activation (a), sizing of thesaccharide to a target molecular weight (MW) range has been performed. 266. The method of paragraph 264 wherein the isolated serotype 38 saccharide is sizedbefore activation with a carbonic acid derivative and an azido linker. 25 267. The method of paragraph 266 wherein the isolated serotype 38 capsularpolysaccharide is sized to a weight average molecular weight between 50 kDa and 500 kDa. 268. The method of paragraph 266 wherein the isolated serotype 38 capsularpolysaccharide is sized to a weight average molecular weight between 50 kDa and 400 kDa. 268. The method of paragraph 266 wherein the isolated serotype 38 capsular 30polysaccharide is sized to a weight average molecular weight between 100 kDa and 500 kDa. 270. The method of paragraph 266 wherein the isolated serotype 38 capsularpolysaccharide is sized to a weight average molecular weight between about 100 kDa and about400 kDa. 186271. The method of paragraph 266 wherein the isolated serotype 38 capsularpolysaccharide is sized to a weight average molecular weight between about 150 kDa and about300 kDa. 272. The method of paragraph 264 wherein the isolated serotype 38 capsularpolysaccharide is not sized before activation with a carbonic acid derivative and an azido linker. 5 273. The method of any one of paragraphs 264 to 272 wherein said carbonic acidderivative is selected from the group consisting of 1,1’-carbonyldiimidazole (CDI), 1,1’-carbonyl-di-(1,2,4-triazole) (CDT), N,N′-Disuccinimidyl carbonate (DSC) and N-hydroxysuccinimidylchloroformate. 274. The method of any one of paragraphs 264 to 272 wherein said carbonic acid 10derivative is 1,1’-carbonyldiimidazole (CDI). 275. The method of any one of paragraphs 264 to 272 wherein said carbonic acidderivative is 1,1'-Carbonyl-di-(1,2,4-triazole) (CDT). 276. The method of any one of paragraphs 264 to 272 wherein said carbonic acidderivative is N,N ′-Disuccinimidyl carbonate (DSC). 15 277. The method of any one of paragraphs 264 to 272 wherein said carbonic acidderivative is N-hydroxysuccinimidyl chloroformate. 278. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), (VI) 20wherein X is selected from the group consisting of CH2(CH2) n, (CH 2CH2O)mCH 2CH2, NHCO(CH2)n,NHCO(CH2CH2O)mCH 2CH2, OCH 2(CH2)n and O(CH 2CH2O)mCH2CH2; where n is selected from 1to 10 and m is selected from 1 to 4. 279. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), wherein X is CH2(CH2)n, and n is selected from 1 to 10. 25 280. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), wherein X is (CH2CH2O)mCH2CH2, wherein m is selected from 1 to 4. 281. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), wherein X is NHCO(CH 2)n, and n is selected from 1 to 10. 282. The method of any one of paragraphs 264 to 277 wherein said azido linker is a 30compound of formula (VI), wherein X is NHCO(CH2CH2O)mCH2CH2, where m is selected from 1to 4. 187283. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), wherein X is OCH 2(CH2)n, and n is selected from 1 to 10. 284. The method of any one of paragraphs 264 to 277 wherein said azido linker is acompound of formula (VI), wherein X is O(CH2CH2O)mCH2CH2, where m is selected from 1 to 4. 285. The method of any one of paragraphs 264 to 277 wherein said azido linker is a 5compound of formula (VII), (VII). 286. The method of any one of paragraphs 264 to 277 wherein said azido linker is 3-azido-propylamine. 287. The method of any one of paragraphs 264 to 286 wherein said agent bearing an 10N-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a terminal alkyne. 288. The method of any one of paragraphs 264 to 286 wherein said agent bearing anN-Hydroxysuccinimide (NHS) moiety and an alkyne group is an agent bearing an N-Hydroxysuccinimide (NHS) moiety and a cycloalkyne. 15 289. The method of any one of paragraphs 264 to 286 wherein said agent bearing anN-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (VIII), (VIII)where X is selected from the group consisting of CH2O(CH 2)nCH 2C=O andCH2O(CH 2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is selected from 0 to4. 290. The method of any one of paragraphs 264 to 286 wherein said agent bearing an 25N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (VIII),wherein X is CH 2O(CH 2)nCH2C=O, where n is selected from 0 to 10. 291. The method of any one of paragraphs 264 to 286 wherein said agent bearing anN-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (VIII),wherein X is CH2O(CH2CH2O)m(CH2)nCH2C=O, where n is selected from 0 to 10 and m is 30selected from 0 to 4. 292; The method of any one of paragraphs 264 to 286 wherein said agent bearing an N-Hydroxysuccinimide (NHS) moiety and an alkyne group is a compound of formula (IX): X 188 (IX). 293. The method of any one of paragraphs 264 to 292 wherein, step a) comprisesreacting the saccharide with a carbonic acid derivative followed by reacting the carbonic acidderivative-activated saccharide with an azido linker in an aprotic solvent to produce an activatedazido saccharide. 5 294. The method of any one of paragraphs 264 to 293 wherein step a) comprisesreacting the saccharide with an amount of carbonic acid derivative that is between 0.01-10 molarequivalent to the amount of saccharide present in the reaction mixture. 295. The method of any one of paragraphs 264 to 294 wherein at step a) the isolatedsaccharide is reacted with a carbonic acid derivative in an aprotic solvent. 10 296. The method of any one of paragraphs 264 to 295 wherein the isolated saccharideis reacted with CDI in an aprotic solvent comprising 0.1% to 1% (v/v) water. 297. The method of any one of paragraphs 264 to 296 wherein step a) further comprisesreacting the carbonic acid derivative-activated saccharide with an amount of azido linker that isbetween 0.01-10 molar equivalent to the amount of polysaccharide Repeat Unit of the activated 15saccharide (molar equivalent of RU). 298. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 1.0 to 100%. 299 The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 5 to 70%. 20 300. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 15 to 50%. 301. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 10 to 40%. 302. The method of any one of paragraphs 264 to 297 wherein the degree of activation 25of the activated saccharide following step a) is between 5 to 15%. 303. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 15 to 35%. 304. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is between 15 to 25%. 30 189305. The method of any one of paragraphs 264 to 297 wherein the degree of activationof the activated saccharide following step a) is about 25%. 306. The method of any one of paragraphs 264 to 305 wherein step b) comprisesreacting the carrier protein with an amount of agent bearing an N-Hydroxysuccinimide (NHS)moiety and an alkyne group that is 0.1-10 molar equivalents to the lysines on the carrier. 5 307. The method of any one of paragraphs 264 to 306 wherein the degree of activationof the activated carrier following step b) is between 1 and 50. 308. The method of any one of paragraphs 264 to 306 wherein the degree of activationof the activated carrier following step b) may be between 5 to 50. 309. The method of any one of paragraphs 264 to 306 wherein the degree of activation 10of the activated carrier following step b) is between 10 to 40. 310. The method of any one of paragraphs 264 to 306 wherein the degree of activationof the activated carrier following step b) is between 15 to 25. 311. The method of any one of paragraphs 264 to 310 wherein the conjugation reactionc) is carried out in aqueous buffer. 15 312. The method of any one of paragraphs 264 to 310 wherein the conjugation reactionc) is carried out in aqueous buffer in the presence of copper (I) as catalyst. 313. The method of any one of paragraphs 264 to 310 wherein the conjugation reactionc) is carried out in aqueous buffer in the presence an oxidant and of copper (I) as catalyst. 314. The method of any one of paragraphs 264 to 313 wherein the initial input ratio 20(weight by weight) of activated azido saccharide to activated alkyne-carrier at step c) is between0.8 and 1.2. 315. The method of any one of paragraphs 264 to 314 wherein following step c),unreacted azido groups in the conjugates, are capped using a suitable azido group capping agent. 316. The method of any one of paragraphs 264 to 315 wherein following step c) 25unreacted alkyne groups are capped using a suitable alkyne group capping agent. 317. The method of any one of paragraphs 283 to 336 wherein said Streptococcuspneumoniae serotype 38 glycoconjugate is according to any one of paragraphs 1-57. 318. A method of making a Streptococcus pneumoniae serotype 38 glycoconjugate,using reductive amination said method comprising the steps of (1) oxidation (activation) of the 30serotype 38 purified saccharide, (2) reduction of the activated saccharide and the carrier proteinto form a glycoconjugate. 319. The method of paragraph 318 wherein the isolated serotype 38 polysaccharide issized before oxidation. 190320. A method of making a Streptococcus pneumoniae serotype 38 glycoconjugate,comprising the step of: (a) reacting said serotype 38 saccharide with an oxidizing agent; (b)compounding the activated saccharide of step (a) with a carrier protein; and (c) reacting thecompounded activated saccharide and carrier protein with a reducing agent to form aglycoconjugate. 5 321. The method of paragraph 320 wherein the oxidizing agent is periodate. 322. The method of paragraph 321 wherein the degree of oxidation of the activatedserotype 38 saccharide is between 2 and 30. 323. The method of paragraph 321 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25. 10 324. The method of paragraph 341 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25 and wherein the initial input ratio (weight by weight)of activated serotype 38 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1. 325. The method of paragraph 321 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25 and wherein the initial input ratio (weight by weight) 15of activated serotype 38 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1,wherein the reduction reaction (c) is carried out in an aprotic solvent. 326. The method of paragraph 321 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25 and wherein the initial input ratio (weight by weight)of activated serotype 38 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1, 20wherein the reduction reaction (c) is carried out in a solution consisting essentially ofdimethylsulphoxide (DMSO). 327. The method of paragraph 321 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25 and wherein the initial input ratio (weight by weight)of activated serotype 38 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1, 25wherein the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) solvent. 328. The method of paragraph 321 wherein the degree of oxidation (DO) of the activatedserotype 38 saccharide is between 10 and 25 and wherein the initial input ratio (weight by weight)of activated serotype 38 saccharide to carrier protein at step b) is between 1.5:1 and 0.5:1,wherein the reduction reaction (c) is carried out in DMSO (dimethylsulfoxide) solvent and wherein 30the reducing agent is sodium cyanoborohydride. 329. The method of any one of paragraphs 320 to 328 wherein said Streptococcuspneumoniae serotype 38 glycoconjugate is according to any one of paragraphs 44-74. 330. The method of paragraph 328 wherein said Streptococcus pneumoniae serotypeglycoconjugate is according to any one of paragraphs 44-74. 35 191As used herein, the term "about" means within a statistically meaningful range of a value,such as a stated concentration range, time frame, molecular weight, temperature or pH. Such arange can be within an order of magnitude, typically within 20%, more typically within 10%, andeven more typically within 5% or within 1% of a given value or range. Sometimes, such a rangecan be within the experimental error typical of standard methods used for the measurement and/or 5determination of a given value or range. The allowable variation encompassed by the term"about" will depend upon the particular system under study, and can be readily appreciated byone of ordinary skill in the art. Whenever a range is recited within this application, every numberwithin the range is also contemplated as an embodiment of the disclosure.The terms "comprising", "comprise" and "comprises" herein are intended by the inventors to be 10optionally substitutable with the terms "consisting essentially of", "consist essentially of", "consistsessentially of", "consisting of', "consist of' and "consists of', respectively, in every instance.An "immunogenic amount", an "immunologically effective amount", a "therapeutically effectiveamount", a "prophylactically effective amount", or "dose", each of which is used interchangeablyherein, generally refers to the amount of antigen or immunogenic composition sufficient to elicit 15an immune response, either a cellular (T cell) or humoral (B cell or antibody) response, or both,as measured by standard assays known to one skilled in the art.Any whole number integer within any of the ranges of the present document is contemplated asan embodiment of the disclosure.All references or patent applications cited within this patent specification are incorporated by 20reference herein.The invention is illustrated in the accompanying examples. The examples below are carried outusing standard techniques, which are well known and routine to those of skill in the art, exceptwhere otherwise described in detail. The examples are illustrative, but do not limit the invention.
Examples 25 Example 1: Serotype 38 capsular saccharides, samples preparation Streptococcus pneumoniae serotype 38 polysaccharide : 25mg of lyophilized native Streptococcus pneumoniae serotype 38 was weighed and dissolvedin 1000µL of D2O. The sample was bath sonicated for 20 minutes at 50°C. The polysaccharidesolution was sized using sonication for 2 minutes with 20% amplitude power for 15 second ON 30and 15 second OFF cycles. Final concentration of the native and sized samples was 25 mg/mL.The sample was transferred into the NMR tube for NMR data collection and analysis.
Deacetylated Streptococcus pneumoniae serotype 38 polysaccharide: 25mg of native serotype 38 polysaccharide was completely deacetylated after incubating with0.25N NH4OH at room temperature for 24 hours with constant stirring. The sample was then 35dialyzed against water and lyophilized. The lyophilized polysaccharide was then resuspended in 1921000µL of D2O. The sample was transferred into the NMR tube for NMR data collection andanalysis.
Reduced Streptococcus pneumoniae serotype 38 polysaccharide: 25mg of native serotype 38 polysaccharide was completely reduced after incubating with 1 molarequivalent of NaBH4 at room temperature for 18 hours with constant stirring. The sample was 5then dialyzed against water and lyophilized. The lyophilized polysaccharide was thenresuspended in 1000 µL of D2O. The sample was transferred into the NMR tube for NMR datacollection and analysis.
Example 2: Structural elucidation of Streptococcus pneumoniae serotype 38 polysaccharide by NMR experiments 10 Both one-dimensional (1D) and two-dimensional (2D) NMR experiments were conducted.1DH spectrum was collected to identify the chemical shift fingerprint for each proton in themolecule. 2D homo- and hetero-nuclear spectra are collected to identify the chemical bondpattern between protons and carbons in the molecule, to map the backbone of the representativesugars in the serotype 38 polymer repeat unit, the inter-sugar glycosidic linkages, and to identify 15the location of the different functional groups on the sugar backbones.
All 1D and 2D data was collected at 75°C using Bruker 600 MHz spectrometer equippedwith BBO cryoprobe. The NMR data was processed using NvX and analyzed using MestraNovaand NMRViewJ (NvJ) software (Methods Mol. Biol. 278, 313, 2004). The proton signals werereferenced using the TMS signal set to 0 ppm, whereas the carbon signals were indirectly 20referenced against the TMS signal (0 ppm). 1D proton data was collected with 32 scans, with recycle delay of 10s. The following 2DNMR experiments were recorded:H-H homonuclear COSY (Correlation Spectroscopy, 2048 x512: total number of point in theH andC dimensions, respectively, with 2 scans, recycle delay1s),H-C HSQC (Heteronuclear Single Quantum Coherence, 2048 x 256: total number of point 25in theH andC dimensions, respectively, with 4 scans, recycle delay 1s),H-C HSQC-TOCSY(Heteronuclear Single Quantum Coherence - Total Correlation Spectroscopy, 2048 x 256: totalnumber of point in theH andC dimensions, respectively, with 48 scans, recycle delay 1s mixingtime of 120 ms),H-C HMBC (Heteronuclear Multiple Bond Correlation, 2048 x 256: totalnumber of point in theH andC dimensions, respectively, long range J ~ 5-10 Hz, with 48 scans, 30recycle delay 1s) andH-C HSQC-COSY (Heteronuclear Single Quantum Coherence –Correlation Spectroscopy, 2048 x 256: total number of point in theH andC dimensions,respectively, with 48 scans, recycle delay 1s),H-C CLIP-HSQC (H decoupled HeteronuclearSingle Quantum Coherence, 2048 x 256: total number of point in theH andC dimensions,respectively, with 8 scans, recycle delay 1s). 1DP data was collected with 256 scans, with 35 193recycle delay of 5s.H-P HMBC (Heteronuclear Multiple Bond Correlation, 2048 x 32: totalnumber of points in theH andP dimensions, respectively, long range J ~ 5-10 Hz).
It has been found two structures depending on the starting strain (two forms: named serineand glycine form). The chemical structure of Streptococcus pneumoniae serotype 38 serine andglycine forms is shown in Figure 1A and 1B respectively. The serotype 38 polysaccharide is a 5penta-saccharide: α-D-glucosamine (A), α-D-2-acetamido-2,6-dideoxy-xylo-hexos-4-ulose ( α-D-Sug) (B), O-acetylated β-D-galactose (C), α-D-galactose (D), and β-D-galactofuranose (E).Residue C (O-acetylated β-D-galactose) is further linked at the 6 position to serine or glycineamino acid, thus representing the serotype 38 serine and glycine forms of polysaccharide.
The β-D-Galp4OAc,6Ser (residue C) of serotype 38 polysaccharide is O-acetylated at carbon 4 10position and the level of acetylation is about 94%. 2D NMR analysis of the serotype 38 polysaccharide The complete structural elucidation of sized serotype 38 (serine and glycine forms)polysaccharide was achieved by doing the complete assignment of all the resonances of eachsugar unit that are present in the repeat unit. Each of the sugar units were assigned using 2D 15heteronuclear NMR experiments that use short rangeH-H (HSQC-COSY), long range (multiplebonds)H-H (HSQC-TOCSY) orC-C (HMBC) correlation to map the resonances within thesugar ring.
The 2D HSQC experiment provides the correlation between theH andC signals that aredirectly bonded and is very sensitive for analyzing the polysaccharides. 2D HSQC-COSY yields 20aH-H short range and HSQC-TOCSY yields aH-H long range (mixing time ~120 ms) protoncorrelation and is very useful in assigning the resonances within the sugar ring. Similarly, theinverse detected 2DH-C HMBC experiment gives rise to cross-peaks between proton andcarbon atoms that are long range scalar coupled through multiple carbon bonds. The intensitiesof these cross peaks are reflected in theJC,H orJC,H values. Generally, three bond correlations 25from the anomeric carbon to the carbon at 3 and 5 positions are seen. Also quite prominent arethe correlations to the neighboring carbon through the glycosidic bond, which are helpful insequential assignment of the sugar units and their connectivity.
All the sugar backbone resonances of the hydrate and keto state were assigned by comparingthe resonances from the short range (HSQC-COSY) and long range (HSQC-TOCSY). 30 TheH-C HSQC correlation spectrum of the serotype 38 polysaccharide with completeassignment of the resonances of all sugars of the serotype 38 repeating unit is tabulated in Tablefor serine-form and glycine-form.
Table 1.Chemical shift assignment of of all sugars of the serotype 38 repeating unit (for serineand glycine forms): 35 194 Serine form Glycine form 1H (ppm) 13C (ppm) 1H (ppm) 13C (ppm) D-a-GlcpNAc (A) A1 5.24 99.9 5.27 99.7(Hydrate form) A2 4.11 53.9 4.12 53.9 A3 4.11 77.6 4.05 77.3 A4 3.71 68.6 3.71 68.5 A5 3.71 72.9 3.71 72.9 A6 3.88 60.9 3.89 60.9 ANAc 2.08 22.8 2.07 22.7 CO 174.4 174.4 D-a-Sug (B) B1 4.80 98.7 4.80 98.7(Hydrate form) B2 4.24 51.8 4.24 51.8 B3 3.91 78.7 3.93 78.3 B4 94.8 94.9 B5 4.33 69.6 4.33 69.6 B6 1.19 11.2 1.19 11.2 BNAc 2.06 22.8 2.07 22.7 CO 174.3 174.0 D-b-Galp4OAc,6Ser (C) C1 4.85 101.5 4.83 101.3 D-b-Galp4OAc,6Gly (C) C2 3.89 73.6 3.89 73.6(Hydrate form) C3 4.25 74.2 4.23 74.2 C4 5.87 66.8 5.86 66.8 C5 4.40 73.8 4.41 73.8 C4OAc 2.12 20.5 2.12 20.6 CO 172.8 172.9 Ser-Ca 4.27 57.5 Ser-Cb 3.83 62.7 Gly-H1 3.86 43.7 Gly-H2 3.79 43.7 D-a-Galp (D) D1 5.24 94.6 5.25 94.6(Hydrate form) D2 3.93 68.3 3.91 68.3 D3 3.94 69.3 3.94 69.4 D4 4.01 78.2 4.00 78.1 D5 4.12 72.3 4.11 72.3 D6 3.70 60.8 3.71 60.8 D-b-Galf (E) G1 5.16 108.3 5.16 108.3(Hydrate form) G2 4.03 83.0 4.02 83.0 G3 4.00 78.1 4.00 78.1 G4 4.06 81.6 4.06 81.7 195 G5 3.87 70.6 3.87 70.7 G6 3.74 64.1 3.74 64.1 D-a-GlcpNAc (A) A1keto 5.06 97.3 5.07 97.2(Keto form) A2keto 4.15 53.6 4.15 53.5 A3keto 3.98 78.2 3.99 78.3 A4keto 3.68 68.7 3.67 68.6 A5keto 3.67 73.2 3.67 73.2 D-a-Sug (B) B1keto 5.05 98.6 5.05 98.6(Keto form) B2keto 4.48 55.6 4.50 55.6 B3keto 4.69 77.1 4.69 76.9 B4keto 204.8 204.8 B5keto 5.06 70.7 5.08 70.7 B6keto 1.22 12.7 1.22 12.8 Example 3: Structural comparison of O-acetylated and de-O-acetylated serotype 38 (serine form) polysaccharide by NMR experiments The comparison of 1DH andC NMR spectrum of acetylated (bottom panel) anddeacetylated (top panel) serotype 38 polysaccharides is shown at Figure 3 and Figure 4. All the 5resonances are annotated in the 1D spectrum, and some key resonances are annotated in theC spectrum. The methyl, carbonyl carbon resonances of the acetate group and the C4 ofresonance β-D-Galp4OAc,6Ser sugar are all absent in the deacetylated serotype 38polysaccharide.
Example 4: Structural characterization of reduced serotype 38 polysaccharide (serine 10 form) by NMR experiments The activation of polysaccharides for conjugation can be conducted using sodiumperiodate (NaIO4) which generates primary aldehyde at selective sugars in the polymer chain.This activated polysaccharide is then conjugated with a carrier protein. One of the critical unitoperations after the conjugation is to reduce the unconjugated activated polysaccharide using 15sodium borohydrate (NaBH4). However, it has been found that during this process the keto sugar(Sug) present in serotype 38 will be reduced. There is a need to understand the potential structuralchange in the serotype 38 after reducing with NaBH4 and its potential impact on theglycoconjugates.
Figure 5 shows the 1DH spectrum of reduced serotype 38 polysaccharide (obtained as 20disclosed at example 1). Upon reduction with sodium borohydrate (NaBH4) the keto sugar (Sug)is reduced to form: FucpNAc and QuipNAc sugars in different ratios. The area under the methylsignals from FucpNAc and QuipNAc residue has been used in determining the populations of 196polysaccharide chains having either FucpNAc or QuipNAc (using the 2DH-C HSQC spectra).The methyl signal from Sug residue has completely disappeared in the 2D HSQC spectra ofreduced 38 polysaccharide, suggesting complete reduction of the polysaccharide. The reducedserotype 38 polysaccharide shows a ratio of 68% and 32% of FucpNAc and QuipNAc sugars,respectively in the repeating units. 5 Comparison of the 1DC spectra of non-reduced and reduced serotype 38polysaccharide clearly illustrated the difference in the chemical resonances observed uponreduction with NaBH4.
Structures of reduced 38 serotype is illustrated at figure 6. Example 5: Conjugation of S. pneumoniae serotype 38 Capsular Polysaccharide using click chemistry 1. Mechanical sizing of Serotype 38 Capsular PolysaccharideThe native polysaccharide was subjected to mechanical sizing under 15000 psi pressure toreduce the MW size. The sizing study was performed to identify the number of passes required 15to achieve the target polysaccharide MW of 140-200 kDa. 2. Activation of Serotype 38 Capsular Polysaccharide with azido linkerSerotype 38 polysaccharide (173 kDa) 400 mg was mixed with 1.2 g imidazole then frozen andlyophilized. After lyophilization, the lyophilized polysaccharide was reconstituted with anhydrousDMSO 200 mL. The reaction mixture was then warmed to 35 °C, and then CDI (100 mg/mL in 20DMSO, 1.25 mL, 2 MEq) was added. The reaction mixture was stirred at 35 °C for 3 hrs. After thereaction mixture was cooled to 23 °C, Water For Injection (WFI) 4 mL (2% v/v) was added toquench free CDI and stirred for 30 min at 23 °C.To the reaction mixture, 3-Azido-1-propylamine 76 µL (2 MEq) and 110 µL of triethylamine (2MEq) was added and then stirred at 23 °C for 20 hrs. After the reaction, the mixture was diluted 25with chilled 10 mM SPB in saline (pH 7.0) (5X). The diluted reaction mixture was then purified byUF/DF using 10K MWCO PES membrane against 10 mM SPB in saline (pH 7.0) (30X volume). 3. Activation of SCP or CRM 197 to alkyne-SCP or alkyne-CRM 197 with Alkyne NHS esterActivation of SCPTo the SCP solution (2 g, 116 mL), 284 mL WFI and 100 mL 0.5 M Sodium Phosphate Buffer 30(SPB) (pH 8.3) were added to achieve final concentration of 4 mg/mL with 0.1 M ionic strengthfor the reaction. After cooled to 8°C, 3-Propargyloxy-propanoic acid NHS ester (POPS) (20 mg/mLin DMSO) 9.2 mL (0.5 MEq to lysine on SCP) was added to the reaction mixture dropwisemaintaining the reaction temperature at 8 ± 3 °C. After reaction mixture was stirred for 30 min at°C, the reaction mixture was purified by UF/DF using 10K MWCO PES membrane against 10 35mM SPB in saline (pH 7.0) (30X diavolume). The 418 mL retentate was taken and 62.7 gm 197sucrose (15% w/v) was added and followed by 0.22 um (Millipak 60) filtration. The retentate wasanalyzed using Lowry assay for protein quantification and SEC-MALLS for Mw.Activation of CRM 197Activation of CRM 197 was similar to activation of SCP except that the amount of linker was adaptedto 0.5 MEq to lysins on CRM 197. 5 4. Click ConjugationTo the mixture of Serotype 38 azido polysaccharide (as obtained at point 2 above) (62.5 mL) andalkyne-SCP (as obtained at point 3 above) (31.2 mL) or alkyne-CRM 197, 1 M SPB (pH 7) 11 mLand 5 mL of WFI were added to make a 1-2 g/L reaction mixture with an ionic strength of 100 mMSPB (pH 7). The mixture was stirred at room temperature for 1 hour followed by addition of mixture 10of copper sulfate (31 µmoL, 6.2 mL) and Tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (155µmoL, 6.2 mL), aminoguanidine (1240 µmoL, 12.4 mL), and sodium ascorbate (1240 µmoL, 12.4mL). The reaction mixture was stirred for 1.5 hours at room temperature.After 1.5 hours, propargyl alcohol 36 µL (20 MEq per alkyne) was added to the reaction mixtureto cap the unreacted azide on polysaccharide. Additional Click reagents (half amount) were 15subsequently added to enhance the capping reactions; mixture of 5 mM copper sulfate 3.1 mLand 25 mM THPTA 3.1 mL, 100 mM aminoguanidine (same volume as copper mixture solution),and 100 mM ascorbate (same volume as copper mixture solution). The reaction mixture wasstirred for an hour.Afterwards, 3-azido-propyl alcohol 115 µL (40 MEq per alkyne) was added to cap the unreacted 20alkyne SCP (or CRM 197) and stirred for another hour. The reaction mixture was purified by UF/DFusing 100K MWCO RC membrane against 10 mM EDTA + 10 mM SPB in saline (pH 7.0) (30Xdiavolume), followed by 2nd UF/DF against 5 mM succinate in saline (pH 6.0) (20X diavolume).After UF/DF, the retentate was filtered through 0.22 µm filter (Millipak 40), and subsequentlyanalyzed. 25 Table 2 shows attributes of some of the conjugates obtained (column 4 and 5).
Example 6: Conjugation of S. pneumoniae serotype 38 Capsular Polysaccharide using Reductive amination chemistry 30 1. Oxidation of Serotype 38 Capsular Polysaccharide using sodium periodate (OxidizedPolysaccharide)Mechanically sized serotype 38 polysaccharide 870 mL (173kDa, 3.0 g) was mixed with 555 mLWFI and 75 mL 1M potassium phosphate buffer (KPB) (pH 6) to make 2 mg/mL concentrationand 50 mM ionic strength solution. After the pH was adjusted to 6.0, sodium periodate (0.1 MEq) 35was added to the reaction mixture. The reaction mixture was stirred at 5 °C for 20 hours, followedby purification by UF/DF using 10K MWCO PES membrane against WFI (20X, v/v) and analyzed. 1982. Conjugation using Reductive Amination Chemistry (RAC) in aqueous system (RAC-Aq)Serotype 38 oxidized polysaccharide (see step 1) (150 mg, 25x sucrose) was mixed with CRM 197300 mg (SPR input ratio: 0.5) and then lyophilized (Co-lyophilized).Lyophilized mixture was reconstituted in 30 mL of 0.1 M KPB (pH 7.5). pH of the solution wasadjusted to 6. After the reaction solution was heated to 30 °C, sodium cyanoborohydride (100 5mg/mL in 0.15M KPB, pH 7.5, aged 3 hours) 91 µL (1 MEq) was added. The reaction wasmonitored by HPLC and after 72 hours another molar equivalent of sodium cyanoborohydride(100 mg/mL in 0.15M KPB, pH 7.5, aged 3 hours) 91 µL (1 MEq) was added. The capping wasdone for 24 hours.The reaction mixture was then diluted with pre-cooled 5 mM succinate in saline (pH 6.0) 300 mL 10and purified by UF/DF using 100K MWCO RC membrane against 5 mM succinate in saline (pH6.0) (50X diavolume). 3. Conjugation using Reductive Amination Chemistry (RAC) in DMSO (RAC-DMSO) withonly NaCNBH3 as a reducing and capping agent (about 30% reduced, column 2 of Table 2)Serotype 38 oxidized polysaccharide (see step 1) (200 mg) was mixed with Sucrose 5.0 g and 15then lyophilized. The lyophilized activated oxidized polysaccharide was then reconstituted withDMSO 100 mL at room temperature. And lyophilized CRM 197 (200 mg) was also reconstitutedwith DMSO 100 mL.Oxidized polysaccharide and CRM 197 were mixed, and the reaction mixture was stirred for 1 hourat room temperature (SPR input: 1, 1 mg/mL reaction concentration). Sodium cyanoborohydride 20(100 mg/mL in 0.15M SPB, pH 7.5) 120 µL (1 MEq) was added to the reaction and stirred at roomtemperature for 20 hrs. After 20 hours, sodium cyanoborohydride (100 mg/mL in 0.15M SPB, pH7.5) 120 µL (1 MEq) was added to quench and then stirred (200 rpm) at room temperature for 48hours. The reaction mixture was then diluted to pre-cooled 5 mM succinate in saline (pH 6.0) 800mL and purified by UF/DF using 300K MWCO RC membrane against 5 mM succinate in saline 25(pH 6.0) (50X diavolume). After UF/DF, the retentate was filtered through 0.22 um filter (Millipak40) and analyzed. 4. Conjugation using Reductive Amination Chemistry (RAC) in DMSO (RAC-DMSO) withNaCNBH3 as a reducing agent and NaBH4 as a capping agent (fully reduced, column 1 of Table2) 30Serotype 38 oxidized polysaccharide (see step 1) (250 mg) was mixed with Sucrose 6.25 g andthen lyophilized. The lyophilized polysaccharide was then reconstituted with DMSO 125 mL atroom temperature. The lyophilized CRM 197 (600 mg) was also reconstituted with DMSO 240 mL.125 mg oxidized polysaccharide and 157 mg K-CRM was mixed, and the reaction mixture wasstirred for 1 hour at room temperature (SPR input:0.8). Sodium cyanoborohydride (100 mg/mL in 350.15M SPB, pH 7.5, aged 3 hours) 76 µL (1 MEq) was added to the reaction and stirred at roomtemperature for 20 hrs. After 20 hours, sodium borohydride (100 mg/mL in WFI) 46 µL (1 MEq)was added to quench the reaction and then stirred (200 rpm) at room temperature for 3 hours. 199The reaction mixture was then diluted to pre-cooled 5 mM succinate in saline (pH 6.0) 600 mLand purified by UF/DF using 100K MWCO RC membrane against 5 mM succinate in saline (pH6.0) (50X diavolume). After UF/DF, the retentate was filtered through 0.22 um filter (Millipak 40)and analyzed.Table 2 below comprises characterizing data for serotype 38 polysaccharide conjugates obtainedby the methods of this invention. Table 2 Serotype 38 Conjugates Conjugate# 1 2 3 4 5 Native Poly MW(KDa)831.5 684 684 684 684Sized Poly MW(KDa)166 173 173 173 173 Chemistry RAC-DMSO RAC-DMSO RAC-Aq Click Click% of keto sugar(Sug) in reducedto formFullyreduced~50%reduced~40%reducedNot reduced Not reduced Degree ofActivation of ActpolyDO 17 DO 16 DO 16 23% 23% Act Poly Mw(kDa)157 169 169 220 220 Conjugate data Carrier protein CRM197 CRM197 CRM197 CRM197SCPConjugation yield(%)19 55 46 62SPR (OutputRatio)0.84 0.56 1.42 0.79 0.76Free Saccharide(%)22 18 20 16Conjugate Mw(kDa)1456 4964 3504 2121 2288 Mw: molecular weight; SPR: Saccharide to protein ratio; NA: Not Available; Act Poly: Activated 10Polysaccharide Example 7: Evaluation of immunogenicity in mice vaccinated with S. pneumoniae serotype 38 glycoconjugates using different chemistries and carrier proteins (Figure 7) 15 The opsonophagocytic geomean titers (OPA GMT) for serotype 38 conjugates in mice, generatedusing different chemistries (RAC-Aq, RAC-DMSO or Click) with different carrier proteins (CRM 197or SCP) were determined under standard conditions. 200The five conjugates have been tested (see attributes of the tested conjugates at Table 2).
Groups of twenty-five 6-8 weeks old female Swiss Webster mice were immunized with 0.01µg/animal or 0.1 µg/animal of test conjugates via the subcutaneous route on week 0. The micewere boosted with the same dose of conjugate on week 3 and then bled at week 5. Eachvaccination was formulated with 100 µg/dose of AlPO4 as an adjuvant. All preclinical 5immunogenicity studies were powered to detect a 4 to 5-fold difference in OPA titers using 25mice per group. Whole blood was collected from mice two weeks after the second vaccination(Week 5, PD 2) and sera used for analyses. Serotype-specific OPAs were performed on week 5sera samples.
Opsonophagocytic activity (OPA) assays are used to measure functional antibodies in murine 10sera specific for S. pneumonia serotype 38. Test serum is set up in assay reactions that measurethe ability of capsular polysaccharide specific immunoglobulin to opsonize bacteria, triggercomplement deposition, thereby facilitating phagocytosis and killing of bacteria by phagocytes.The OPA titer is defined as the reciprocal dilution that results in a 50% reduction in bacterial countover control wells without test serum. The OPA titer is interpolated from the two dilutions that 15encompass this 50% killing cut-off.
OPA procedures were based on methods described in Hu et al. (2005) Clin Diagn Lab Immunol(2):287–295 with the following modifications. Test serum was serially diluted 2.5-fold andadded to microtiter assay plates. Live serotype 38 target bacterial strains were added to the wellsand the plates were shaken at 25°C for 30 minutes. Differentiated HL-60 cells (phagocytes) and 20baby rabbit serum (3- to 4-week old, PEL-FREEZ®, 12% final concentration) were added to thewells, and the plates were shaken at 37°C for 45 minutes. Following incubation, 10µL aliquot weretransferred to the wells of MULTISCREEN® HTS filter plates (MILLIPORE®) containing 50 µL ofwater. Liquid was filtered through the plates under vacuum, and 50 µL of HYSOY® medium wasadded to each well and filtered through. The filter plates were then incubated at 37°C, 5% CO2 25overnight and were then fixed with 70% EtOH solution. The plates were then stained withCoomassie Blue and destained once. Colonies were imaged and enumerated on a CellularTechnology Limited (CTL) (Shaker Heights, OH) IMMUNOSPOT® Analyzer. Raw colony countswere used to plot kill curves and calculate OPA titers.
OPA titers (geometric mean titer (GMT) with 95% confidence interval (CI)) at five weeks at 30different doses are shown in Table 3. The results are also presented in Figure 7. 201 Table 3 - OPA titers following vaccination with Pn338 conjugates using RAC-Aq, RAC- DMSO or Click chemistry and CRM 197 or SCP carrier protein . The conjugates were used to vaccinate animals in the presence of adjuvant. Female Swiss-Webster mice, 6- 8 weeks old; Doses: 0.01 or 0.1 μg/animal + AlPO4; Vaccinate: 0 and 3 wk.; terminal bleed wk. 5 Readout: OPA 0.01 0.1RAC/DMSO-CRM Fully reduced (conjugate#1 of Table 2)GMT 15 175% of non-responders 68 13 RAC/DMSO-CRM ~50% reduced(conjugate #2 of Table 2)GMT 12 498 % of non-responders 75 0 RAC/Aq-CRM ~40% reduced (conjugate #3of Table 2)GMT 14 4095% of non-responders 67 4 Click-CRM (conjugate #4 of Table 2)GMT 6 77% of non-responders 96 36 Click-SCP (conjugate #5 of Table 2)GMT 53 900 % of non-responders 33 0GMT: Geomean Titers Example 8: Additional S. pneumoniae serotype 38 conjugate using Reductive Amination Chemistry in Aqueous system (RAC-Aq) Additional serotype 38 conjugate has been generated using RAC-Aq (see example 6).Table 4 below comprises characterizing data for serotype 38 polysaccharide conjugates obtained 5by the methods of this invention. Table 4 Serotype 38 Conjugates Conjugate# 6 Native Poly MW (KDa) 376 Sized Poly MW (KDa) 140 Chemistry RAC-Aq Degree of Activation of Act poly DO 15 Act Poly Mw (kDa) 149 Conjugate data Carrier protein CRM197 Conjugation yield (%) 67 202 SPR (Output Ratio) 1.07 Free Saccharide (%) 29 Conjugate Mw (kDa) 3722Mw: molecular weight; SPR: Saccharide to protein ratio; Act Poly: Activated Polysaccharide Example 9: Additional S. pneumoniae serotype 38 conjugates using Click chemistry (Click) Additional serotype 38 conjugate has been generated using Click (see example 5).Table 5 below comprises characterizing data for serotype 38 polysaccharide conjugates obtainedby the methods of this invention. 5 Table 5 Serotype 38 Conjugates Conjugate# 7 8 9 10 Sized Poly MW (KDa) 140 211 146 211 Activated polysaccharide attributes Degree of Activation of Act poly 12% 12% 20% 20% Act Poly Mw (kDa) 149 194 151 214 Activated carrier attributes Degree of Activation (DoA) 20 20 20 20 Activated carrier MW, kDa 104.1 104.1 104.1 104.1 Conjugate data Carrier protein SCP SCP SCP SCP Conjugation yield (%) 56 91 73 92 SPR (Output Ratio) 0.63 0.99 0.91 0.97 Free Saccharide (%) 15 17 16 11 Conjugate Mw (kDa) 1061 5611 3382 9598 Mw: molecular weight; SPR: Saccharide to protein ratio; NA: Not Available; Act Poly: ActivatedPolysaccharide Example 10: Evaluation of immunogenicity in mice vaccinated with S. pneumoniae serotype 38 glycoconjugates using different chemistries and carrier proteins (Figure 8) 10The opsonophagocytic geomean titers (OPA GMT) for serotype 38 conjugates in mice, generatedusing different chemistries (RAC-Aq or Click) and difference carrier proteins (CRM 197 or SCP)were determined under standard conditions. 203Seven conjugates have been tested (see attributes of the tested conjugates at Tables 2,4 and 5).Groups of twenty-five 6-8 weeks old female Swiss Webster mice were immunized with 0.01µg/animal or 0.1 µg/animal of test conjugates via the subcutaneous route on week 0. The micewere boosted with the same dose of conjugate on week 3 and then bled at week 5. Eachvaccination was formulated with 100 µg/dose of AlPO4 as an adjuvant. All preclinical 5immunogenicity studies were powered to detect a 4 to 5-fold difference in OPA titers using 25mice per group. Whole blood was collected from mice two weeks after the second vaccination(Week 5, PD 2) and sera used for analyses. Serotype-specific OPAs were performed on week 5sera samples.Opsonophagocytic activity (OPA) assays are used to measure functional antibodies in murine 10sera specific for S. pneumonia serotype 38 (see example 7).OPA titers (geometric mean titer (GMT) with 95% confidence interval (CI)) at five weeks atdifferent doses are shown in Table 6. The results are also presented in Figure 8.
Table 6 - OPA titers following vaccination with Pn38 conjugates using RAC-Aq or Click chemistry and CRM 197 or SCP carrier protein. The conjugates were used to vaccinate animals in the presence of adjuvant. Female Swiss-Webster mice, 6-8 weeks old; Doses: 0.01 or 0.1 μg/animal + AlPO4; Vaccinate: 0 and 3 wk.; terminal bleed wk. 5 Readout: OPA 0.01 0.1RAC/Aq-CRM (conjugate#3 of Table 2)GMT NA 3334%of non-responders NA 4 RAC/Aq-CRM (conjugate#6 of Table 4)GMT NA 1023 %of non-responders NA 4 Click-SCP (conjugate #5 ofTable 2)GMT 40 663 %of non-responders 48 8 Click-SCP (conjugate #7 ofTable 5)GMT 9 74 %of non-responders 79 28 Click-SCP (conjugate #9 ofTable 5)GMT 113 264 %of non-responders 24 16 Click-SCP (conjugate #10of Table 5)GMT 29 869 %of non-responders 44 0 Click-SCP (conjugate #8 ofTable 5)GMT 18 1002 %of non-responders 56 4 NA: Not Available 15GMT: Geomean Titers 204 Example 11: Additional S. pneumoniae serotype 38 conjugates using Click chemistry (Click) Additional serotype 38 conjugate has been generated using Click (see example 5),however N,N′-Disuccinimidyl carbonate (DSC) (1.5 MEq) was used instead of CDI. Table 7 showcharacterizing data. 5 Table 7 Serotype 38 Conjugates Conjugate# 11 Sized Poly MW (KDa) 202 Activated polysaccharide attributes Degree of Activation of Act poly 30% Act Poly Mw (kDa) 246 Conjugate data Carrier protein SCP Conjugation yield (%) 83 SPR (Output Ratio) 0.8 Free Saccharide (%) >5 Conjugate Mw (kDa) 5291 Mw: molecular weight; SPR: Saccharide to protein ratio; NA: Not Available; Act Poly: ActivatedPolysaccharide All publications and patent applications mentioned in the specification are indicative of 10the level of those skilled in the art to which this invention pertains. All publications and patentapplications are hereby incorporated by reference to the same extent as if each individualpublication or patent application was specifically and individually indicated to be incorporated byreference.Although the foregoing invention has been described in some detail by way of illustration 15and example for purposes of clarity of understanding, certain changes and modifications maybe practiced within the scope of the appended claims.
Claims (34)
1. A glycoconjugate comprising an isolated S. pneumoniae serotype 38 saccharide withthe following repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and wherein the O-acetyl group at position 4 of β-D-Galp4OAc,6(Y) is present in about 0% to about 100% of therepeating units, conjugated to a carrier protein.
2. The serotype 38 glycoconjugate of claim 1 wherein said serotype 38 glycoconjugate isprepared by click chemistry.
3. A serotype 38 glycoconjugate comprising a serotype 38 capsular saccharide with thefollowing repeating unit: where n represents the number of repeating units, wherein Y represents either a Serine or aGlycine residue, wherein all the repeating units comprise the same Y residue and where Xrepresents either a N-acetyl-D-fucosamine (D-FucNAc) residue or a N-acetyl-D-quinovosamine(D-QuiNAc) residue.
4. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (IV): (IV),wherein X is selected from the group consisting of CH2(CH2) n’, (CH 2CH 2O)mCH2CH 2,NHCO(CH2)n’, NHCO(CH2CH2O) mCH2CH2, OCH 2(CH2) n’ and O(CH 2CH2O)mCH2CH 2; where n’ isselected from 1 to 10 and m is selected from 1 to 4, [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- Sug-(1 → 4)- α-D- Galp- (1→]n↑β-D- Galf [→ 3)-β-D-Galp4OAc,6 (Y) -(1→3)- α-D- GlcpNac-(1→3)- α-D- X -(1→ 4)-α-D- Galp- (1→]n↑β-D- Galf 206wherein X' is selected from the group consisting of CH2O(CH 2) n’’CH 2C=O,CH2O(CH 2CH2O)m’(CH2)n’’CH2C=O, where n’’ is selected from 0 to 10 and m’ is selected from 0to 4, wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units.
5. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (IV), whereinX is CH2(CH2) n’, where n’ is 2 and wherein X' is CH2O(CH 2)n’’CH2C=O where n’’ is 1.
6. A serotype 38 glycoconjugate comprising a serotype 38 saccharide covalentlyconjugated to a carrier protein (CP) through a spacer and having the general formula (V), (V) wherein the structure in square backet represents a repeat unit of the serotype 38 saccharide andwherein n represents the number of repeating units.
7. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa.
8. The glycoconjugate of any one of claims 1 to 7 wherein said serotype 38 glycoconjugatehas a weight average molecular weight (Mw) of between 1,000 kDa and 10,000 kDa.
9. The glycoconjugate of any one of claims 1 to 8 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa and wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa.
10. The glycoconjugate of any one of claims 1 to 9 wherein the degree of conjugation ofsaid serotype 38 glycoconjugate is between 2 and 15.
11. The glycoconjugate of any one of claims 1 to 10 wherein the degree of conjugation ofsaid serotype 38 glycoconjugate is between 4 and 10.
12. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecular 207weight (Mw) of between 1,000 kDa and 10,000 kDa and wherein the degree of conjugation of saidserotype 38 glycoconjugate is between 4 and 10.
13. The glycoconjugate of any one of claims 1 to 12 wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5.
14. The glycoconjugate of any one of claims 1 to 12 wherein the ratio of serotype 38saccharide to carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1.
15. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5 and wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10.
16. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1 and wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10.
17. The glycoconjugate of any one of claims 1 to 16 wherein said serotype 38glycoconjugate comprises less than about 20% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide.
18. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5, wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10 and wherein said serotypeglycoconjugate comprises less than about 20% of free serotype 38 saccharide compared tothe total amount of serotype 38 saccharide.
19. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1, wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10 and wherein said serotype 208glycoconjugate comprises less than about 20% of free serotype 38 saccharide compared tothe total amount of serotype 38 saccharide.
20. The glycoconjugate of any one of claims 1 to 19 wherein at least 60% of the serotypeglycoconjugate has a K d below or equal to 0.3 in a CL-4B column.
21. The glycoconjugate of any one of claims 1 to 19 wherein between 65% and 80% ofthe serotype 38 glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.
22. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.5 and 1.5, wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10, wherein said serotype 38glycoconjugate comprises less than about 20% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide and wherein between 65% and 80% of the serotype 38glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.
23. The glycoconjugate of any one of claims 1 to 6 wherein the weight average molecularweight (Mw) of said S. pneumoniae serotype 38 saccharide before conjugation is between 150kDa and 300 kDa, wherein said serotype 38 glycoconjugate has a weight average molecularweight (Mw) of between 1,000 kDa and 10,000 kDa, wherein the ratio of serotype 38 saccharideto carrier protein in the glycoconjugate (w/w) is between 0.7 and 1.1, wherein the degree ofconjugation of said serotype 38 glycoconjugate is between 4 and 10, wherein said serotype 38glycoconjugate comprises less than about 20% of free serotype 38 saccharide compared to thetotal amount of serotype 38 saccharide and wherein between 65% and 80% of the serotype 38glycoconjugate has a Kd below or equal to 0.3 in a CL-4B column.
24. The glycoconjugate of any one of claims 1 to 23 wherein the carrier protein of theserotype 38 saccharide glycoconjugate is selected in the group consisting of: TT, DT, DT mutantsand a C5a peptidase from Streptococcus (SCP).
25. The glycoconjugate of any one of claims 1 to 23 wherein the carrier protein of theserotype 38 saccharide glycoconjugate is rhizavidin [aa 45-179J-GGGGSSS-SP1500- AAA-SP0785] (CP1).
26. The glycoconjugate of any one of claims 1 to 23 wherein the carrier protein of theserotype 38 saccharide glycoconjugate is Rhavi-linker-PdT(G294P)-linker-SP0435 [aa 62-185]fusion protein (SPP2).
27. The glycoconjugate of any one of claims 1 to 23 wherein the carrier protein of theserotype 38 saccharide glycoconjugate is SCP.
28. An immunogenic composition comprising a S. pneumoniae serotype 38 saccharideglycoconjugate according to any one of claims 1-27.
29. The immunogenic composition of claim 28 further comprising glycoconjugates from S.pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F,22F, 23F and 33F.
30. The immunogenic composition of claim 28 further comprising glycoconjugates from S.pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F,22F, 23A, 23B, 23F, 24F, 33F and 35B.
31. The immunogenic composition of claim 30 wherein the S. pneumoniae saccharidesfrom serotypes 1, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15A, 15B, 18C, 19A, 19F, 22F, 23A,23B, 23F, 24F, 33F, 35B and 38 are conjugated to CRM 197 and the S. pneumoniae saccharideserotype 3 is conjugated to SCP.
32. The immunogenic composition of any one of claims 28 to 31 further comprising oneadjuvant.
33. The immunogenic composition of any one of claims 28 to 32 for use as a vaccine.
34. The immunogenic composition of any one of claims 28 to 32 for use in preventing,treating or ameliorating an infection, disease or condition associated with S. pneumoniae serotypein a subject. Dr. Hadassa Waterman Patent Attorney G.E. Ehrlich (1995) Ltd. 35 HaMasger Street Sky Tower, 13th Floor Tel Aviv 6721407
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363493046P | 2023-03-30 | 2023-03-30 | |
| US202463563499P | 2024-03-11 | 2024-03-11 | |
| PCT/IB2024/052957 WO2024201324A2 (en) | 2023-03-30 | 2024-03-27 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL323619A true IL323619A (en) | 2025-11-01 |
Family
ID=90721033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL323619A IL323619A (en) | 2023-03-30 | 2025-09-28 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240325515A1 (en) |
| EP (1) | EP4687966A2 (en) |
| JP (1) | JP2026515371A (en) |
| KR (1) | KR20250163977A (en) |
| CN (1) | CN121038808A (en) |
| AU (1) | AU2024246082A1 (en) |
| CO (1) | CO2025013417A2 (en) |
| IL (1) | IL323619A (en) |
| MX (1) | MX2025011233A (en) |
| PE (1) | PE20252774A1 (en) |
| TW (1) | TWI910585B (en) |
| WO (1) | WO2024201324A2 (en) |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
| US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
| GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
| DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
| ATE128628T1 (en) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE. |
| EP0625910B1 (en) | 1992-02-11 | 2003-07-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Dual carrier immunogenic construct |
| IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
| JP3506431B2 (en) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Diphtheria toxin receptor binding domain |
| DE69313134T2 (en) | 1992-06-25 | 1998-02-26 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTIES |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| DK0616034T3 (en) | 1993-03-05 | 2005-02-21 | Wyeth Corp | Plasmid for the preparation of CRM protein and diphtheria toxin |
| KR100310510B1 (en) | 1993-03-23 | 2002-07-04 | 장 스테판느 | Vaccine composition containing 3-0-deacetylated monophosphoryl lipid A |
| EP0720485B1 (en) | 1993-09-22 | 2003-11-19 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| AU713040B2 (en) | 1994-07-15 | 1999-11-18 | University Of Iowa Research Foundation, The | Immunomodulatory oligonucleotides |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| US6355255B1 (en) | 1998-12-07 | 2002-03-12 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| US5846547A (en) | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
| CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
| US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
| EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| US6218371B1 (en) | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| BR9909915A (en) | 1998-04-09 | 2000-12-26 | Smithkline Beecham Biolog | Adjuvant compositions |
| GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| CN1263510C (en) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | Polysaccharide-protein conjugate or oligosaccharide-protein conjugate, preparation method and application thereof |
| ES2284287T3 (en) | 1998-10-16 | 2007-11-01 | Glaxosmithkline Biologicals S.A. | ADJUSTMENT SYSTEMS AND VACCINES. |
| CA2355364C (en) | 1998-12-21 | 2014-03-18 | Medimmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
| PL205041B1 (en) | 1998-12-23 | 2010-03-31 | Id Biomedical Corp | Isolated polynucleotide, vector comprising isolated polynucleotide, vector transformed or transfected host cell, method for production of isolated polypeptide coded by isolated polynucleotide, isolated polypeptide, chimeric polypeptide, composition for vaccines and its use in treating streptococcus infection |
| CA2366152A1 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Streptococcus pneumoniae vaccine |
| WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| DK1187629T3 (en) | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| HK1049106A1 (en) | 1999-09-24 | 2003-05-02 | Smithkline Beecham Biologicals S.A. | Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| IL148671A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| WO2001098334A2 (en) | 2000-06-20 | 2001-12-27 | Shire Biochem Inc. | Streptococcus antigens |
| AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
| US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
| MXPA05009579A (en) | 2003-03-13 | 2005-11-17 | Glaxosmithkline Biolog Sa | Purification process for bacterial cytolysin. |
| EP1603950A2 (en) | 2003-03-17 | 2005-12-14 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
| US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| PL1866342T3 (en) | 2005-04-08 | 2019-04-30 | Wyeth Llc | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
| IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | Multivalent pneumococcal polysacharide-protein conjugate composition |
| US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| CA2665169C (en) | 2006-10-10 | 2017-02-21 | Wyeth | Purification of streptococcus pneumoniae type 3 polysaccharides |
| HUE039169T2 (en) | 2007-03-23 | 2018-12-28 | Wyeth Llc | Shortened purification process for the production of capsular streptococcus pneumoniae polysaccharides |
| EA200901578A1 (en) | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE |
| DK2424562T3 (en) | 2009-04-30 | 2015-12-07 | Coley Pharm Group Inc | Pneumococcal vaccine and uses thereof |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| RU2632651C2 (en) | 2011-05-11 | 2017-10-06 | Чилдрен'С Медикал Сентер Корпорейшн | Modified biotin-binding protein, fusion proteins based thereon and their application |
| PT2885007T (en) | 2012-08-16 | 2018-12-10 | Pfizer | Glycoconjugation processes and compositions |
| RU2672053C2 (en) | 2012-12-20 | 2018-11-09 | Пфайзер Инк. | Glycoconjugation process |
| CN103495161B (en) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | A kind of mixture and preparation method thereof of polynary pneumococcal capsular polysaccharide-protein conjugate |
| IL312327B2 (en) | 2014-01-21 | 2026-02-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| BR112016015835B1 (en) | 2014-01-21 | 2023-12-26 | Pfizer Inc | PROCESS FOR PREPARING CONJUGATES COMPRISING CAPSULAR POLYSACCHARIDES OF STREPTOCOCCUS PNEUMONIAE |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| JP7680185B2 (en) | 2017-02-24 | 2025-05-20 | メルク・シャープ・アンド・ドーム・エルエルシー | Enhanced immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates |
| EP3691677A4 (en) * | 2017-10-04 | 2021-07-07 | Pogona, Llc | SACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS AND METHOD OF USING THEREOF |
| CN112969474A (en) | 2018-09-12 | 2021-06-15 | 艾芬尼维克斯公司 | Multivalent pneumococcal vaccine |
| JP7239509B6 (en) | 2019-02-22 | 2023-03-28 | ファイザー・インク | Method for purifying bacterial polysaccharides |
| US20220184199A1 (en) * | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| JP7714690B2 (en) * | 2021-05-28 | 2025-07-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| MX2024002779A (en) | 2021-09-09 | 2024-06-11 | Affinivax Inc | Multivalent pneumococcal vaccines. |
-
2024
- 2024-03-27 AU AU2024246082A patent/AU2024246082A1/en active Pending
- 2024-03-27 JP JP2025556494A patent/JP2026515371A/en active Pending
- 2024-03-27 WO PCT/IB2024/052957 patent/WO2024201324A2/en not_active Ceased
- 2024-03-27 KR KR1020257035775A patent/KR20250163977A/en active Pending
- 2024-03-27 PE PE2025002178A patent/PE20252774A1/en unknown
- 2024-03-27 EP EP24718590.3A patent/EP4687966A2/en active Pending
- 2024-03-27 CN CN202480023905.2A patent/CN121038808A/en active Pending
- 2024-03-29 US US18/621,962 patent/US20240325515A1/en active Pending
- 2024-03-29 TW TW113111933A patent/TWI910585B/en active
-
2025
- 2025-09-23 MX MX2025011233A patent/MX2025011233A/en unknown
- 2025-09-28 IL IL323619A patent/IL323619A/en unknown
- 2025-09-30 CO CONC2025/0013417A patent/CO2025013417A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202444421A (en) | 2024-11-16 |
| CO2025013417A2 (en) | 2025-10-09 |
| EP4687966A2 (en) | 2026-02-11 |
| AU2024246082A1 (en) | 2025-10-16 |
| US20240325515A1 (en) | 2024-10-03 |
| WO2024201324A2 (en) | 2024-10-03 |
| CN121038808A (en) | 2025-11-28 |
| PE20252774A1 (en) | 2025-12-22 |
| MX2025011233A (en) | 2025-10-01 |
| TWI910585B (en) | 2026-01-01 |
| JP2026515371A (en) | 2026-05-18 |
| KR20250163977A (en) | 2025-11-21 |
| WO2024201324A3 (en) | 2024-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7579900B2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| AU2022281543B2 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| JP7585203B2 (en) | Immunogenic multi-heteroantigenic polysaccharide-protein conjugates and uses thereof | |
| US20240325515A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| US20240350608A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| TWI887857B (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| WO2024224266A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | |
| RU2837543C2 (en) | Immunogenic compositions containing conjugated capsular saccharide antigens, and use thereof | |
| US20260014241A1 (en) | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |